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Abstract 
The heritability of colorectal cancer (CRC) has been estimated between 7.4% and 
26% from a range of analyses based on family lineages and genetic similarity. 
Certain rare, high penetrance variants are well characterized, though these are 
estimated to account for only ~5% of all CRC cases. The majority of GWAS-
identified risk SNPs for CRC fall within non-coding regions, and the mechanisms by 
which the majority of these variants contribute to disease predisposition are yet to 
be elucidated. However, recent studies have highlighted the contribution of 
alternative splicing to cancer progression, and have linked variants altering splicing 
patterns to predisposition to other complex traits. 
This study has analysed RNA-seq from 221 samples of colonic mucosa (the precise 
tissue of origin of CRC) from a Scottish cohort to identify variants associated with 
quantitative changes in the splicing patterns of genes (sQTLs). All individuals were 
genotyped from blood samples via SNP-chips, and imputation increased the number 
of testable variants to 4 million. Transcript expression was quantified with the 
alignment-free Salmon algorithm. Two separate approaches with complementary 
methodologies were used to identify sQTLs: the sQTLseekeR package which 
analyses whole transcripts, and the Leafcutter package which infers changes in 
intron usage. Between the two, over 15,000 variants were identified as 
corresponding to changes in the ratio of expression of transcripts or the ratio of 
intron excision from over 6,800 protein-coding and lncRNA genes. Effect size and 
expression thresholds were applied to retain only the top 8% most likely functionally 
relevant sQTLs. 
The thresholded sQTLs were found to be enriched in peaks of active chromatin 
marks, DNase accessible regions and putative regulatory elements, relative to a 
population of 100,000 non-sQTL SNPs sampled from the same search windows and 
with the same proportions of minor allele frequencies as the sQTL SNPs. They were 
similarly enriched within regions predicted to be active from probabilistic 
deconvolution of signals from multiple histone marks constructed by the Roadmap 
Epigenetics Consortium. sQTLs were enriched within linkage blocks containing 
eQTLs (expression quantitative trait loci) identified from the same cohort, and 
eQTLs identified from GTEx sigmoid and transverse colon tissues; however the lead 
SNPs associated with sQTLs and eQTLs were different in 97% of cases, implying a 
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strong degree of independence between the two classes of event. Thresholded 
sQTL variants identified by the Leafcutter package were found to be significantly 
enriched within a meta-GWAS for CRC consisting of 20,818 cases and 37,822 
controls. Between both packages, sQTLs were found for 9 genes associated with 
CRC in the NHGRI-EBI GWAS catalog, 4 genes curated in the COSMIC database 
as relevant to CRC progression, and a further 29 oncogenes or tumour suppressors 
implicated in any cancer. 
Together these observations imply that the alteration of patterns of transcript 
expression in the colonic mucosa mediated by germline SNPs is one of the genetic 
mechanisms underpinning predisposition to CRC. The sQTLs identified herein could 
be further used in colocalisation analyses to fine-map GWAS causal variants, and in 
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Lay summary 
DNA stores instructions within cells, telling them when to grow and how quickly to do 
so. The majority of cancers are caused by mutations in a person’s DNA which lead 
cells to multiply and spread too quickly. Most mutations which drive cancer are 
accumulated incidentally throughout a person’s lifetime, either through mistakes 
made in copying DNA whilst making new cells, or from exposure to mutagens such 
as UV light or cigarette smoke. 
However, some people are born with certain mutations already in their DNA which 
make them more predisposed to develop a particular cancer over the course of their 
lifetime. There are certain mutations like this which are well known to greatly 
increase the likelihood of developing cancer of the colon, and people with these 
conditions can first develop tumours from a very early age and have a poor life 
expectancy. These such mutations are very rare in the general population however, 
and there are other more common mutations which less strongly predispose to 
colorectal cancer - though when combined together can still make a significant 
contribution to an individual’s likelihood of developing it. 
Genes are individual sequences of DNA which send a specific instruction to the cell. 
This means that when a mutation occurs within the sequence of a gene, it is 
relatively easy to predict the consequence it will have by translating how the 
instruction has been changed. The rare, high-impact mutations predisposing to 
colon cancer tend to occur within genes, however the majority of the more common 
and lower-impact mutations occur in regions outside of genes - so their 
consequences are less easy to predict. 
This project aimed to investigate a certain class of these DNA variants termed 
“alternative splicing quantitative trait loci”, which do not change the way genes are 
coded, but change the degree to which different sub-sections of genes are 
expressed. This required decoding the DNA of many individuals in combination with 
analysing their RNA from the specific tissue where colon cancer develops; the 
colonic mucosa. RNA is the way that instructions encoded in genes are delivered 
from DNA storage out of the nucleus into the cell body. The hypothesis of this thesis 
is that “alternative splicing quantitative trait loci”, which alter the amounts by which 
different portions of the RNA messages are sent out, may account for some of the 
common, low-impact DNA variations which can predispose people to colon cancer.  
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Chapter 1 Introduction 
1.1 Colorectal cancer and its causes 
Colorectal cancer (CRC) is the fourth most common cancer in the UK1, and is the 
second leading cause of cancer-related mortality2. The disease can be classified 
into four stages of increasing severity, and the majority of cases of CRC are only 
diagnosed at a late stage in the United Kingdom3. The American Joint Committee on 
Cancer (AJCC) classifies CRC into four different stages based on the size of the 
tumour, the number of affected lymph nodes and number of distal metastases, 
termed the “TNM” system4. Survival is high for patients diagnosed early in the 
stages of disease progression with over 94% five-year-survival for stage 1 
diagnoses, as compared to less than 9% five-year-survival for patients diagnosed at 
stage 45,6. Screening programmes to detect faecal occult blood as a marker of CRC 
presence reduce relative risk of CRC by up to 25%(RR 0.75, 95% confidence 
interval 0.66-0.84)7; however only 10% of cases are currently diagnosed in this 
way8. Understanding the causes of CRC predisposition is therefore particularly 
important as this would enable patient stratification to target screening and early 
detection resources to individuals at the highest risk9.   
1.1.1 Physiology of the colon 
The large intestine is separated into two sides according to position relative to the 
splenic flexure (Figure 1.1). The right side contains the caecum, appendix, 
ascending colon and transverse colon. The left side constitutes the descending 
colon and sigmoid colon, which after the rectosigmoid junction marks the transition 
into the rectum and anus. Together the large intestine and rectum comprise the 
colorectum. The two sides of the colorectum originate from different subcellular 
populations during embryogenesis: regions on the right of the splenic flexure 
originate from the midgut and those on the left from the hindgut10.  
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Figure 1.1 Colon physiology. Adapted from Wikimedia Commons11. 
The gastrointestinal tract is separated into 4 distinct layers: mucosa, submucosa, 
muscularis externa and serosa (Figure 1.2). The colonic mucosa is further 
separated into 3 key layers: columnar surface epithelial cells, the lamina propria 
(connective tissue) and an outer muscular layer (muscularis mucosa)10. Simple 
tubular glands are formed by invaginations of the epithelial cells into the mucosa 
and are termed “crypts of Lieberkühn”. The crypts increase surface area for the 
absorption of water and solutes in the large intestine, and also constitute the 
structure for epithelial cell turnover. 
The base of each crypt is populated by intestinal stem cells12 which are able to 
differentiate into any of the cell types specific to the colonic epithelium, including: 
absorptive enterocytes, goblet cells which secrete mucins to coat the intestine and 
protect against pathogens13, enteroendocrine cells which act as chemoreceptors 
and secrete gastrointestinal hormones in response to the luminal environment14, 
paneth cells which secrete antimicrobial defensin proteins and lysosomes15 and tuft 
cells which produce intestinal opioids16 and aid in activation of the type-2 cytokine 
immune response of paneth cells against intestinal parasites such as helminth 
worms17. 
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The submucosa is a layer of connective tissue containing nerves (Meissner’s 
plexus) and blood vessels10. The muscularis layer contains an inner circular and 
outer longitudinal sheet of muscle which allow for the motility of the coloretum via 
peristalsis. The outermost layer of the colorectum constitutes the peritoneum which 
contains blood vessels for the support of the abdominal organs and binds them to 
each other and the walls of the abdominal cavity18. 
 
 
Figure 1.2 Layers of colon wall. From American Cancer Society (ACS)19. 
 
1.1.2 The stem cell theory of cancer 
Intestinal epithelial cells at the surface of crypts are rapidly turned over and 
sloughed off on average every 5-7 days20. This requires rapid and continuous re-
population of differentiated epithelial cells from LGR5+ stem cells at the base of 
crypts, which are dependent on Wnt ligands for maintenance of their stem-cell 
state21 (Figure 1.3). Whilst the requirement of paracrine Wnt has been known for 
over a decade22, the exact source had remained unknown until it was discovered in 
2018 that GLI1-expressing subepithelial mesenchymal cells were necessary for 
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intestinal epithelial renewal in mice23. The stem cells are also fed BMP agonists 
including GREM1, GREM2 and CHRDL1 from subepithelial myofibroblasts and 
smooth muscle cells below, which serve to maintain the required signalling axis for 
crypts to form in the appropriate orientation24. The signalling gradient changes as 
cells progress up the axis with terminal differentiation being induced by activation of 
the TGF beta pathway via removal of restrictions on BMP ligands25, along with 
activation of components of the Notch pathway26, Myc signalling network27,28 and 
increased release of ephrin ligands29,30.  
It is theorised that the stem cells are the population from which colorectal cancer 
initiates as they are the only cells that have the potential to produce all other 
epithelial cell types and which persist long enough to acquire the genetic mutations 
or epigenetic aberrations necessary to fulfil the multi-hit hypothesis31. The cancer 
stem cell hypothesis purports that there is then a latent minority population of stem 
cells which retain plasticity and serve to re-establish tumours following development 
of resistance to chemotherapy, radiotherapy or targeted agents32–34. LGR5+ stem 
cells were proven to be the cell of origin for intestinal tumours when APC was 
selectively deleted in them in a mouse model, which generated macroscopic 
adenomas within 3-5 weeks35. This was in contrast with shorter-lived transit 
amplifying cells which when subjected to the same mutation failed to develop 
tumours other than microadenomas which stalled in growth shortly after induction35. 
There exists a second pool of rarer intestinal stem cells which express BMI1 and 
inhabit a region encompassing the 4 cells distal to LGR5+ cells at the bases of 
crypts36,37, and they have been shown to be able to regenerate LGR5+ cells upon 
artificial ablation of crypt bases as a simulation of intestinal damage38. These cells 
are also able to initiate tumours if exposed to the necessary genetic/epigenetic 
perturbations36. 
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Figure 1.3 Stem cell renewal of crypt structure. From Barker 201420. TA: transit 
amplifying. 
There is an opposing theory of “top-down” carcinogensis based on histological 
observations of early polyps appearing at the luminal surface of crypts with no 
contact to the stem cell compartment39 which hypothesises that terminally 
differentiated cells may re-gain pluripotency through specific genetic or epigenetic 
lesions40. Constitutive NF-kB expression has been shown to upregulate Wnt 
signalling to a sufficient level to allow conversion of LGR5- cells to LGR5+ cells with 
stem-like properties capable of tumour initiation upon concomitant mutation of APC 
and KRAS41. Whilst the two theories are not necessarily mutually exclusive, crypt-
fission driven by the hyperproliferative progeny of mutated LGR5+ stem cells is 
accepted as the primary mechanism by which early adenomas spread to 
neighbouring crypts12,42.  
 
1.1.3 CRC aetiology is influenced by physiology and gender  
There are differences in epidemiology and etiology observed between CRC 
occurring in the two sides of the colon divided by the splenic flexure43,44. A study of 
9,550 cases of colorectal cancer from Florida’s statewide registry found right-sided 
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cancers had a higher incidence rate in females than males (55% vs 45%) and were 
on average identified at a later age than left-sided tumours (median 73.7 vs 69.4 
years)45. A retrospective survival analysis of 77,978 patients found right-sided 
cancers to have poorer prognosis with a median survival of 78 vs 89 months, and a 
5% greater hazard ratio for risk of mortality compared to left-sided cancers (1.04: 
95% confidence interval, 1.02-1.07)46. In her thesis entitled “Post-GWAS functional 
characterisation of colorectal cancer risk loci”, Dr Li Yin Ooi observed 55 genes 
differentially expressed >1.5 log-fold-change (12 > 2.0 log fold change) between 
right (39) and left (79) sided normal colonic mucosa samples via microarray47. The 
difference in survival is complicated by stage at diagnosis: right-sided tumours are 
less likely to be diagnosed early. A study of 3,552 Japanese colorectal cancer cases 
found 22% of left-sided cancers were diagnosed at stage 1 compared to just 15% of 
right-sided48. 
The fact that females have a higher incidence of right-sided CRC, which is less 
readily detected and has a poorer prognosis, may explain the poorer survival rates 
for females over the age of 65 compared to males49. However males of all ages are 
more likely to develop CRC than females. In the UK, 1 in 14 men will develop CRC 
over the course of their lifetime compared to 1 in 19 women2. 
 
1.1.4 Molecular pathology of CRC  
Adenocarcinomas are cancers derived from epithelial cells, whilst sarcomas are 
derived from mesenchymal cells. 95% of colorectal cancers are adenocarcinomas, 
with the remaining percentage consisting of carcinoid tumours, squamous cell 
carcinoma, lymphoma and the rarest being sarcoma50. The AJCC TNM system 
classifies Stage 0 (or “in situ”) CRC as tumours which are only growing on the most 
superficial luminal mucosa layer of the colon4. Stage I tumours have grown through 
the mucosa and the muscularis mucosa into the submucosa and potentially also into 
the muscularis propria but no further. Stage II tumours may have grown into the 
outermost layer of the colon and potentially through the colon wall into other organs 
but without spreading from the primary site. Stage III is defined by the spread of the 
cancer to lymph nodes and Stage IV is reached once any metastases in allosteric 
organs or tissues are observed. 
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Sporadic CRC can be divided into two main groups. 84% of the cases are classified 
as presenting “chromosomal instability” (CIN), mainly attributable to somatic copy 
number alterations and chromosomal translocations51 which can be caused by 
telomere instability and/or improper chromosomal segregation during mitosis52. 
Though whilst termed unstable relative to other CRC cases, as a whole CRC is one 
of the least genomically unstabile cancers when compared with others such as high-
grade serous ovarian cancer (HGCOC) and breast invasive carcinoma (BRCA)53,54. 
The other 16% of CRC cases present a hypermutated genome caused by 
microsatellite instability (MSI), which can be further subclassified into those caused 
by defects in DNA mismatch repair pathways (MMR: 13%) or those with DNA-
polymerase Epsilon mutations (POLE: 3%)55. 
CIN tumours most often arise with an initial dysregulation of Wnt signalling. >80% of 
adenomas present loss of APC function56 and a further ~10% have mutational or 
epigenetic inactivation of other components of the same pathway e.g. β-catenin57. 
Driver mutations, including in KRAS and PIK3CA, are then accumulated as the 
tumour progresses in size and dysplasia, followed by further loss of tumour 
suppressors including SMAD4 and TP53 which usually precede invasive growth 
beyond the wall of the colon and metastasis55. Almost 50% of CIN tumours possess 
constitutively activating KRAS mutations, in contrast to the BRAF mutations most 
commonly being responsible for driving the EGFR proliferative pathway in MSI 
tumours58. 
Sporadic MSI tumours most commonly initiate by promoter hypermethylation of 
MLH1, possibly by overexpression of DNMT3B59, which leads to defective 
surveillance of single-base mismatches during DNA replication and a particular 
propensity for mutations in microsatellites of repeating units of 1-4bp55. Disruption of 
other genes which can lead to the phenotype include MSH2, MSH6, PMS1 and 
PMS660, but interestingly not all CRC with the MSI phenotype have identified 
mutations in known MMR genes61, which implies there may be uncharacterized 
facets to the DNA repair process62. A subset of MSI CRC tumours have ultramutator 
phenotypes due to mutations in the intrinsic exonuclease domains of DNA 
Polymerase Epsilon or Delta 1, POLE or POLD1, which are responsible for 
proofreading of base-substitution simultaneous with DNA replication63. The most 
common driver mutations for MSI CRC are constitutively activating mutations in 
BRAF64 such as V600E which renders the catalytic cleft of BRAF permanently 
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accessible and can increase its activity by 500-fold, removing the cell’s dependence 
on extracellular signals for activation of the MAPK proliferative pathway65.  
 
 
1.1.5 Consensus Molecular Subtypes of CRC 
CIN tumours can be further subdivided based on their expression profiles, which are 
known to capture latent biologically relevant information about tumour 
characteristics66. The Colorectal Cancer Subtyping Consortium (CRCSC) used 
microarray profiling of 3,962 CRC samples from 18 datasets to perform supervised 
clustering into consensus subtypes of biological and clinical relevance67. Six groups 
had previously created subclassifications of CRC, with between three and six 
classes defined by each group. The consortium began by constructing a network 
whereby nodes were each of the 27 different sets previously created by these 
groups, and edges were the Jaccard similarity between set membership of each of 
the nodes. They applied a Markov Clustering algorithm to this network which 
resulted in four consensus molecular subtypes, named CMS1-468. 3,104 (78%) of 
the samples were classified directly into these clusters by the Markov Clustering, so 
the authors used these as a gold-standard set to train a random forest algorithm to 
assign samples to subtypes based on gene expression. Applying this algorithm to 
the 858 originally unassigned samples they were able to unambiguously allocate a 
further 339 samples to a single subtype, with the remaining 519 samples (13% of 
total original samples) being unclassified. Those that were unclassified did not 
represent a further outgroup, but were intermediate or ambiguous between the 4 
major subtypes, possibly reflecting intratumour heterogeneity or lower quality 
sequencing. 
The majority of the cancers classified as MSI by the two-class system fell into 
subtype CMS1 which is characterized by a hypermutator phenotype and 
hypermethylation profiles, with a high frequency of BRAF constitutive activating 
mutations co-occuring with these characteristics69. Pathway analysis of genes most 
highly expressed in CMS1 tumours also revealed signatures of immune cell 
infiltration (specifically class 1 T helper cells and cytotoxic T cells), along with 
upregulation of genes involved in immune surveillance evasion70. 
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The CIN tumours were deconvoluted into the remaining three classes. CMS2 had 
the most frequent instances of copy number gains and losses. CMS3 had fewer 
copy number variants, and more CpG island methylation than CMS2 or CMS4, and 
had the highest frequency of KRAS driver mutations. APC loss was significantly 
more frequent in CMS2-4 than CMS1. >25% of tumours across all groups had TP53 
mutations with the greatest amount (>75%) in CMS2. The fact that there were no 
clearly defined co-occurrences of key driver mutations in any of the CMS2-4 tumour 
subtypes indicates that simple genomic aberrations cannot be relied upon for 
dependable stratification of intrinsic tumour biology, and serves to highlight the 
power of transcriptional analyses and the latent features they can uncover. The 
molecular subtypes are clinically relevant: CMS1 tumours have a better prognosis 
than CMS2-4 tumours71 and greater likelihood of showing clinical response to 
immunotherapies72,73, likely due to the large number of non-self tumour-neoantigens 
that can be generated as a result of hypermutator phenotypes74,75. In contrast, there 
is a clinical need for multi-drug regimens for the CMS2-4 subtypes where there is 
rarely a single dominant driver gene76. 
1.1.6 Mendelian traits predisposing to CRC 
Whilst the majority of CRC cases are sporadic, there are high-penetrance germline 
mutations which strongly predispose individuals to develop colorectal cancer, and 
other lower impact variants which together are estimated to account for 
approximately 20% of CRC cases77. The most potent inherited syndrome is Familial 
Adenomatous Polyposis (FAP), which if left unchecked leads to individuals 
developing hundreds to thousands of precancerous polyps throughout their large 
intestine. There are also extracolonic phenotypes associated with FAP which can 
include tumours in the small intestine, stomach, adrenal gland adenomas thyroid 
gland carcinomas, desmoid tumours arising from fibroblasts throughout the body 
and hypertrophy of retinal pigment epithelium in the eye78.The incidence has been 
estimated to be between 1/8,000 to 1/14,000 live births79,80, and sufferers have a 
50% chance of developing adenoma by age 15 and 95% chance by age 3581 with 
equal penetrance across genders. FAP is caused by mutations in the APC gene82, a 
tumour suppressor which in the absence of Wnt signalling usually functions to 
facilitate the phosphorylation of beta-catenin by GSK3B, which results in it being 
tagged with ubiquitin for proteasomal degradation83. With APC inactivated, beta-
catenin is constitutively free to transition into the nucleus, where as a coactivator of 
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T cell transcription factor (TCF) and lymphoid enhancer factor (LEF) it mediates 
expression of cell proliferative and pro-survival genes84. 
FAP is an autosomal dominant condition, however inheritance of two faulty copies of 
APC is embryonic lethal; in accordance with Knudson’s two-hit hypothesis that 
individuals who inherit a single mutated APC allele then go on to lose the other in 
somatic cells85. The APC gene has a domain key to beta-catenin interaction, and 
whereas the majority of FAP mutations are truncating or nonsense, there is a 
hotspot “mutation cluster region” observed around codon 1300, likely as a result of 
selection pressure to retain the N-terminal function of APC whilst deactivating the C-
terminus responsible for the beta-catenin degradation86.  
Lynch Syndrome is caused by mutations in the DNA mismatch repair pathway, and 
predisposes to colorectal cancer, with a 70% bias towards incidence of right-sided 
tumours87. Unlike sporadic CRC, in which the MSI/CMS1 phenotype is most 
commonly caused by promoter methylation of MLH1, Lynch syndrome is more 
evenly attributable between approximately 45% MLH1 and 45% MSH2 inactivating 
mutations88. The remaining 10% is made up predominantly of mutations to MSH6, 
PMS1 or PMS2. The penetrance of germline mismatch repair genes is not as 
complete as in FAP, and also exhibits a gender bias, with estimates of between 74-
94% penetrance in males and 30-63% in females89,90. Through faulty mismatch-
repair Lynch syndrome also predisposes to endometrial cancer and carcinoma of 
the small intestine, stomach, ovary, kidney and breast91. Distinct to Lynch syndrome, 
MUTYH-associated polyposis is also caused by mutations in DNA-repair, 
specifically in the MUTYH gene involved in DNA base excision repair. It has a milder 
phenotype than APC mutations, and carriers of this recessive allele are classified as 
either having MUTYH-associated polyposis or “attenuated” FAP92, which is a term 
that can also be applied to less severe cases of FAP with less damaging mutations 
which only lead to between 10-99 colonic adenoma polyps. 
There are other rarer Mendelian diseases with incidences of between 1/30,000 to 
1/200,000 in the population which predispose to CRC to a lesser extent than Lynch 
Syndrome or FAP. Peutz-Jeghers syndrome and Cowden syndrome are mediated 
by disruptive mutations to the tumour suppressor genes STK11/LKB1 and PTEN 
respectively, both of which play roles in moderating the AKT-PI3K signal 
transduction pathway93,94. Juvenile polyposis is caused by mutations in either 
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SMAD4 or BMPR1A, both of which contribute to the TGF-beta signalling pathway, 
and SMAD4 also plays a role in tempering Wnt signalling95. 
1.1.7 Common risk variants predispose to CRC 
Outside of these inherited syndromes, CRC is a complex trait which has both 
environmental and genetic components. GWAS studies have identified 79 loci 
significantly associated with increased risk of developing CRC in European 
cohorts96, though each individual locus is relatively common and typically confers a 
low risk. The TGFβR1*6Ala mutation may be present in up to 14% of the Caucasian 
population and carries an odds ratio of 1.20 for CRC risk97. The SNP rs5934683 
upstream of the SHROOM2 gene on the X chromosome at Xp22.2 has an allele 
frequency of 0.36 and an odds ratio of 1.07. This gene acts as a tumour suppressor 
which contributes to the control of cell motility, and the risk allele is an eQTL which 
reduces SHROOM2 expression in the colonic mucosa98. 
1.1.8 Environmental risk factors and gene-environment 
interactions 
There are multiple environmental risk factors which are proposed to modulate the 
likelihood of individuals to develop CRC during the course of their lifetime, some of 
which are modifiable. A meta-analysis of 106 observational studies concluded a 
relative risk of 1.25 (95% CI, 1.14-1.37) for mortality from colorectal cancer per 
person year for ever-smokers vs never-smokers99. A meta-analysis of 7 studies of 
long-term alcohol consumption showed a positive linear dose-response with CRC 
incidence, with a relative risk of 1.49 (95% CI: 1.27, 1.74) between the lowest and 
highest intake categories100. 
Red meat consumption is proposed to increase the risk of colorectal cancer due to 
the production of carcinogenic N-nitroso compounds and aldehydes during the 
digestion of iron-rich haem, and from the nitrite composition that preserved or 
processed meats often contain101. Nevertheless, the overall relative risk increase 
between the highest and lowest red meat consumption from meta-analyses was 
only 1.11 (95% CI: 1.03–1.19), and there was significant heterogeneity in the 
association between populations and demographics102. Conversely, dietary fibre is 
hypothesised to reduce CRC risk, theoretically by diluting the concentration of any 
carcinogenic metabolites in the lumen and through the release of short-chain-fatty-
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acids upon its digestion by gut microflora which reduce intestinal pH and have anti-
inflammatory properties103,104. 
The caveats with all observational and retrospective studies is they may be subject 
to recall bias by the participants, and the possibility of confounding interactions and 
co-associations between many factors, for instance diet, obesity and exercise 
combined. Obesity prior to CRC diagnosis has been associated with poorer survival 
prospects105, and a multiethinic prospective study of 982 individuals found a history 
of exercise for >1 hour per week associated with a decreased odds ratio for the 
occurrence of adenomatous polyps of 0.67 (95% CI 0.40 - 0.90)106.  
In a 9.5 year follow up study of a >5,000 strong German cohort aged between 50-74 
years at baseline, there was a significant association between circulating 25-hydroxy 
vitamin D level (25-OHD) and cancer mortality between deficient vs sufficient 
individuals107. In a prospective Scottish cohort of 1,598 patients, it was found that 
postoperative 25-OHD level was associated with survival outcome (hazard ratio 
0.68, 95% CI 0.50-0.90) for patients with stage I-III CRC when comparing individuals 
from the upper and lower vitamin D tertiles108. 
Gene x Environment interactions, whereby the magnitude of effect of exposure to a 
particular modifier is influenced by genotype of the individual at a particular locus, 
contribute to the incidence of almost all complex traits, including CRC. The same 
study which observed an association between postoperative vitamin D levels and 
CRC survival was also able to model a statistically significant (P=0.008) interaction 
between CRC mortality and a combination term of the rs11568820 variant of the 
vitamin D receptor gene and circulating vitamin D level108; however a follow up 
Mendelian Randomisation study did not find a statistically significant association 
between 25-OHD score and CRC risk (individual-level OR 1.03, CI 0.51-2.07)109. 
Gene x environment interaction associations with CRC risk have also been 
hypothesized between smoking exposure and variants of the NAT2 gene 
responsible for detoxifying carcinogenic aromatic amines110, and between the 
protective effect conferred by NSAID usage and variants of the glutathione 
transferase enzyme MGST1 which is involved in production of inflammation-
mediating prostaglandin fatty acids111,112  
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1.1.9 Contribution of inflammation, immunity and the 
microbiome 
There are numerous links between inflammation and CRC. It is suggested that 
localised damage of mucosa in conditions such as ulcerative colitis may present the 
opportunity for mutated clonal cells to expand during the epithelial proliferation 
necessary to repair and initiate new crypts12. Or, signals from an inflammatory 
microenvironment such as cytokines could promote de-differentiation of non-stem 
cells41. Coupled with the fact that inflammatory cells can release increased levels of 
reactive oxygen species which readily form DNA adducts, cells with somatic 
mutations which de-differentiate could lead to the generation of cancer stem cells - 
as would be proposed by the “top-down” hypothesis of tumour initiation113. 1-2% of 
CRC cases are attributed as a direct consequence of inflammatory bowel disease, 
and 15% of all deaths of IBD sufferers is as a consequence of CRC with risk of 
developing the disease increasing 0.5-1% yearly following diagnosis114. A meta-
analysis of 60,122 patients with Crohn’s disease found that affected individuals had 
a relative risk of CRC 28.4 times that of the baseline population (95% C.I. 14.46-
55.66)115. Whilst it could be that individuals independently co-inherit predisposition to 
both IBD and CRC, inflammation may be culpable for CRC predisposition because it 
has been observed that long-term administration of non-steroidal anti-inflammatory 
drugs can have a protective effect in reducing incidence of CRC. One meta-analysis 
of 25,570 patients receiving a daily dose of aspirin for ≥5 years (originally for the 
intention of preventing vascular events) had their odds ratio of CRC reduced to 0.79 
(95% C.I. 0·68–0·92)116. A retrospective study of 1,594 IBD patients similarly 
proposed that the anti-inflammatory mesalamine may have a protective effect 
against development of CRC in this population117. Although the nature of the 
protective mechanism is as yet unconfirmed, there are theories under active 
investigation that the inhibition of mTOR signalling by such drugs could be the 
link118,119. 
The microbiome is increasingly being implicated in initiation and progression of 
cancer, and associations have been found between CRC and presence of certain 
bacterial populations within the intestine, where 99% of the microorganisms that 
humans host are located120. There may be an additional contribution of diet which is 
either receptive or unfavourable to commensal or pathogenic microorganisms. 
Infection with Helicobacter pylori has been found to be associated with colorectal 
neoplasia and cancer121, presumably due to their secretion of cyctotoxin-associated 
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gene a (CagA) into host luminal cells, which has inflammatory and carcinogenic 
properties122. The presence of Fusobacterium species in colorectal carcinoma tissue 
associates with a poorer prognosis123, which could be as a result of the increased 
expression of growth-promoting interleukin 17 and TNFα which are produced by the 
gut immune cells in their presence124. Certain distinct microbiomes have been 
detected in individuals with different consensus molecular subtypes of colorectal 
cancer, with the CMS1 subtype being the most drastically altered compared to other 
subtypes with individuals having larger relative populations of certain Fusobacterium 
and Porphyromonas species125. The link between the CMS1 phenotype and the 
microbiome could be because one of the primary fermentation products of gut 
bacteria are short chain fatty acids such as butyrate126, which have been shown to 
contribute to regulation of cytokines in colonic macrophages by altering the activity 
of histone deacetylases127 - similar to the epigenetic dysregulation that is a hallmark 
of CMS1 tumours. 
 
1.1.10 Heritability and missing heritability 
Multiple estimates for the heritability of CRC have been made 
In 2000, Lichtenstein et al. estimated the relative contribution of heritable and 
environmental factors to incidence of sporadic cancers using a cohort of 44,788 
monozygotic and dizygotic twins from Sweden, Denmark and Finland128. Using the 
concordance of incidence of CRC in genetically identical monozygotic twins or 
dizygotic twins (assumed to be 50% genetically related), structural equation 
modelling was used to fit a model to estimate the contribution of narrow sense 
heritability, shared environmental effects (e.g. childhood diet/exposure to second 
hand smoke) and non-shared environmental effects (which captures any stochastic 
incidence of oncogenic mutations) to risk of developing CRC. This study estimated 
the heritability of CRC to be 35%, however there is a large 95% confidence interval 
attached to this ranging from 10% to 48%. The range is likely large because of the 
small number of twins included in the study; there were 1,262 twins discordant for 
CRC and 62 concordant. The same model estimated shared environmental factors 
to contribute 5% (95% C.I. 0.00-2.3%) and non-shared environmental factors to 
contribute 60% (95% C.I. 52-70%). This model indicates that environmental factors 
are the major contributor to colorectal cancer risk, with a smaller yet significant 
genetic component. Although there is a higher incidence of CRC in males than in 
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females, this study found no difference in genetic heritability between genders. 
Cohorts were also split by age into those developing CRC at younger or older than 
75 years (35% of CRC cases occurred in twins before the age of 63). Heritability 
explained a larger proportion of variance in incidence of CRC in the younger cohort, 
likely due to an increased probability of sporadic mutations causing cancer in older 
twins. This study made a number of assumptions including: random mating between 
parents, identical environments, susceptibility to cancer following an underlying 
normal distribution, dizygotic twins sharing exactly 50% of their alleles, and no 
interaction between genetic and environmental components contributing to risk of 
CRC. Any environmental contribution identified in this study may also be population 
specific, being based on only Nordic cohorts. 
The same group carried out another study in 2002 making use of the entirety of the 
Swedish Family-Cancer Database to leverage relatedness information for all 
possible pairs of relations, not just twins129. They assumed an underlying normal 
distribution of liability to each cancer type, with liability being contributed to from 
multiple different sources: additive genetic factors, shared living environment, 
shared childhood environment and non-shared environmental factors (which 
includes sporadic somatic mutations). They estimated the proportion of heritability of 
each cancer attributable to additive genetic factors based on tetrachoric correlations 
of incidence between different relations who shared different proportions of different 
sources of liability. From this structural equation modelling they estimated the 
additive genetic heritability of CRC to be 13% (95% C.I. 12% to 18%). Given the 
differences between the environment shared between siblings or between parent-
offspring pairs, this study was now able to partition shared-environment into two 
sub-categories (compared to the single category from the group’s previous 2000 
study129), one being shared childhood environment. This shared childhood 
environment was calculated to contribute 6% (95% C.I. 5% to 7%) of the heritability 
of CRC (it was more important in other cancers such as Stomach and Cervix in situ, 
both where it contributed 13%). Regular shared environment, including that shared 
between generations such as in parent-offspring pairs, contributed 12% (95% C.I. 
11% to 13%) to CRC heritability. The single largest factor contributing to CRC 
liability was still non-environmental effects incorporating stochastic somatic 
mutations at 69% (95% C.I. 68% to 70%).  This study improved upon the group’s 
previous iteration because it was able to use a much larger sample size and 
deconvolute shared environmental effects into two distinct compartments. 
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Limitations of this study are that it likely suffers from population-specific biases 
having only used data from Swedish individuals. 
Jiao et al. took a different approach in their 2014 study. Instead of using explicit 
family relationships, they simply analysed genotypes for 8,025 cases and 10,814 
controls from SNP arrays and calculated their genetic similarity based on the 
observed variants. Assuming high-quality genotyping, this technique should be more 
accurate than relying on self-reported family relationships, which assume 
relatedness between siblings to be 0.5 when there could be much variability around 
this depending on meiotic recombination, and which also may suffer from occasional 
errors of incorrectly attributed parentage. Using a restricted maximum likelihood, 
they estimated the heritability of CRC to be 7.42%, only 0.65% of which was 
explained by variants within 250Kbp of the 31 known associated GWAS loci at the 
time130. They estimated a Genotype x Environment contribution of smoking to 
account for 6.94% of the variance in heritability of CRC, however a limitation of their 
study was that they only had relatively sparse genotyping data from 550K and 730K 
CHIPs, with a maximum of 620K with MAF > 0.01. 
Muñoz et al. assessed CRC heritability from two separate cohorts of UKBioBank 
individuals in their 2016 study. They first utilised 1.56M records of self-reported 
family histories of CRC, and heritability was estimated using either a simple family-
based model or structural equation modelling which took into account shared family 
environments. The second was genotypes from 525K SNP arrays for 114,000 
unrelated individuals. Their estimates for genetic heritability of CRC was 26% (CI 
24%-28%) from family-based models, 24% (CI 21%-26%) from SEM and 12% (CI 
0%-28%) from the SNPs131. This highlights that shared familial environment likely 
explains a portion of predisposition to CRC, and that SNP arrays fail to 
comprehensively capture 100% of the genetic variation responsible for 
predisposition.  
Sources of Missing Heritability 
There may be missing heritability from these estimates due to SNP-arrays used for 
GWAS studies not capturing structural variants, copy number mutations, indels or 
epigenetic modifications. The estimates reported in these studies only represent 
narrow-sense heritability not broad-sense, and not all Gene x Environment or Gene 
x Gene interactions would be captured in these models. 
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Corradin et al. propose another source of potential missing heritability: variants 
which fall outside of the LD blocks of GWAS SNPs, but through which the 3D 
architecture of the genome are brought into proximity with GWAS SNPs and interact 
with them132. They find that the genotypes of these proximal variants can influence 
the magnitude of clinical disease risk ascribable to GWAS SNPs, as well as 
modulating expression of transcripts relevant to the disease condition. 
 
1.2 Central Dogma: DNA - RNA - Protein 
1.2.1 Structure of DNA 
Deoxyribonucleic acid stores genetic information in the nucleus of all eukaryotic 
species using the bases adenine (A), cytosine (C), guanine (G) and thymine (T). 
The human genome has an average GC content of 46.1%, though it ranges 
between 35 to 60% with a bias for greater GC content in genes and regulatory 
regions133. Genes are the basic unit of genetic storage which encode the order in 
which amino acids should be assembled if the gene is destined to produce a 
polypeptide. The portions of gene sequence which code for amino acids are termed 
exons, and in eukaryotic genomes they are interspersed by larger tracts of non-
coding sequence called introns. Introns are identified by a GU dinucleotide at their 5’ 
end, and an AG at their 3’ end. There is also a “branchpoint sequence” (BPS) 
located within the intron, usually towards the 3’ end, which mediates binding of key 
components of the spliceosome, and following this there is a polypyrimidine tract of 
up to 50bp which aids in spliceosome recognition of the BPS134(Figure 1.4). Introns 
are excised co-transcriptionally from nascent mRNA molecules as they are 
produced by RNA Pol II135, and they allow for greater flexibility of gene expression 
by facilitating the production of alternative isoforms from the same original gene 
sequence. 
 
Figure 1.4 Sequences defining splice sites of an intron. From Biologydictionary.net136. 
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Promoters and enhancers 
Promoters are ~100-200bp sequences located immediately upstream of genes 
which have affinity for and recruit transcription factors (TFs), potentially aided in their 
binding by co-factors which do not contact the DNA directly137. TFs aid recruitment 
of members of the basal transcription machinery, including the RNA polymerase 
complexes, and mediate the accurate initiation of transcription at the appropriate 
transcription start site (TSS)138. Enhancer sequences often lie distal to promoters up 
or downstream of the genes they control, and as far as >1Mbp in the case of the 
SSH gene and its ZRS enhancer element which controls limb bud formation during 
development139. Enhancer sequences also have affinity for TFs, and provide extra 
impetus for gene expression by recruiting activator proteins, bringing the 
transcription machinery into close proximity with the promoter region, and 
stimulating chromatin remodelling to keep DNA open and accessible140. There can 
be multiple different TSSs for a given gene141, and the spatiotemporal control of 
which site is used to what degree in different tissues and developmental stages is 
determined by the cell-type-specific expression of transcription factors and the 
chromatin accessibility of necessary enhancer sequences142. Clusters of enhancer 
elements that interact physically have been termed “super-enhancers”, and can play 
a role in activating genes which are key to defining the identity of a particular cell 
type143. They are regularly bound by TFs that constitute the culmination of a cell 
signalling pathway, and they have been found to harbour higher densities of non-
coding disease associated variants than expected given their raw sequence content 
(2.4x enrichment, based on a survey of 5,303 SNPs identified from 1,675 GWAS 
studies for a variety of traits)144, highlighting their importance for healthy tissue 
development and homeostasis. 
RNA polymerase 
The RNA polymerase II complex is responsible for the majority of transcription of 
active genes in eukaryotic cells145. The 550kDa complex is assembled from a 
minimum of 12 separate proteins, including a pre-initiation complex of transcription 
factors which are responsible for unwinding the DNA helix, the stabilising mediator 
complex, and RPB1 which performs the main catalytic function of polymerising RNA 
bases according to the template DNA strand146. RPB1 contains repeats of a highly 
conserved heptad of amino acids at its C-terminus, which become phosphorylated 
on serines 2 and 5 in order to activate transcription147. The complex has an in-built 
proofreading capability to cleave-out mis-incorporated nucleotides, which achieves 
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an error rate of approximately 1 in 1x106 bases148. The elongation rate of the RNA 
Pol II complex ranges between 1 and 6 kbp per minute, with its processivity being 
dependent on chromatin structure and local epigenetic modifications149. 
1.2.2 The spliceosome and alternative splicing 
Splicing is mediated by the spliceosome, a complex of multiple ribonucleoproteins 
(RNPs), which oversees the necessary two-step process to remove each end of an 
intron from a sequence of pre-mRNA and fuse the ends of the adjacent exons 
together (Figure 1.5). A core of approximately 80 different RNA and protein 
components are conserved between yeast and humans, with up to 175 in total 
contributing to mammalian splicing150, which highlights the increased variety and 
level of regulatory control over splicing exhibited in higher eukaryotes151. The key 
ribonuclear proteins necessary for the function of the spliceosome are named U1, 
U2, U5 and U4/U6 after their uridine-rich RNA components. Each contains a small 
nuclear ribonucleic acid (snRNA - two in the case of U4/U6) which base-pair with 
each other and the nascent mRNA, and with a variable number of associated 
proteins which aid the dynamic conformational changes necessary to produce the 
catalytic active site of the spliceosome152. Unlike the RNA Polymerase II complex, 
which can transcribe an entire transcript after assembling once, the entire 
spliceosome needs to re-assemble to excise each intron of a gene sequence. 
During the process of alternative splicing, the intron-identifying features are 
recognised multiple times by different components of the spliceosome complex to 
ensure accurate splicing and to provide opportunities for fine-tuning of regulation. 
The cleaving of the nascent mRNA backbone is facilitated by a trans-eseterification 
reaction, which itself is independent of ATP. However ATPases and GTPases are 
required to mediate the complex conformational rearrangements that are necessary 
for the spliceosome to transition from one active state to another. These include 
DExD/H-type ATPases/helicases, which have conserved amino acid motifs of Asp-
Glu-any-Asp (DExD) repeats153, and peptidyl-prolyl cis/trans isomerases (PPIases). 
The active site of the spliceosome is constructed from the snRNAs, the mRNA itself, 
and contributions from the U2 complex protein SF3B6 and the helicase 
PRPF8154,155. 
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Figure 1.5 Splicing via “Intron-recognition” mechanism. From Scotti et al. 2016156. 
 
Splicing mechanism 
The intron recognition mechanism is conserved from yeast to humans. The first step 
is identification of the 5’ SS by the U1 snRNP and its ATP-dependent formation of 
hydrogen bonds with the sequence, which is facilitated by the DExD-helicase 
DDX46. The sequence-based interaction is relatively weak by itself, so is stabilised 
by the protein components of the U1 subunit and serine-arginine-rich proteins (SR) 
bound to any nearby exonic splice enhancer sites (ESSs)157. Next, the SF1 protein 
selectively binds to the branchpoint sequence158 and the U2 auxiliary factor (U2AF) 
binds to the polypyrimidine tract. U2AF has a 65kDa and 35kDa domain, the former 
of which interacts with the C-terminal RNA recognition motif of SF1 to mediate their 
coordinated binding with the intron. The 35kDa portion of U2AF simultaneously 
binds to the 3’ SS of the intron. These entities together constitute the spliceosome 
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“E complex”, also known as the “commitment complex”, which signals 
commencement of the splicing process. 
The “A complex” is then formed as the snRNA component of U2 replaces SF1 on 
the branchpoint binding site in an ATP-dependent manner. This demonstrates the 
pattern of the spliceosome requiring multiple different components to recognise the 
same mRNA elements sequentially. The interaction is stabilised by the SF3a and 
SF3b protein complexes of the U2 snRNP, and by the arginine-serine-rich domain of 
the 65kDa U2AF subunit159.  At the same time, the SF3B14 protein subunit of U2 
binds to the final adenosine of the branchpoint site which will take part in the first 
transesterification reaction to excise the 5’ end of the intron160.  
The next stage of the process is the recruitment of the U4/U6 and U5 snRNPs to 
form the “B complex”. The U4/U6 and U5 snRNPs associate as the pre-assembled 
“tri-snRNP” which form in Cajal bodies, microscopically visible membrane-less 
compartments within the nucleus which are possibly stabilised by means of phase 
separation mediated by intrinsically disordered domains of their protein 
constituents161. When recruited, the U5 snRNA component makes contact with 
nucleotides in both the 5’ and 3’ exon, and the U6 snRNA binds to U2162. The B 
complex now contains all of the core snRNPs of the spliceosome, however it is not 
catalytically active. That requires dissociation of U1 and U4 to form the “B* 
complex”, a change of state which requires the DExD helicases DDX23 and 
SNRNP200 under the control of PRPF8 and the GTPase EFTUD2163,164. 
Whilst part of the combined U4/U6 snRNP, the U4 snRNA pair-binds with a highly 
conserved “ACAGAG” motif of the U6 RNA. During the rearrangement from B to B*, 
the U6 motif is freed as U4 is displaced so that it may bind to the 5’ SS and the 
surrounding sequence of the intron165. This forms the “C-complex”, whereby the 
adenosine of the branchpoint sequence is brought into sufficiently close proximity 
with the guanine of the 5’ SS for its 2’ OH to perform nucleophilic attack on the 
phosphodiester bond as part of the first transesterification reaction. This cleaves the 
phosphate backbone at the boundary of the exon and leaves it with a free 3’ OH152. 
Another conformational change then occurs, mediated by DHX38 and DHX8162, 
which brings the OH in to contact with the first nucleotide after the guanine of the 3’ 
SS and allows for the second transesterification event to take place. This produces 
an mRNA with the ends of the two proximal exons ligated together, and the 
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spliceosome, still bound to the excised intron lariat, now dissociates in order to be 
recycled for future catalysis. SNRNP200 is required again in order to aid the 
disassembly, as is the helicase DHX15166. At this stage of the cycle, the U5 snRNP 
has accumulated protein chaperones which amount to a particle of size 35S. The 
snRNP must dissociate back down to a size of 20S before it can recombine with the 
U4/U6 complex to re-form the tri-snRNP necessary to initiate intron catalysis150. 
For the longer introns found commonly in higher eukaryotes, an alternative 
mechanism termed “exon recognition” can be used to initiate the formation of the 
spliceosome complex167. In this situation, U1 first binds to the 5’ SS downstream of 
the exon in question, whilst U2 and U2AF bind to the branchpoint sequence and the 
polypyrimidine tract at the 3’ end of the intron upstream of the exon. SR proteins 
binding to exonic splice enhancer sequences within the exon mediate cross-exon 
associations between these two subunits150. There subsequently occurs a 
conformational rearrangement that is not yet characterised, but involves the 
transition from the cross-exon, A-like complex to the canonical cross-intron B 
complex, from which intron canonical removal can proceed168. RBM5 is a regulatory 
protein which exploits this process to inhibit the apoptotic signalling protein FAS, 
because it blocks transition from a cross-exon to cross-intron state and so prevents 
the inclusion of the gene’s exon 6 which makes the protein membrane soluble and 
so able to promote programmed cell death169. 
Determinants of splicing 
It is clear that many different mRNA sequences have the ability to influence the 
decision to excise an intron, as do the relative expression levels of a multitude of 
accessory proteins and transcription factors. Splicing of introns does not simply 
occur in the order that introns are transcribed - otherwise the facilitation of 
alternative splicing by competition between splice sites would not be feasible. 
Introns of the FGA gene were found to be preferentially spliced in the order: intron 3, 
intron 2, intron 4 and intron 1, and mutations altering the specificity of these splice 
sites or introducing cryptic splice boundaries can lead to a lack of circulating 
fibrinogen and the Mendelian disorder congenital afibrinogenemia170. 
Introns whose splice site recognition sequences have the greatest affinity for the U1 
and U2AF complexes which initiate the splicing process are those most efficiently 
excised. However the splicing code is degenerate in higher eukaryotes151, therefore 
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other additional signals influence the likelihood of introns to be removed. Exonic 
splicing enhancer (ESE) and silencer (ESS) sequences bind serine-rich SR proteins 
and heterogenous nuclear RNPs proteins respectively171, and in concert with similar 
positively and negatively influential intronic sequences (ISEs and ISSs) play a 
significant role in determining the tissue specific patterns of intron excision (Figure 
1.6)172. The expression of different splicing-associated factors can also influence 
patterns of alternative splicing, e.g. PUF60 has homologous binding sites to 
U2AF65, but plays a more important role in the recognition of introns with weaker 3’ 
splice sites173. 
 
Figure 1.6 Splicing regulatory sequences. From Scotti et al. 2016156. 
Secondary structures of mRNA, such as hairpin-loops and G-quadruplexes, may 
also play a role in regulating the activity of the spliceosome, by obscuring 
spliceosome recognition elements or by bringing the ends of the intron into closer 
proximity with the catalytic centres174. There exists a number of “class II” introns in 
the human genome which are able to self-catalyse their own excision, using the 
same chemistry of transesterification as the matured spliceosome does. They 
represent ancient sequences which predate the spliceosome and are likely from 
where its component snRNA sequences originally evolved175. 
The use of different promoters can also influence downstream splicing decisions. 
This effect is not mediated simply by the strength of the promoter, but by influences 
of the promoter on either elongation rate of RNA Pol II, or on the particular set of 
splicing factors recruited to the Pol II C-terminal domain176. Using the in vivo reporter 
system of a minigene containing exon 33 of human fibronectin, small molecule 
drugs which inhibit elongation rate of Pol II promote more inclusion of the exon177, as 
do Pol II mutants with slower processivity178. This suggests that a slower elongation 
rate of Pol II allows more time for recognition of relatively weaker splice sites 
through assembly of spliceosomal components before stronger splice sites are 
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transcribed and become available to compete for their binding. Converse cases 
have also been observed, for instance slower Pol II elongation can allow more time 
for binding of the negative regulator of splicing ERT-3, which competes with U2AF65 
at the polypyrimidine tract, leading to increased skipping of CFTR exon 9179. 
Epigenetics has also recently been demonstrated to play a role in influencing 
alternative splicing, both by the architecture of chromatin compaction and by means 
of specific post-translational modifications of histones. The observation has been 
made that the median length of exons (137bp) is uncannily similar to the length of 
DNA bound by a single nucleosome (147bp)152, and that introns have a sparser 
nucleosome content than exons180. It has been hypothesised that introns evolved 
from insertions of transposable elements, given that the sequences most amenable 
to these intercalations are the linker regions in between nucleosomes181. The 
occupancy of exons by nucleosomes alters the transcription kinetics of RNA Pol II, 
as it must pause and wait for the DNA to transiently dissociate from histones before 
proceeding182. By slowing down the rate of transcription, there is increased 
opportunity for the proper recognition of exon-delineating sequences and so 
increased likelihood of intron excision177. 
A further mechanism of epigenetic influence may be via the recruitment of specific 
splicing factors. H3K4me3 is enriched at the 5’ ends of genes, and has been shown 
to assist in recruitment of early-assembling members of the spliceosome complex, 
such as the U2 snRNP, through interactions with the chromodomain helicase 
binding protein CDH1183. H3K36me3 is a histone modification which is most 
commonly deposited at nucleosomes colocalised with exons184, and has been 
shown to recruit the splicing silencer PTBP1 (polypyrimidine tract binding protein 1) 
by means of the adaptor protein MRG15, which masks spliceosome recognition 
sequences and so can promote skipping of the proximal exon185. The chromatin-
associated protein PSIP1 has also been shown to associate with H3K36me3, and to 
increase the localisation of the splicing factor SRSF1 to alternatively spliced 
exons186. In the same way that epigenetic profiles influence tissue-specific gene 
expression, they likely also play a part in orchestrating particular patterns of 
splicing187. 
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1.2.3 mRNA maturation  
In addition to splicing, there are further maturation processes which nascent mRNA 
must go through before exiting the nucleus and entering the cytoplasm. The 5’ end 
of the mRNA molecule is “capped” by the addition of an extra guanosine through a 
non-standard 5’ to 5’ phosphodiester bond, which is then methylated at the 7-
nitrogen188. The cap differentiates mRNAs destined for translation into protein from 
nucleus-resident RNAs, such as the spliceosome’s snRNAs, by facilitating export to 
the cytoplasm through nuclear pores and accurate entry of the mRNA into the 
ribosomal translation machinery189. 
The 3’ end of any transcripts produced by RNA Pol II (except for a specific set of 
histone-coding transcripts which are expressed during the replicative S-Phase of the 
cell cycle) undergo cleavage by the CPSF endonuclease complex, which is directed 
by polyadenylation recognition motifs that are generally A and U rich190. Multiple 
adenosine mono-phosphates are then added to the 3’ cleaved end by poly A 
polymerase (PAP), which creates a “poly-A tail”191. This is a necessary requirement 
for mature mRNA to be exported from the nucleus, and once in the cytoplasm 
protects the transcript from premature degradation by endogenous 
exoribonucleases192. Up to 70% of eukaryotic transcripts have multiple possible 
polyadenylation sites which can produce 3’ untranslated regions of different lengths 
and sequence contents, and some alternative sites are located prior to certain 
exons, meaning that cleavage can shorten the gene sequences and lead to loss of 
coding regions in a manner similar to that of alternative splicing193. Ribosomal and 
transfer RNAs are synthesised by RNA Pol I and RNA Pol III respectively and do not 
possess poly-A tails194,195. 
The 5’ and 3’ UTRs (untranslated regions) of transcripts can contribute to the control 
of gene expression in a variety of ways. The 5’ region is key for efficient recruitment 
of the mRNA to the ribosome, and can influence the choice of start codon through 
affinity for translation initiation factors or by adopting different secondary structures 
which may mask certain start codons and promote the use of different open reading 
frames196. The 3’ UTR can harbour binding sites for miRNAs which induce 
degradation of isoforms via the RISC complex, and so shorten the half-life of 
transcripts in the cytoplasm197. They can also interact via AU-rich elements with 
RNA binding proteins (RBP) which can influence mRNA targeting and localisation198. 
Different alternative 3’ UTRs of the same transcripts produced as a result of 
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alternative cleavage and polyadenylation sites can form different secondary 
structures which could either obscure or present miRNA and RBP binding sites199. 
Classes of alternative splicing events 
All of these mechanisms for differential regulation of splicing and mRNA maturation 
provide the opportunity for great diversity of alternative transcripts to be produced 
from the same gene. There can be exon-skipping events with one or more exons 
included or excluded, and there can be mutually exclusive exons whereby the 
utilisation of one splice site concomitantly influences the inclusion of a different exon 
(Figure 1.7). A well-characterised example of this is exons IIIb and IIIc of the 
fibroblast growth factor receptor, FGFR, which have tissue specific patterns of 
mutually exclusive expression in normal prostate epithelium or mesenchymal stem 
cells185. Individual exons can be extended at their 5’ or 3’ ends by the use of 
alternative splice sites, and similarly the 5’ and 3’ UTRs can be lengthened in either 
direction or alternative UTRs commencing from different points can be used. Usage 
of an alternative first exon can be triggered by the direction of transcription 
machinery to different transcription start sites. If a splice site is mutated or masked 
to such a degree that it is not recognisable at all by the spliceosome, then intron 
retention can occur. Combinations of multiple alterations can arise within the length 
of a single transcript, which are termed “complex events”200. It has been estimated 
that up to 94% of human genes undergo alternative splicing, and that in 86% of 
those events at least one of the isoforms other than the most highly expressed still 
constitutes at least 15% of the total expression, implying that these alternative 
transcripts are unlikely to simply be an artefact of imperfect or noisy splicing201. 
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Figure 1.7 Different possibilities and combinations of alternative splicing events. From 
Ardlie et al. 2015200.  
 
Diseases caused by mis-splicing 
There are well-characterised examples of germline mutations in key splice-site 
recognition sequences causing severe Mendelian disorders, which highlights the 
importance of expression of the correct transcript in the correct tissue at the 
appropriate time. There are very few mutations found in the snRNA components of 
the snRNP complexes however, and such mutations are likely embryonic lethal156. 
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A mutation in an alternative 3’ splice site 19bp upstream of exon 2 of the β-globin 
gene results in a transcript with a premature stop codon and causes β+-
thalassaemia202. Duchenne and Becker Muscular Dystrophy can be caused by 
skipping of exons 45-55, or by creation of a novel splice donor and acceptor sites in 
the DMD gene203. A mutation which creates a novel 5’ splice site recognisable by 
the U1 snRNP in exon 7 of the PINK1 gene has been shown to cause early-onset 
Parkinson’s disease from analysis of 31 members of a Spanish family with a 
historical pedigree of the condition204. Multiple disorders of different pathologies can 
arise as a result of various mutations perturbing different aspects of splicing of the 
LMNA gene. In healthy individuals, LMNA encodes two separate nuclear lamin 
peptides from alternative splicing of the same primary transcript, which both serve to 
maintain nucleus structure. Mutations at the 3’ splice site of exon 4 of LMNA lead to 
extension of the exon by 9 nucleotides, and the addition of the resulting 3 amino 
acids to the resultant protein leads to dilated cardiomyopathy, in which there is 
suboptimal development of the heart’s ventricles205. Intron retention of either intron 8 
or 9 of LMNA can lead to type 2 lipodystrophy or limb girdle muscular dystrophy 
respectively, both of which are caused by the resulting aberrantly spliced transcripts 
possessing premature stop codons and being degraded by the Nonsense Mediated 
Decay pathway (NMD)206,207. The premature ageing disease Hutchinson-Gilford 
progeria syndrome can be caused by introduction of a cryptic 5’ splice site via 
mutation within exon 11 of the LMNA gene, which results in a 150bp deletion as the 




1.3.1 Introduction to GWAS theory and methodology 
Genome wide association studies (GWAS) allow for hypothesis-free identification of 
variants which are significantly associated with disease phenotypes. They require 
the recruitment of large numbers of diseased and non-diseased individuals for 
genetic profiling209. GWAS is usually performed with genotypes derived from SNP-
arrays. This limits the scope of the genome which can be surveiled; however 
imputation can be used to extrapolate the presence of some variants not covered by 
arrays based on external databases of human haplotypes such as the 1000 
Genomes cohorts210. Summary statistics from multiple individual studies can be 
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combined in a meta-analysis using fixed-effects or random-effects models, 
depending on assumed heterogeneity of the samples. Whilst studies of family 
lineages with strong pedigrees of certain diseases are usually the most fruitful 
resource for discovering rare variants with high effect sizes, GWAS provides the 
ability to identify larger numbers of more common yet more moderate effect size 
variants (Figure 1.8)211. 
 
 
Figure 1.8 Variants amenable to discovery by GWAS as a function of frequency and 
effect size. From Manolio et al. 2009211. 
 
Linkage Disequilibrium 
Unequal rates of reassortment of genotypes during meiosis in germline cells leads 
to certain regions of the genome being co-inherited more frequently than would be 
expected by chance. Variants located in such regions are said to have high linkage 
disequilibrium (LD) with each other212. LD can be quantified by the D’ value, which is 
derived from the expected probabilities of observing each haplotype combination of 
alleles given the individual allele frequencies observed in the population. D’ = 0 
when two SNPs are completely independent or in perfect Hardy-Weinberg 
equilibrium, and values of +1 or -1 mean that there is complete disequilibrium when 
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one of the four possible combinations of haplotypes between two SNPs is never 
observed. LD is commonly reported as r2, which is the square of the Pearson 
correlation between two haplotypes, calculated by  
𝑟𝑟 =
𝐷𝐷
�𝑝𝑝1 ∗ 𝑝𝑝2 ∗ 𝑞𝑞1 ∗ 𝑞𝑞2
 
where p and q are the reference and alternative allele frequencies respectively at 
each of two loci, denoted by 1 and 2213. When using a chi-squared test to assess the 
deviation of haplotype frequencies from their expected values given the individual 
allele frequencies, r2 possesses the convenient property that 𝜒𝜒2 = 𝑟𝑟2 ∗ 𝑁𝑁, where 𝑁𝑁 is 
the number of chromosomes. Two variants with an r2 of greater than or equal to 0.8 
are generally considered to be in strong linkage disequilibrium with each other96. 
Most SNPs identified by GWAS, especially when using SNP arrays, are likely to not 
be the causal variant, but instead tag the region of linkage disequilibrium in which 
the true causal SNP lies214.  
Genomic characteristics of GWAS-linked loci 
Up to 90% of SNPs which have been linked to complex traits via GWAS are located 
in non-coding regions215–217. It is theorised that such variants affect predisposition to 
disease by modulating tissue-specific patterns of gene regulation. Kindt et al. 
assessed the enrichment within 54 genomic feature annotations of 1,909 GWAS-
linked variants and any associated SNPs in high LD, using permutation tests which 
appropriately accounted for intrinsic co-occurrence between certain genomic 
features (e.g. between gene density, evolutionary conservation and chromatin 
organisation). Combining all their observations into a general logistic regression 
model, they found that the top two features which most strongly predicted the 
presence of a GWAS-associated variant were regions of open chromatin and 
whether or not the SNP represented an eQTL214. They also found a modest, yet 
statistically significant enrichment of trait-associated risk SNPs within intronic 
variants, and only a modest enrichment within evolutionarily conserved regions. 
1.3.2 eQTLs 
eQTLs (expression quantitative trait loci) are variants which are associated with a 
change in the expression level of a gene, when appropriate confounding variables 
such as age and gender are controlled for. They can either act in cis, whereby the 
variant is within the same genomic region as the gene whose expression it affects 
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(commonly defined arbitrarily as ±1Mbp), or in trans, meaning that the variant is 
located further away than this distance or on a different chromosome. eQTLs are 
observed to be tissue specific, and dependent on environmental conditions at the 
time of sequencing218. eQTL variants are enriched within regulatory features such as 
transcription factor binding sites at promoters and enhancers, and within regions of 
open chromatin219. Wen et al. identified 6,555 cis-eQTLs from lymphoblastoid cells 
from 420 individuals and found them to be 1.49-fold enriched with the 4% of 
genome-wide SNPs they predicted to affect binding affinities of TFBSs220. eQTLs 
have also been shown to be enriched within DNase Hypersensitive Sites and 
enriched for variants linked to complex-diseases via GWAS219. Dermitzakis et al. 
analysed RNA-seq and WGS from 4 tissues from the TwinsUK cohort221, and found 
that there was a linear association between the likelihood of a lead eQTL SNP being 
a causative variant and inhabiting a region of DNase accessibility219. They also 
developed an algorithm (CaVEMaN), based on non-parametric bootstrapping, to 
identify the most likely causal eQTL SNP for a gene when there were multiple 
significant SNP-to-gene associations. They observed that the candidate causal 
eQTL SNPs identified with this tool were enriched for having more highly significant 
p-values from GWAS associations to 16 disease traits when compared to all 
putative eQTL variants identified in their analysis219. Singh et al. identified 1,312 
eQTLs using array expression from four intestinal tissues of 65 individuals (terminal 
ileum, ascending colon, sigmoid colon, descending colon), of which 11 were tag 
SNPs for GWAS associations with Inflammatory Bowel Disease (of which there 
were 163 identified at time of publication)222. Trans-eQTLs, whereby the associated 
SNP is >1Mb away from the gene in question or is located on a different 
chromosome, can also be identified in humans. It has been estimated that trans-
eQTLs contribute up to 70% of the variance in mRNA expression levels, however 
individual trans-eQTLs tend to be of lower effect-size and more  tissue-specific than 
cis-eQTLs223. 
Even if a disease phenotype can be explained by a germline coding mutation, non-
coding cis-regulatory variants have been shown to significantly influence the 
penetrance of that variant. Castel et al. used individuals from the GTEx consortium 
(which excludes individuals with inherited disorders) to confirm that in the general 
population there is evidence of purifying selection against combinations of alleles 
which would increase the expression of deleterious coding variants. Analysing 
individuals heterozygous for pairs of regulatory SNPa and deleterious coding 
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variants affecting the same gene, they found a small reduction (0.70%) of allelic 
expression of such deleterious coding alleles, but the effect was highly significant 
when compared to combinations of regulatory SNPs with neutral synonymous 
coding variants (P=4.57x10-9)224. They also analysed 615 cancer patients from 
TCGA, and found an enrichment of haplotype combinations which increased the 
expression of tumour suppressor alleles harbouring deleterious mutations (relative 
to a matched set of normal GTEx individuals) or increased the splicing in of exons 
with similarly disadvantageous variants224. The absolute risk of developing breast 
cancer by age 80 is 54% for women harbouring BRCA2 mutations, however this 
increases to 82% if individuals also possess particular polymorphisms in FGFR2 
and TOX3 which augment the risk by trans interactions between the gene 
products225. 
1.3.3 CRC aetiology explained by GWAS 
In addition to the well characterised, high-penetrance germline mutations which 
strongly predispose to CRC, many lower penetrance but higher frequency variants 
have been associated with CRC via GWAS98,226,227. Such studies have served to 
demonstrate that CRC follows the same pattern as other complex traits of owing the 
majority of its heritability to non-coding variants228, and as the sample sizes in the 
studies increase, progressively lower effect-size variants are identified229. A full list 
of associations is available from the NHGRI-EBI (National Human Genome 
Research Institute in collaboration with the European Bioinformatics Institute) 
GWAS Catalog230. The effect size of a variant in predisposing individuals to a 
disease is commonly reported from GWAS studies as an “odds ratio” (OR). OR is 
first calculated by partitioning observed individuals into “exposed” or “not exposed” 
and “healthy” or “diseased”. In the case of a GWAS study, “exposed” relates to an 
individual possessing a particular allele or not. The OR is the ratio of exposed 
diseased individuals (DE) over not exposed diseased individuals (DN), divided by the 





An OR of greater than 1 implies that the presence of an exposure is correlated with 
a disease state, though it is not necessarily an indication of whether the exposure is 
causative. 
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Variants from non-coding regions can be linked to the genes they are most likely to 
influence the regulation of through tissue-specific eQTLs, epigenetic annotations 
(including ATAC-seq) and promoter-capture Hi-C96,231. Gene set enrichment analysis 
of genes linked to CRC predisposition through GWAS has identified pathways well-
known to be implicated in dysregulation of mucosal growth such as the Wnt-β-
catenin pathway (as highlighted by GWAS associations with the CTNNB1, TCF7L2 
and DACT1 loci), and TGF-β (e.g. GREM1, SMAD7, SMAD9, BMP2, BMP4)96,231. 
Known tumour suppressors implicated in CRC progression have been identified, 
including the chromatin remodelling gene TET2 and the CDKN2A and CDKN2B 
cyclin dependent kinase inhibitors located at 9p21.3231. New pathways not 
previously linked to colonic carcinogenesis have also been highlighted by newer, 
higher-powered meta-analyses, including Krüppel-like factors (KLF2, KLF5) which 
promote intestinal stem cell proliferation and endothelial cell blood vessel formation, 
and members of the Hedgehog signalling pathway (BOC, HHIP) which encode a 
Hedgehog co-receptor molecule and inhibitor respectively231. Immune-related 
pathways are another recurrent source of associations, particularly in the MHC 
region of chromosome 6p21.33, with the genes HLA-C and HLA-DRB5, HLA-DRB1 
and HLA-DQA1 all implicated96. 
The regulation of lncRNAs has also been affiliated with CRC predisposition via 
GWAS. Locus 7p13 contains the gene SNHG15 which produces a lncRNA that has 
been shown to bind to the zing-finger domain of SNAI2 and prevent its degradation 
by ubiquitination, which leads to promotion of the epithelial to mesenchymal 
transition in colorectal cancer232. 17p12 harbours a candidate causal variant in 
exon1 of LINC00675, which is usually downregulated in colorectal cancer tissue 
compared to normal mucosa because it functions to suppress cell proliferation by 
modulating Wnt/β-catenin signalling233. The locus 9p21 overlaps a super-enhancer 
located intronically within the antisense lncRNA ANRIL, which is observed to be 
upregulated in CRC compared to matched non-neoplastic tissue, and which leads to 
reduced cell proliferation and rates of lymphatic metastasis when knocked down in 
CRC cell lines and mouse models of the disease respectively234,235. Law et al. 
identified an eQTL for the lncRNA RP11–378A13.196, which inhabits the same locus 
2q35 in which the variant rs992157 has previously been associated with an OR for 
CRC risk of 1.10236. This transcript has not yet been linked to CRC, but it has been 
shown to be in the top 20 most differentially expressed genes between lung 
adenocarcinoma and adjacent non-tumour tissue237. 
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In 2018, a GWAS for CRC risk was carried out which made use of shallow WGS 
(3.8-8.6x) of 1,439 CRC sufferers and 720 controls of European ancestry to 
increase the coverage of rare variants imputable into larger meta-GWAS studies 
(eventually incorporating 125,478 individuals). This led to the identification of the 
first rare variants (MAF < 0.01) implicated in CRC, as well as 39 newly identified 
common variants and re-validation of existing common loci. The rarest variant to be 
significantly associated was rs145364999 (MAF 0.0031), located intronically to 
CHD1 on 5q21.1. Interestingly, the rarer allele is actually protective, with an odds 
ratio of reduced predisposition to CRC of 0.52 (95% CI 0.40–0.68)231, and the 
authors hypothesise that is might mediate its effects by lowering CHD1 expression 
which is required for the NF-κβ signalling necessary in tumour cells whose growth is 
driven by PTEN inactivation238. 
An association at 19q13.33 encompassing the FUT2 gene (fucosyltransferase II) 
could implicate gene-environment interactions with the microbiome in predisposition 
to CRC96. Variations at this locus which cause people to be non-secretors of FUT2 
at the mucosal surface have been associated with reduced diversity of microbial 
populations, due to the resultant lack of modification of cell surface glycans which 
commensal bacteria harness, and have also been linked to Inflammatory Bowel 
Disease which is known to be a significant risk factor for the development of 
CRC239,240. 
In 2009, after the first 10 common variants associated with predisposition had been 
identified, Tenesa et al. constructed a model which predicted that approximately 170 
common SNPs could account for almost all of the genetic variance for CRC risk228. 
The number of loci identified now stands at >100, however views have changed in 
that the tail of the “L-shaped” distribution of predisposition probably extends far 
longer than 170 variants, and will include many trans and epistatic interactions, in 
addition to variants which have variable penetrance depending on environmental 
exposures241.  
1.3.4 Polygenic risk scores 
One goal of GWAS is the identification of multiple genetic loci predisposing to CRC 
for combination into a polygenic risk score (PRS) which can identify patients where 
increased screening efforts should be targeted. The benefit of screening for 
increasing overall survival has already been demonstrated both in the general 
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population and in those at high risk of developing CRC: a meta-analysis by the 
Cochrane Institute of 320,000 participants randomised to either receive screening 
for occult faecal blood or no screening showed a 16% reduction in relative risk of 
mortality from CRC242, whilst a 15 year study of 205 families with a history of Lynch 
Syndrome (including 745 carriers of MLH1 or MSH2 mutations) showed a 
decreased risk of developing CRC with surveillance frequencies of 1-2 years 
compared to 2-3 years243. Huyghe et al. derived a PRS from 95 SNPs independently 
associated with CRC, and modelled the age at which individuals at various quantiles 
along the risk spectrum would benefit from screening. They estimated that >50% of 
males and 10% of females would benefit from beginning screening at earlier than 
age 50, which is the current guideline implemented by the NHS in Scotland231. One 
complication of implementing such strategies is that risk allele frequencies and LD 
structures between true causal and tagging variants vary across populations, 
meaning that PRS scores currently derived from cohorts with mainly European 
ancestry will be less applicable to other populations244. 
However, a recent study of 5,675 individuals diagnosed with CRC in Scotland by the 
CCG Group failed to identify any significant correlations between PRS constructed 
from common variants and clinically relevant endpoints such as overall survival245. 
Incorporating PRS into well-established predictive models of survival including age, 
gender and stage at diagnosis also failed to improve predictions245. This implies that 
the genetic components which influence predisposition may be superseded by 
somatic aberrations which then dictate survival and response to clinical interventions 
once tumours have developed. 
 
1.4 Splice-QTLs 
Whilst half of the GWAS loci identified in a recent meta-GWAS from 2019 did have 
tissue-specific eQTLs for at least one gene in their vicinity96, this leaves open the 
possibility for the remaining 50% to be influenced by a different mechanism of 
regulatory control, such as by splice-QTLs (sQTLs). sQTLs are variants associated 
with a change in the relative abundances of different transcripts expressed from the 
same gene246 (Figure 1.9). They do not necessarily alter the total expression of a 
gene and therefore can occur independently of an eQTL, though some variants may 
have the effect of changing both the total expression and relative abundances of 
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transcripts of a single gene247. Like eQTLs, sQTLs can either act in cis or trans248, 
with cis variants predicted to disrupt sequences defining or aiding the recognition of 
splice sites and trans being attributable to changes in expression or regulation of 
core spliceosome components. 
 
Figure 1.9 Differences between eQTLs and sQTLs 
Left panel shows quantification of an eQTL event whereby the total expression of a gene 
changes in response to a variant. Right panel illustrates an sQTL for a gene expressing 
three different transcripts denoted by orange, green and blue points. As the genotype 
changes, there is a concomitant shift in the relative expression or the orange and the blue 
transcripts, as evidenced by the ratio of total gene expression which they contribute, whilst 
the green transcript remains unchanged. From Monlong et al. 2014247. 
 
1.4.1 Identifying and quantifying sQTLs 
There are a variety of methods for quantifying the phenotype of alternative splicing, 
which is more complex to capture than total gene expression levels. Techniques 
have been developed based on the usage of exons, transcripts or introns. One of 
the earliest studies first calling QTLs from RNA-seq as opposed to microarrays used 
linear regression to correlate the genotypes of SNPs with the expression of 
individual exons249. They termed their discoveries “sQTLs”, but they could more 
accurately be called exon-expression-QTLs (eeQTLs). A limitation of this approach 
is that it wastes power by necessitating many non-independent tests of all individual 
exons, and it doesn’t preclude identifying classic gene-level eQTLs which would 
manifest as eeQTLs for every exon expressed by the gene. 
A contemporaneous study published in the same issue of Nature by Pickrell et al. 
used “percent spliced in” (PSI) to discover sQTLs. They divided the number of reads 
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mapped to each exon by the total number mapped to the gene as a whole in order 
to calculate a ratio of the splicing in of each exon250. This has the advantage of 
controlling for total gene expression, but still requires multiple independent tests for 
every exon. 
Other later studies adopted PSI, but instead of taking each individual exon over the 
total expression for the gene, they defined PSI for each individual exon as the ratio 
of reads providing evidence for its inclusion in relation to those providing evidence of 
its exclusion. This approach was used by the authors of the GLiMMPS package, 
which only used reads spanning exon boundaries as proof of inclusion or 
exclusion251. They employed a general linear mixed model to account for within-
sample uncertainty in PSI as a random effect, and within genotype variability as a 
fixed effect. Jia et al. also used PSI, but incorporated all reads into their estimations 
of exon-usage, not just those falling on exon boundaries252. They adopted a random 
effects meta regression in order to simultaneously model within-sample uncertainty 
of exon-level quantification and between-sample uncertainty of expression in 
relation to genotype (Table 1.1). 
An inherent limitation of individual exon-centric approaches is that they provide little 
information about changes at the level of whole isoforms, and therefore can be more 
challenging to interpret biologically. The first studies to take this approach identified 
transcript-ratio QTLs (trQTLs), whereby they searched for variants associated with 
changes in relative expression of whole transcripts in relation to total gene 
expression253,254. Whilst providing more biologically interpretable results, these 
studies still suffered from the limitation of undertaking multiple non-independent 
tests for each transcript of a gene. 
Therefore multivariate approaches have been adopted more recently to account for 
the interdependence of all isoforms of a gene, in that the ratios of expression of all 
isoforms is constrained to always sum to 1.0. The sQTLseekeR package uses the 
principle of non-parametric multivariate analysis of variance (MANOVA) to assess 
associations between genotypes and transcript expression ratios247. For each 
genotype of a bi-allelic SNP (e.g. AA, AT, TT), each individual is represented as a 
point in multidimensional space with as many axes as there are expressed 
transcripts, where the expression ratio of each transcript provides the coordinate in 
each dimension. The variance of transcript expression for each genotype is 
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quantified via a Hellinger distance255, calculated as the sum of the squared 
differences between each point and the “centroid” - i.e. the point exactly central to 
the points from all individuals of that genotype. A non-parametric test devised by 
Anderson256 based on MANOVA is used to assess whether the variance between 
genotype groups is greater than the variance within them. The magnitude of 
differences between the intra and inter-genotype variability of transcript expression 
ratios produces an F-statistic, which is assigned nominal significance by comparison 
to a null distribution constructed from permutations of individuals between genotype 
groups. Multiple testing correction is then applied via Storey’s q-value to find 
genome-wide significant sQTLs. 
sQTLseekeR also includes a mechanism to control for false positive sQTLs which 
can be caused by “splicing variance quantitative trait loci” (svQTLs). These are 
SNPs which correspond to changes in the variance of expression of a feature257. A 
SNP which increases variance in transcript-level expression has clear potential to 
produce a false positive sQTL - especially if the number of samples corresponding 
to the allele which causes the greatest variance is relatively small. Therefore 
sQTLseekeR also calculates the likelihood of each SNP representing an svQTL and 
discounts such events so that the final list only contains sQTLs where the transcript 
expression ratios change significantly, but the variance of transcript expression 
doesn’t. 
The DRIMSeq package also takes a multivariate approach, and uses the Dirichlet 
multinomial distribution to simultaneously model the expression of all isoforms of a 
gene246. An advantage is that it allows the absolute expression levels of each 
transcript to be taken into account when estimating the uncertainty in relative 
transcript expression ratios. However DRIMSeq has been shown to be more 
conservative than sQTLseekeR in indentifying sQTL events when both sQTLseekeR 
and DRIMSeq were run by the DRIMSeq authors on the same dataset of transcript 
quantification246. Neither sQTLseekeR not DRIMSeq have the ability to apply 
covariates in their model to capture variation in transcript expression ratio in relation 
to potential confounding factors, such as age or gender. 
The limitation of isoform-centric packages, such as sQTLseekeR and DRIMSeq, is 
that they require provision of a known transcriptome build and so can only find 
splicing events involving switching between previously identified isoforms. Altrans is 
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an exon-based algorithm which uses split reads and read pairs from genomic 
alignments to quantify the fraction of reads supporting “exon link coverage” between 
pairs of exons258. Altrans then converts the exon link coverages into the equivalent 
of a PSI phenotype by calculating the fraction of coverage between each pair of 
exons compared to the total coverage of the gene. Altrans defines exon-boundaries 
according to a predefined genome build, however it has the notable ability to 
introduce a degree of novelty by identifying links between exons for which there is 
no previous record of an isoform possessing such a combination of exons. Altrans 
requires a separate QTL-mapping algorithm in order to find associations between 
variants and changes in these exon links. The Altrans authors recommend the 
algorithm FastQTL, which calculates linear regressions between phenotypes and 
genotypes in cis, and is able to account for any covariates supplied in numeric or 
ordinal format259. FastQTL calculates nominal p-values of association by performing 
random permutations of the genotypes associated with each phenotype, which can 
subsequently be corrected for genome-wide multiple testing.  
Leafcutter is another PSI-based tool, though it infers the presence of introns as 
opposed to exon-links. The rationale is that the presence of introns can be captured 
unambiguously in split reads or pairs of reads further separated than would be 
expected given the library’s insert size distribution, whereas inferring the structure of 
an exon which is not entirely spanned by a single read or read pair carries some 
inherent probabilistic uncertainty260. Like Altrans, Leafcutter begins from a bam file 
of genomic alignments, but it allows for additional novelty because it identifies 
putative intron excision events de novo, agnostically of any genome-build using just 
the reads observed in the study. Leafcutter constructs graph-representations of 
splicing events by linking all inferred introns which share at least one intron 
boundary into a network termed an “intron-cluster”. The equivalent of PSI 
phenotypes are then calculated as the ratio of usage of one potential intron 
compared to all other introns belonging to the same cluster. Singleton nodes in the 
graphs (i.e. intron clusters only containing a single intron) are discarded as these 
imply splice sites used constitutively across the study cohort and therefore are not 
informative for sQTL analyses. Once the intronic phenotypes are quantified, 
Leafcutter again requires an additional QTL-mapping algorithm to find associations, 
and FastQTL can be applied in this context also. A limitation of Leafcutter is that it is 
not proficient in identifying alternative usage of 5’ or 3’ UTRs, because these are not 
usually marked by the presence or absence of introns. 
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The two algorithms sQTLseekeR and Leafcutter (along with the QTL associating 
algorithm FastQTL) were chosen to be used in this study as a result of their 
complementary mechanisms (Table 1.1).  
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Montgomery et al. 2010 Variants associated by linear regression with expression levels of 
exons. 
60 CEU LCLs 293 (0.01) 
PSI Pickrell et al. 2010 PSI defined as the fraction of reads mapping to each exon divided 
by all reads mapping to a gene. 
69 YRI LCLs 187 (0.1) 
GLiMMPS Zhao et al. 2013 Uses only the reads spanning exon boundaries which either support 
evidence of inclusion or exclusion of an exon. Applies a general 
linear mixed model accounting for within-sample uncertainty in PSI 
as a random effect, and within genotype variability as a fixed effect. 
41 CEU LCLs 140 (0.1) 
Random effects 
meta-regression 
Jia et al. 2014 Random effects meta-regression which models within-sample 
uncertainty of exon-level quantification, and between-sample 
uncertainty of expression in relation to genotype. 
78 CEU LCLs 447 (0.05) 
Altrans Ongen et al. 2015 Uses linear regression performed by FastQTL to associate SNPs 
with changes in the PSI of exon-junction-coverage based on known 
exon boundaries with potentially novel exon combinations. 
373 EUR LCLs 1,427 (0.01) 
89 YRI LCLs 166 (0.01) 
Leafcutter Li et al. 2018 Uses linear regression performed by FastQTL to associate SNPs 
with changes in the PSI of de novo inferred intron inclusion. 
372 EUR LCLs 5,774 (0.05) 
85 YRI LCLs 1,982 (0.05) 
1,294 (0.01) 
trQTLs Lappalainen et al. 2013 Calculates the transcript expression ratio for each transcript over 
the total gene expression, then runs linear associations between 
each individual transcript and SNP in cis. 
373 EUR LCLs  620 (0.05) 
89 YRI LCLs 83 (0.05) 
Battle et al. 2014 Calculates the transcript expression ratio for each transcript over 
the total gene expression, then runs non-parametric Spearman rank 
922 individuals 
from the DGN 
1,370 (0.05) 
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correlations with SNPs in cis. Cohort 
sQTLseekeR Monlong et al. 2014 Uses non-parametric multivariate analysis of variance (MANOVA) 
to associate SNPs to changes in relative isoform expression. 
91 CEU LCLs 155 (0.05) 
95 FIN LCLs 184 (0.05) 
94 GBR LCLs 175 (0.05) 
93 TSI LCLs 185 (0.05) 
89 YRI LCLs 168 (0.05) 
DRIMSeq Nowicka et al. 2016 Models isoform expression using the Dirichlet-multinomial 
distribution, which allows for the level of expression to be taken into 
account when quantifying uncertainty in expression estimates. 
91 CEU LCLs 3,036 (0.05) 
89 YRI LCLs 1,867 (0.05) 
Table 1.1 Methods for identifying sQTLs. Abbreviations of GEAUVADIS populations: Utah with European ancestry (CEU), Finns (FIN), British 
(GBR),Toscani (TSI) and Yoruba (YRI), CEU+FIN+GBR+TSI (EUR). DGN: Depression Genes and Networks253. LCLs lymphoblastoid cell lines 
 
  43 
 
1.5 Alternative splicing in complex trait 
predisposition and cancer 
1.5.1 sQTLs in complex trait predisposition 
sQTLs have been demonstrated to contribute to predisposition to a number of 
complex traits. 
In their 2016 study, Li et al. used Leafcutter to identify 2,893 sQTLs from 86 YRI 
GEAUVADIS LCLs (note, this is distinct from the 2018 study detailed in Table 1.1). 
Hypothesising that tissue-specific diseases for these white blood cells could include 
inflammatory and autoimmune disorders, they found the sQTL SNPs to be more 
significantly enriched than eQTLs in GWAS variants predisposing to multiple 
sclerosis, and equally as enriched as eQTLs in variants predisposing to rheumatoid 
arthritis261. 
The same group revisited the topic of sQTLs in disease in their 2018 paper, this time 
using 372 CEU LCL samples from GEAUVADIS. They identified 5,774 sQTLs at 
FDR 0.05 and again observed the same pattern of sQTLs being more significantly 
enriched than eQTLs in variants linked to multiple sclerosis by GWAS, and sQTLs 
and eQTLs demonstrating parity of enrichment for rheumatoid arthritis260. The 
authors then used S-PrediXcan262 to perform a transcriptome-wide association study 
(TWAS) between splicing traits and variants associated by GWAS to 40 complex 
traits. Supplementing the genetic information with splicing phenotypes allowed them 
to associate 18 novel genes with rheumatoid arthritis, of which 13 were not able to 
be identified through the use of gene expression phenotypes alone. Across the 40 
traits analysed, inclusion of the splicing phenotypes associated with sQTLs 
increased the number of genes able to be putatively associated with complex traits 
by an average of 2.1-fold over using genotypes alone260. 
Lehmann et al. combined tumour and normal tissue expression from 282 kidney 
renal clear cell carcinoma (KIRC) patients, alongside 458,266 germline variants and 
128 recurrent somatic mutations to call 228 cis and 23 trans sQTLs at FDR 0.05. 
None of the somatic mutations yielded any cis-sQTLs, only trans-effects. They found 
cis-sQTLs from loci which were annotated as being either causative of or in high LD 
with variants from the NHGRI-GWAS catalog associated with a range of cancers. An 
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sQTL in the mitochondrial solute carrier SLC25 originated from a locus linked to 
testicular cancer susceptibility, and an sQTL in the BABAM1 gene has been linked 
by GWAS to oesophageal squamous cell carcinoma predisposition248. None of the 
variants were associated with KIRC predisposition specifically, though this could be 
because at time of publication it had received less attention in terms of large multi-
centre GWAS studies. There were only 6 known loci associated with KIRC at the 
time; the most recent meta-analysis in 2017 using 10,784 cases and 20,406 controls 
has increased the number to 13263. 
Takata et al. analysed RNA-seq from post-mortem dorsolateral prefrontal cortex 
brain tissue of 206 individuals from the CommonMind Consortium. They identified 
1,595 significant sQTL events using the PSI method, taking the fraction of read 
counts supporting each exon’s inclusion against exclusion. They tested for 
enrichment of these sQTLs in SNPs associated with 15 different complex traits from 
the GWAS catalog when compared with a null population of 48,000 non-sQTL SNPs 
with matched minor allele frequencies. Of the three disease traits for which there 
were significant enrichments after Bonferroni multiple testing correction, the greatest 
effect size was in schizophrenia (OR=3.72, P=9.9x105, one-tailed Fisher’s exact 
text), the others being multiple sclerosis (OR=3.71, P=0.036) and inflammatory 
bowel disease (OR=1.43, P=0.0014)264. The magnitude of significance of the 
enrichment for the brain-related disease serves to highlight the tissue-specificity of 
splicing in this organ. 
Raj et al. used Leafcutter to identify sQTLs in 3,006 genes from post-mortem 
dorsolateral prefrontal cortex (DLPFC) samples from 450 subjects with a mean age 
of 88, to investigate the contribution of alternative splicing in the ageing brain to 
Alzheimer’s disease predisposition. The sQTLs they identified from DLPFC were 
more likely to be enriched for SNPs linked to Alzheimer’s via GWAS than other 
types of QTLs including eQTLs, methylation-QTLs and sQTLs identified from 
monocytes265. Their analysis was able to confirm that alternative splicing was the 
likely mechanism behind 3 previously annotated GWAS predisposition loci for the 
PICALM, CLU and PTK2B genes265, whilst other studies had previously implicated 
an increase in splice isoforms including the 2nd exon of CD33 encoding an Ig V-set 
domain with increased Alzheimer’s risk266,267. The authors also performed two 
separate TWASs, one combining expression of 4,746 genes with the germline 
variants, and one using PSI of 15,013 introns alongside SNPs. They identified more 
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genome wide associations using the splicing as opposed to expression phenotypes 
(16 vs 5), of which 8 were associations with novel genes. Performing network 
analysis of protein-protein interactions using the new and known genes involved in 
susceptibility, they found a significant enrichment for the endocytosis and 
autophagy-lysosomal pathways, which makes biological sense given the link 
between Alzheimer’s and dysregulated protein-degradation and trafficking268. This 
demonstrates the benefit of including splicing phenotypes to provide mechanistic 
insights when investigating predisposition to complex traits269. 
1.5.2 Mutations in spliceosome components can represent 
trans-acting driver events in cancer 
Observations of recurrent somatic variants in members of the spliceosome complex 
have led to them being classified as oncogenes and tumour suppressors. Their 
mutation leads to widespread dysregulation of splicing, and trans effects on many 
genes. 
Seiler et al. analysed >10,000 samples from 33 different tumour types from TCGA 
and identified likely driver genes or tumour suppressors using two complementary 
algorithms: MutSigCV270 and a ratiometric approach devised by Vogelstein et al.271, 
whereby oncogenes are defined as genes showing patterns of repeated mutation at 
the same codons, whilst tumour suppressors suffer recurrent loss of function 
mutations along the length of their sequence. The authors detected 119 members 
from a catalog of 404 spliceosome-associated genes as being significantly enriched 
for non-silent mutations, with the most recurrently mutated genes tending to be 
involved in earlier stages of spliceosome assembly - particularly from Complex A 
though to Complex C272. The gene most prolifically affected by hotspot mutations 
was SF3B1, which also showed cancer-type specific patterns of mutation: the 
R625C/H mutation was most common in skin and uveal melanomas, K700E most 
frequent in breast cancer, and E902L was specifically present only in bladder 
cancer272. The disease-specific nature of these mutations implies that the particular 
dysregulations of transcriptional systems caused by each mutation are favourable to 
survival in different tissue microenvironments. The splicing factor SRSF2 possessed 
a recurrent hotspot mutation at proline 95, which has been demonstrated to alter its 
RNA binding kinetics. This alteration causes a trans mis-splicing of the 
methyltransferase EZH2 in haematological malignancies, causing its subsequent 
degradation273. Point mutations of EZH2 itself are common in such blood cancers, 
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however mutation of the SRSF2 proline 95 is observed to be almost entirely 
mutually exclusive with such variants, reinforcing the status of the SRSF2 mutation 
as a driver which can produce a similar phenotype to the EZH2-specific changes272. 
The splicing-associated RNA binding protein RBM10 showed patterns of loss-of-
function mutations consistent with a tumour suppressive role, which was supported 
by in vitro and in vivo experiments where its knockout lead to increased colony 
formation or tumour growth respectively274,275. Whilst mutations in spliceosome 
factors are likely to have wide-ranging effects on the transcriptional landscape which 
aid cancer progression, RBM10 mutation has been specifically shown to cause 
knock-on mis-splicing of the TSC2 tumour suppressor in lung cancer 
adenocarcinoma, which plays a key role in mediating the mTOR pathway in this 
malignancy272, and to cause inclusion of exon 9 of the NUMB gene which ablates its 
role in negative regulation of NOTCH signaling275.  
Whilst this thesis will focus on variants influencing regulatory control of alternative 
splicing in cis, the phenomenon of core spliceosomal components being regularly 
somatically mutated serves the highlight the relevance of splicing regulation and 
perturbation to cancer. 
1.5.3 Aberrant somatic splicing in cancer 
Multiple studies have observed perturbations to splicing in cancer which have been 
implicated in driving progression of the disease 
Supek et al. searched for evidence of synonymous mutations affecting cancer 
progression using whole exome sequencing (WES) from 3,851 cancer samples from 
11 tumour types. They compared rates of synonymous and missense mutations in 
known oncogenes and tumour suppressor genes to non-cancer-related genes 
matched for a variety of molecular characteristics including regional point mutation 
rates, mRNA expression, histone mark occupancy, base composition and replication 
timing. They found that oncogenes contained a 23-30% excess of synonymous 
mutations compared to the matched gene sets (P=3.0x10-6), that the synonymous 
mutations clustered in conserved genic regions similar to patterns of missense 
mutations (P=1.0x10-6), and that they preferentially led to the gain of ESEs and the 
loss of ESSs (P=0.02)276. If an oncogene in a particular sample contained one such 
synonymous mutation, it was then less likely to also contain a driver missense 
mutation, implying that these synonymous mutations can adopt the mantle of driving 
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cancers by perturbing spliceosome recognition sequences. Using RNA-seq from 
2,000 of the samples and a multivariate distance-based metric to assess differences 
in the expression and variance of genes’ constituent exons, the authors estimated 
that approximately 50% of all recurrent synonymous mutations had an effect on the 
spliced content of the oncogenes they inhabited (P=4.0x10-4)277. The authors 
estimated that between 20-50% of all synonymous mutations in driver genes had 
been selected for, making up 6-8% of the total somatic mutations observed in these 
genes. A corollary of their study was that dosage sensitive oncogenes, i.e. those 
which most often undergo copy number amplifications in cancer as opposed to 
SNVs, have an enrichment of somatic mutations in their 3’ UTRs (P=0.03), regions 
which are known to regulate intracellular mRNA levels, thus highlighting a further 
mechanism by which non-coding somatic mutations in regions regulating mRNA 
processing can influence cancer276. 
Puente et al. analysed 452 cases of chronic lymphocytic leukaemia (CLL) and 54 
cases of a precursor disease state, monoclonal B-lymphocytosis (MBL), from the 
ICGC consortium, and identified recurrent non-coding mutations which appeared to 
influence disease progression. They observed recurring non-coding mutations in the 
3’ UTR of NOTCH1 in 13 patients. These alterations created a new splicing acceptor 
site within the 3’UTR, which caused the use of a cryptic donor site within the last 
exon of NOTCH1 and truncated the last 158 coding bases278. The splicing event 
was confirmed by RNA-seq and western blot, and removed a PEST domain which 
usually functions to increase protein stability and so ensure proper activity of 
NOTCH1. Patients with such splice-altering mutations had similar or worse 
prognoses in terms of time-to-first-treatment and overall survival as patients with 
previously identified coding mutations in NOTCH1, demonstrating the efficacy of this 
non-coding alteration to drive disease progression. 
The Lehmann et al. study of KIRC tumour and normal expression identified 16 
sQTLs with >25% effect size for genes which were annotated in COSMIC as being 
involved in cancer progression. Examples included splicing events in the gene 
PMF1 implicated in bladder carcinoma, the tumour necrosis factor-associated 
C1QTNF3, and the gene TMEM176 which was found to express a tumour-specific 
splice isoform and has been previously linked to lymphoma and lung 
carcinoma248,279. 
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Climente-González et al. found that mutations in oncogenes affecting splicing can 
have the same effects on disrupting protein-protein interaction networks as 
missense point-mutations. They observed 76 protein domain families which had 
somatic mutations linked to splicing changes more commonly in driver genes 
possessing mutational hotspots than non-drivers (<2.2e-16, Wilcoxon). Cancer 
drivers were enriched for splicing changes affecting the gain or loss of a functional 
protein domain (OR=1.9, P=2.0e-5), and these changes occurred independently of 
driver point mutations in a significant proportion of samples, indicating they could be 
functioning to promote similar oncogenic processes280. An example is the RAC1B 
isoform of RAC1, which harbours an extra 19 residues downstream of the “switch II” 
domain which impairs its GTPase activity. This isoform has been shown to be 
upregulated in colorectal, breast and lung adenocarcinoma, where it synergises with 
KRAS mutations to concomitantly increase tumour cell proliferation281. 
Intron-retention is a particularly potent alternative splicing mechanism through which 
tumour suppressors can be inactivated in cancer. Jung et al. analysed WES and 
RNA-seq from 1,812 patients of 6 of the most common tumour types from TCGA to 
identify 1,112 somatic mutations which effectively acted as sQTLs, causing either 
intron retention (338), exon skipping (503), creation of a cryptic intronic splice site 
(191) or creation of a cryptic exonic splice site (80)282. To ensure that strictly only 
cis-acting SNVs were identified, the authors excluded 62 cancer samples with 
mutations in genes known to have trans-acting effects on splicing, including SF3B1 
and U2AF1. The intron retention events affected a subset of genes which were 
significantly enriched in four different databases of tumour suppressor genes 
(P≤8.0x10-5), but not enriched in either of two curated lists of oncogenes (P>0.05). 
97% of intron-retention events generated a premature termination codon (PTC), with 
the subsequent mechanism of TSG inactivation likely being nonsense mediated 
decay (NMD) of the resultant mRNA. From analysis of tumour suppressors 
commonly identified in their dataset, including CDH1 and PTEN, the authors 
postulate that intron-retention may act in concert with other mechanisms of tumour 
suppressor silencing, such as loss of heterozygosity or allele-specific promoter 
methylation, when individuals are heterzygous for the SNV causing intron retention. 
TP53 was the gene in which variants causing intron-retention were most commonly 
found, with 252 of 1,812 samples harbouring such a mutation282. This highlights the 
pervasiveness of somatic splicing aberrations being co-opted by cancer to facilitate 
disease progression. 
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A study by Dvinge and Bradley of 805 matched tumour and normal samples from a 
more diverse range of 16 TCGA cancers further highlights the importance of intron-
retention events. They found evidence for significantly increased rates of intron 
retention in tumour compared to normal tissue RNA-seq in all except breast cancer 
(though this could be because of inefficient intron removal in the normal breast 
controls: an increased intron retention was seen in breast normal tissue vs 14 other 
normal tissues, but no significant different was seen between breast cancer and 
other cancers), even in the absence of common spliceosome mutations in 
components such as SF3B1, SRSF2 and U2AF1283. 
Shiraishi et al performed a larger scale analysis of cis-regulatory splicing associated 
variants (SAVs), using 8,976 samples from 31 cancer types with matched 
tumour/normal RNA-seq from TCGA. They used split reads and exon junction-
spanning reads to identify novel intron-exon boundaries and combined them with 
known RefSeq annotation, then used a Bayesian bipartite network (“SAVNet”) to 
infer association between somatic variants and tumour-specific splicing changes at 
these sites. They imposed strict positional constraints of only considering bases 
within -6 or +6 of a known or novel splice site, which allowed them to increase their 
power and sensitivity and so identify 14,438 SAVs, of which 13,414 were SNVs and 
1,024 INDELs284. 49.7% of the variants they identified fell outside the canonical 
donor and acceptor GT and AG dinucleotides, with the next most common positions 
being the bases +3 and +5 relative to known or novel donor sites. A previous study 
by the same group using minigene reporter assays had already demonstrated the 
ability of alternative splicing to be influenced by bases outside of the canonical 
sites285. Variants causing exon-skipping were most commonly found in or near 
exons possessing features associated with exons spliced out via the exon-
recognition, not intron-recognition, spliceosome mechanism, i.e. shorter exon length, 
higher GC content, and longer flanking intron lengths. Impairment of intron 
recognition was slightly more commonly observed through disruption of the 5’ donor 
site than the 3’ acceptor. Novel splice donor sites were created widely throughout 
known exons and introns, whereas novel acceptor sites tended to be generated 
from within the polypyrimidine tract of known introns. 63.3% of the genes frequently 
affected by SAVs (≥10 samples) were tumour suppressors. Contrary to previous 
similar analyses by Jung et al., Shiraishi et al. observed disruption of tumour 
suppressor genes more commonly through exon skipping and alternative splice-site 
generation than though intron retention, though a significant proportion of events 
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(12%) were still due to the latter. Consistent with inactivating tumour suppressors via 
the triggering of NMD, transcripts with intron retention events had significantly lower 
expression when assayed by RNA-seq compared to WT transcripts, though exon 
skipping and alternative splice site usage events did also show reduced expression 
if their splicing changes corresponded to a frameshift. SAVs were also found in a 
number of oncogenes, among them a recurrent event in the exon 14 donor site of 
the hepatocyte growth factor receptor, MET, which resulted in an in-frame exon-
skipping event which has been demonstrated to constitutively activate c-Met in non-
small cell lung cancer284,286. 
These analyses highlight the ability of somatic variations in splicing to aid and drive 
cancer progression. 
1.5.4 Non-coding germline variants influencing splicing can 
predispose to cancer 
Early efforts to assess the mechanisms of non-coding mutations predisposing to 
cancer centred around regulatory control of gene expression. For example, through 
use of ChIP-seq, nucleosome occupancy and chromosome-conformation 
fluorescence imaging, Schödel et al. characterised a non-coding locus on 11q13.3 
predisposing to renal cell carcinoma as being an enhancer of CCND1 expression 
containing a hypoxia-inducible factor (HIF) binding motif287. Similarly, an intronic 
variant within the LMO1 gene has been demonstrated to predispose to 
neuroblastoma by producing a novel cis-acting enhancer for the gene through 
creation of a GATA binding site.288 
However, increases in the read length and depth of RNA-sequencing have led to 
increasing scope for non-coding variants predisposing to cancer to be able to be 
linked to splicing alterations. Stacey et al. identified 4 new loci linked to basal cell 
carcinoma via a GWAS involving 4,572 cases, one of which they ascertained 
caused intron retention from exon 8 to 10 of CASP8. According to RNA-seq, carriers 
of the risk allele had significantly reduced expression of the full-length CASP8 
transcript and concomitantly increased expression of intron 8 retention according to 
a multivariate linear regression (β=-0.65, P=1.7x10-12)289. They replicated their 
findings in RNA-seq from the GTEx project collected from sun-exposed skin 
samples, with intron retention and reduced expression of the canonical transcript 
again significantly correlating with the C risk allele (β=-0.64, P=7.2x10-9). CASP8 is 
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a key signalling mediator in the apoptotic pathway, and variants in this region have 
also been linked to other cancers, including breast and melanoma289. The intron 
retention event likely corresponds to reduction in CASP8 expression via a nonsense 
mediated decay signal in proximity to exon 10, and its loss could render incipient 
cancer cells less likely to be proactively culled. 
Tanha et al. demonstrated that homozygous or heterozygous carriers of the 
germline SNP rs2274407 have a worse 3 year disease free survival of paediatric 
acute lymphoblastic leukaemia (ALL) from a cohort of 145 cases (P=1.9x10-4, 
OR=13.17, 95% CI=2.55-68.11)290. The variant lies in the 3’ acceptor site of exon 8 
of the ABCC4 gene which encodes MRP4 (“multidrug resistance-associated protein 
4”), known to be involved in the efflux of multiple xenobiotic organic anions. The 
SNP causes loss of approximately 300bp of exon 8 through weakening of the 
canonical acceptor site, and may lead to poorer clinical outcome due to reduced 
tolerance to chemotherapy, meaning that drug regimens might be attenuated or 
curtailed early for carriers of the variant before achieving a therapeutic benefit. 
In relation to colorectal cancer specifically, Soukarieh et al. used minigene reporter 
assays to profile the effects of 22 germline mutations in exon 10 of MLH1 associated 
with Lynch syndrome, and found that 17 of them affected splicing either through 
interruption of canonical splice sites, ESEs  or ESSs291. Building on this work, Rhine 
et al. surveilled a further 36 known pathogenic exonic variants across 5 other exons 
of MLH1, and which fell outside of classical splicing-associated sequences (they 
defined these as falling outside of -5 to +6bp in relation to the 5’ SS and -20 to +3 
around the 3’ SS). They found that 11 out of 36 (30.5%) of these variants 
significantly affected splicing, which all fell within just 2 of the exons tested (6/6 in 
exon 8 and 5/7 in exon 15), and that they had significantly greater predicted effects 
on the strength of exonic regulatory elements compared to WT sequences than 
exonic mutations not found to influence splicing (P=0.0280, Mann-Whitney)292. This 
highlights that the number of variants affecting splicing may be underesimated, and 
that synonymous and even nonsynonymous coding variants outwith classically 
defined splice sites may have a previously unappreciated influence on alternative 
splicing regulation. The authors had assumed that the variants would act by 
hindering intial recognition of splicing-related sequences and spliceosome 
assembly, however from an in vitro assay of the complex they discovered that 63% 
of variants functioned by impeding transition from complex A to complex B, and 37% 
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prevented activation of complex B to B*. 
 
1.5.5 Potential therapeutic targeting of aberrant splicing in 
cancers 
Given the role that aberrant splicing plays in cancer, multiple approaches have been 
taken or proposed to therapeutically target the spliceosome and its associated 
processes. 
Cancers driven by overexpression of the c-Myc transcription factor have a hallmark 
of excessive transcriptional activity, with a 1.5-fold increase in absolute intracellular 
RNA levelsl293. This provides a therapeutic window whereby normal cells are able to 
tolerate some degree of spliceosome inhibition, whilst Myc-activated cancer cells 
are operating at near maximum splicing capacity. Then treated with spliceosome 
inhibitors, cancer cells undergo genome-wide intron retention, producing many mis-
spliced transcripts and resulting non-functional polypeptides that must be removed 
by the cell. If the intracellular lysosomes are not able to cope, the cells will perish 
under conditions termed “proteotoxic stress”294. shRNA knockdown of the 
spliceosomal component BUD31 in breast cancer cell lines driven by c-Myc 
significantly impaired proliferation through inhibiting BUD31’s interactions with core 
spliceosomal components of the U2 Complex295. The addition of HER2 or EGFR 
driver constructs to the cell lines did not increase the magnitude of the response, 
implying that the effect is indeed c-Myc-specific. Pladienolide and spliceostatin A, 
small molecule inhibitors of SF3B1 derived from microbial sources, cause increased 
apoptosis in breast and lung cancer cell lines296. The SF3B1 small molecule inhibitor 
Sudemycin D6 has been shown to impair spliceosome function and cause synthetic-
lethality in c-Myc driven cancer cell lines and mammalian models295. 
Khales et al. performed analysis of genome and RNA sequencing of 32 tumour 
types across 8,705 TCGA tumour-normal pairs and found that there was an 
increase in diversity of alternative splicing events of up to 30% in tumour vs normal 
tissue, with an average of 930 “neojunctions” of exon-exon links per tumour not 
observed in any GTEx normal tissue samples297. The authors predicted mis-splicing 
events which would lead to the generation of tumour-neoantigens with MHC-1 
binding potential and so the ability to elicit an immune response, and found an 
average of 1.7 such neojunctions per tumour sample (and 0.6 SNVs per sample 
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predicted to cause neoantigens). Given that a number of the neoantigens were 
recurrent across >100 cancer samples, the authors predict that such analyses could 
be used to generate broadly applicable chimeric antigen receptor T cell (CAR-T) or 
cancer vaccine therapeutics, or they could simply be used to stratify patients by 
those most likely to respond to immunotherapies such as programmed cell death 
checkpoint inhibitors. 
1.6 Hypothesis and aims of thesis 
Colorectal cancer has consistently been demonstrated to have a significant heritable 
component, and early diagnosis and intervention can markedly improve prognosis 
and survival. Common sQTL SNPs with low effect size have been demonstrated to 
significantly contribute to other complex traits including autoimmune and 
neurological diseases. Aberrant somatic splicing caused by both trans-acting 
mutations in core spliceosomal components and cis-acting synonymous and non-
synonymous variants can contribute to the progression of a number of cancers, 
including CRC. Certain high-penetrance germline mutations causing mis-regulation 
or mis-splicing of genes have been demonstrated to contribute to predisposition to a 
rare number of cases of certain cancers, including CRC. 
Therefore this project hypothesises that common germline sQTLs may explain the 
mechanism of action of a significant portion of the non-coding variants predisposing 
to colorectal cancer. This project aims to comprehensively identify sQTLs in colonic 
mucosa samples of a Scottish cohort, the precise tissue of origin of CRC, and to 
characterise the loci involved. 
The first results chapter justifies the choice of RNA quantification platform, and 
includes quality assessments of the data. It also contains an exploration of gender 
differences in gene co-expression in colonic mucosa. 
The second results chapter details the results of sQTL identification via two separate 
and complementary algorithms. It describes the significance and effect size of the 
sQTLs, shows their distribution in relation to their target feature, and explores the 
classes of alternative splicing change that are observed. Thresholds are also 
applied to filter for only the highest confidence and greatest effect-size sQTLs to 
further characterise. 
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The third results chapter assesses the predicted functional impacts of variants linked 
to sQTLs, and uses genome-wide annotations of regulatory features such as DNase 
hypersensitivity and ChIP-sep of histone modifications to characterise the genomic 
regions which sQTLs occupy. The genomic inflation of sQTL SNPs is assessed in 
relation to p-values from a meta-GWAS of CRC predisposition, and examples are 
given of sQTLs for genes associated with CRC predisposition and progression. 
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Chapter 2 Methods and Data Collection 
This chapter details the collection of normal colonic mucosa samples from human 
donors, and their RNA sequencing in two separate batches. There are further 
technical methods contained within each of the subsequent results chapters relating 
to the specific analyses carried out within them. 
2.1 Donor cohorts 
As this project is primarily concerned with predisposition to CRC mediated by 
relatively common, moderate-to-low effect size alleles, no individuals with Mendelian 
disorders strongly predisposing to CRC, e.g. FAP or Lynch Syndrome, were 
included in this study. 
Where normal colonic mucosa was obtained, it was stripped from the underlying 
stromal and muscle layers so that subsequent RNA-seq best represented the 
transcriptome of the specific tissue-of-origin of CRC35. 
2.1.1 SOCCS and COGS cohort (batch 2013152) 
The first batch of normal mucosa samples came from individuals routinely recruited 
to two on-going cohorts designed to study genetic predisposition to CRC. These are 
the Scottish Study of Colorectal Cancer (SOCCS) and the Colorectal Cancer 
Genetic Susceptibility (COGS) study, as described in previous work by Zgaga et 
al.298 and Theodoratou et al.299. The majority of normal mucosa samples obtained 
from these cohorts were extracted during surgery to resect CRC tumours, which 
could have been of the right or left side of the colon. Approximately 3mm2 samples 
were extracted from the same side of the colon as the tumour, but at least 30cm 
away from the tumour site to avoid sample contamination with cancer cells. Whole 
blood samples for genotyping were taken pre or post operatively. 
Ethical and regulatory approval for COGS and SOCCS was obtained from the South 
East Scotland Research Ethics Committee (under project references 11/SS/0109 
and 01/0/05 respectively) and the NHS Lothian Research and Development 
Department (with references 2013/0014 and 2003/W/GEN/05 respectively). All 
participants were provided with detailed information describing the study protocol 
and its aims, and gave informed written consent. Confidential medical and genetic 
information was handled in compliance with UK legislation and tissue samples were 
managed in compliance with the Tissue Act Scotland, 2006. 
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RNA from samples from 96 individuals in the SOCCS and COGS cohorts, extracted 
by Dr Li Yin Ooi as part of her PhD thesis, were sequenced together under the 
identifier of “batch 2013152”47. 
2.1.2 SCOVIDS cohort (batch 10525) 
The second batch of normal mucosa samples were sourced from the Scottish 
Vitamin D Study (SCOVIDS). This study was designed by Dr Peter Vaughan-Shaw 
to investigate relationships between circulating vitamin D levels and gene 
expression in normal colonic mucosa of Scottish individuals. These were mainly non 
CRC-sufferers who were sampled in the outpatient clinic or day surgery wards. 
There were two “arms” to this cohort: one observational in which a single mucosa 
sample was taken simultaneously with a single time point of whole blood, and a 
second interventional arm whereby patients taking vitamin D supplements donated 
normal mucosa and blood samples at multiple timepoints including 0, 6 and 12 
weeks. 
Ethical and regulatory approval to prospectively recruit and sample participants for 
SCOVIDS was granted by the South East Scotland Research Ethics Committee 
under project reference 13/SS/0248 and the NHS Lothian Research and 
Development Department under reference 2014/0058. 
The SCOVIDS cohort contributed 125 unique individuals to this project, which were 
sequenced under the identifier of “batch 10525”. Including the extra samples from 
multiple timepoints, there were 187 primary tissue samples sequenced in batch 
10525. 
In addition, there were also 18 cell line samples sequenced in batch 10525. These 
were from three different colorectal cancer lines (HCT116, SW480 and LS174T), 
each either untreated or treated with vitamin D supplementation in triplicate. These 
samples are not of primary concern to this thesis, however they provided a useful 
QC of RNA extraction and sequencing, as detailed in the first results chapter. 
Between the two batches, there was a total of 301 primary and cell line RNA-seq 
samples, of which there were 221 unique primary donors (96 from batch 2013152 
and 125 from batch 10525) on which sQTL discovery was performed. For the 50 
individuals from the SCOVIDS cohort with multiple timepoints, only mucosa RNA-
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seq from timepoint 0 was used for sQTL discovery so that results were not 
confounded by interventional vitamin D supplementation. 
2.2 RNA sequencing 
RNA was extracted from colonic mucosa samples using the “Ribopure RNA 
extraction kit” (Applied Biosystems) according to the manufacturer’s protocol. RNA 
integrity and yield was quantified using the 2100 Bioanalyzer®. Extracted RNA was 
reverse transcribed using Moloney Murine Leukemia Virus reverse transcriptase 
(Promega) and random primers (Promega) at 370C for 30 minutes and 950C for 5 
minutes1. 
RNA samples were submitted to the Edinburgh Genomics sequencing facility, where 
QC, ribosomal-depletion, strand-aware library preparation and Illumina adapter 
ligation was performed. Ribosomal RNA was depleted using the New England 
Biolabs NEBNext rRNA Depletion Kit according to the manufacturer’s protocol. 
Samples from batch 2013152 were sequenced on the Illumina HiSeq 2500 in “rapid 
mode”, producing 100bp paired-end reads. Samples from batch 10525 were 
sequenced with 150bp paired-end reads. The mean number of reads for batch 
2013152 was 130 million, compared to 155 million for batch 10525 (Figure 2.1). 
 
1RNA was extracted for batch 2013152 by Dr Li Yin Ooi and batch 10525 by Dr Peter 
Vaughan-Shaw. 
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Figure 2.1 Number of fragments sequenced from each of the batches of primary 
samples and cell lines 
 
2.3 Distribution of clinical metadata 
Baseline clinical metadata for batch 2013152 was extracted from SOCCS and 
COGS databases by Dr Li Yin Ooi, with any missing data manually collected from 
the electronic hospital database or clinical case notes. Metadata for batch 10525 
was collected during recruitment and sampling of the SCOVIDS cohort by Dr Peter 
Vaughan-Shaw. 
Given that the majority of participants from batch 2013152 were undergoing surgery 
for CRC, whilst participants from batch 10525 were mainly non-diseased volunteers 
to the SCOVIDS study, there was a greater proportion of individuals over the age of 
60 in batch 2013152 compared to batch 10525 (Figure 2.2). 
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Figure 2.2 Distributions of clinical metadata 
a) Distribution of ages by historic or current CRC status b) Distribution of ages by gender. 
Right-sided cancers are less readily detected, and therefore are less likely to be 
operated on48. This is reflected in the distribution of sides within batch 2013152, with 
34 right-sided samples compared to 62 left-sided (Figure 2.3). Given that all of the 
SCOVIDS participants were sampled as outpatients as opposed to open or 
laparoscopic surgery, all of their samples were obtained from the left side of the 
colon via rectal sampling. This resulted in an overall skew towards left-sided 
samples within the whole of the dataset used by this project. Whilst Dr Li Yin Ooi 
detected some differences in expression between left and right-sided samples by 
microarray, only 12 genes had a log fold change of greater than 2.047. Given this 
small difference, samples from both sides of the colon were analysed together in 
this study to increase power for the identification of sQTLs. 
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Figure 2.3 Number of individuals sampled from each side of the colon.  
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Chapter 3 Processing of Expression Data 
3.1 Introduction 
This chapter deals primarily with QC analysis of the RNA-seq data, as any 
conclusions drawn in this thesis rest upon the accurate quantification of transcript-
level expression. 
During the course of this project, there was an advance in the field of expression 
analysis as “alignment-independent” RNA-seq quantification tools, such as 
Kallisto300 and Salmon301, were released and began to be widely adopted. These 
methods markedly changed the way that read counts were assigned to genomic 
features, with the intention of producing more accurate transcript level quantification. 
Therefore the decision was taken to apply these tools to the expression data from 
both batches of sequencing and compare their output to the previous alignment-
based quantification, which used STAR302 to align reads to the genome and 
Cufflinks303 to quantify feature expression.  
The chapter then explores the batch effects resulting from two separate sets of 
samples being sequenced approximately 2 years apart. Two different methods, 
ComBat and PEER, are applied in an attempt to remove batch effects, however it is 
found that their outputs are incompatible with the sQTL detection tools used 
downstream.  
A network analysis is also carried out to check for any systematic differences in 
gene co-expression between male and female samples, so that their inclusion 
together in the same sQTL discovery analysis can be justified. 
 
3.1.1 Quantification of mRNA expression 
RNA-seq consists of quantitative sequencing-by-synthesis from a cDNA library 
generated from the mRNA molecules present in a cell. Cells are first lysed, and RNA 
is isolated and fragmented. Random primers are added upon which DNA 
polymerase acts to produce single-stranded complementary DNA (cDNA)304. The 
RNA template is then digested and another round of polymerisation produces 
double-stranded DNA fragments305. The desired fraction of fragment lengths are 
selected, usually by gel electrophoresis. In the Illumina workflow, specific “Y-
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shaped” adapters are then ligated to the ends of the fragments. The library is 
washed over a flow cell and the adaptors anneal to complementary probes 
immobilised to the cell surface. The adaptors also act as primers, and “bridge-
amplification” creates dense local clusters of the target sequence to increase the 
signal for imaging306. Fluorescently labelled nucleotides are washed over the flow 
cell, which are blocked at their 3’ end meaning the sequence can only be extended 
by a single base at a time. The process of adding and imaging single bases is 
continued for a number of cycles until the desired read length is achieved. Paired-
end sequencing operates on both ends of each fragment, and usually leaves a tract 
of unsequenced bases in between. The two reads are termed “mate pairs”, and 
there is an “insert size distribution” across the library relating to the size of the 
intervening sequence, which depends on the size-selection step of the protocol and 
the length of the feature (transcript) being sequenced. Paired-end sequencing aids 
accuracy when mapping reads back to a genome or transcriptome as it places 
additional positional constraint on where the sequenced ends must align relative to 
each other, and also allows for more efficient detection of intron-exon boundaries 
when their relative position is significantly different from that expected given the 
insert size distribution.  
Despite random priming being used, there are still sequence-specific biases which 
can be introduced into RNA-seq, depending on inherent inequalities between the 
likelihood for particular motifs to have different affinity kinetics for their own 
complementary primer, and so be more or less likely to be sequenced307. There are 
obvious length and expression biases in that longer and more highly expressed 
features have greater likelihood to be sequenced - though the relationship between 
these parameters and the probability of being sequenced is not precisely linear, and 
are also dependent on the total library size304.  
After sequencing, there are two different approaches for quantifying RNA-seq reads 
against features such as genes or transcripts. Traditionally, a two-step process has 
been employed whereby reads are firstly aligned to the whole genome using a tool 
such as STAR302 or TopHat308 which produce BAM alignment files detailing the most 
likely genomic locations of each read, to which a second algorithm such as 
featureCounts309 or Cufflinks303 is applied to assign the alignments to the genomic 
features they overlap i.e. genes or transcripts.  
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Two algorithms were developed in 2016, Kallisto and Salmon, which take a different 
approach of performing the quantification in a single step against a reference 
transcriptome. These “alignment-independent” approachs, termed “pseudo-
alignment” by Kallisto and “quasi-mapping” by Salmon, are both faster and more 
storage efficient because large BAM files containing information about each 
individual read do not need to be produced - the output is simply a list of features 
contained in the reference transcriptome and their corresponding quantification 
values. Utilising only a single process also means there is less opportunity for 
technical biases occurring from using two separate alignment and quantification 
algorithms. 
Kallisto generates k-mers from sequenced reads and quantifies them against a de 
Bruijn graph of all k-mers in the transcriptome, combined with paths detailing the 
edges between k-mers representing known transcripts300. It builds equivalence-
classes of k-mers which correspond to the same transcript, and prunes absent k-
mers from the reference transcriptome to increase the speed of inference. 
Salmon also considers k-mers of reads, and quantifies them against a hash-table 
index of k-mers from the reference transcriptome in a two-phase process310. The 
first phase streams reads in a random order and uses stochastic Bayesian inference 
to construct various bias-models and build estimates for the abundance of each 
equivalence class of observed sequences301. In the second phase it iteratively 
updates these estimates via expectation maximisation using the bias models until 
the abundance estimates converge. Unlike Kallisto, Salmon does track the position 
and orientation of reads within the transcripts it assigns them to, and so is able to 
construct more fine-grained bias models for the beginning, middle and end of 
transcript sequences, which Bohnert et al. showed can be differentially affected by 
technical biases with successfully sequenced fragments being more likely to 
originate from the start or end boundaries of transcripts311.  
The unit of quantification for RNA-seq can simply be “counts”, 𝑋𝑋𝑖𝑖, i.e. the number of 
reads assigned to a given gene or transcript feature, 𝑖𝑖. Because alignment-
independent algorithms quantify transcripts probabilistically, they are able to assign 
non-integer counts for a feature because a read does not have to be strictly 
assigned to a single transcript, and instead can have a non-zero probability of 
having originated from multiple different transcripts. 
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Alternatively, units such as FPKM or TPM can be used to normalise expression of 
features within each sample for the read depth and feature length, given that longer 
features have greater likelihood to produce sequenced reads. The “effective length” 
(𝑙𝑙𝑖𝑖) of a feature is the number of base positions from which a read of the observed 
length could potentially have been produced if it did originate from that feature. It is 
defined as the feature length minus the mean of the fragment length distribution for 
that sample plus 1, because there must be at least 1 base for the random priming to 
have begun from. For features with length less than the mean fragment length, the 
effective length as calculated by this method is 1. 
𝑙𝑙𝑖𝑖 =  𝑙𝑙𝑖𝑖 −  𝜇𝜇𝐹𝐹𝐹𝐹𝐹𝐹 + 1 
The feature-specific biases which Salmon calculates are incorporated into the 
estimates of effective transcript-length for each sequence in the reference 
transcriptome, which subsequently affects the likelihood of assigning a read to a 
particular feature. 
FPKM (fragments per kilobase of sequence per million mapped reads) is the 
observed number of counts for a feature corrected for the length of the feature in 
kilobases, then corrected by the total library size (𝑁𝑁 reads), which is finally scaled by 
a factor of 1 million to make the values more interpretable312. 







If FPKM were to be a true measure of “relative molar RNA concentration”, then for a 
given transcript species in an analysis its average should be invariant, however 
Wagner et al. demonstrated that this is not always the case313. TPM (transcripts per 
million mapped reads) is a different measure which has become widely adopted 
because it avoids such statistical discrepancies. TPM is calculated by correcting the 
counts observed for a feature by its effective length, then dividing by the sum of all 
corrected feature counts in the library, and scaling by 1 million for interpretability314.  








As a result, TPM is effectively a measure of the expected number of reads that 
would be attributable to transcript 𝑖𝑖, given the abundances of all other transcripts in 
the sample, for each 1 million fragments sequenced from the library. 
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The majority of RNA in a cell is ribosomal (80-90%315), whereas the desired target of 
RNA-seq is mature mRNA molecules. Therefore mRNA is enriched either by affinity 
capture of the poly-adenylated tails of mature transcripts with thymine oligos316, or 
by treating cell lysates with DNA oligos with affinity for ribosomal sequences then 
introducing RNase H enzymes which digest DNA-RNA duplexes, thus depleting 
ribosomal RNA317,318. 
3.1.2 Genome Builds 
The initial round of RNA-seq analysis and sQTL identification performed on batch 
2013152 was aligned against the GRCh37 reference genome. The transition from 
GRCh37 to GRCh38 incorporated 1,158 different fixes, including the filling of 198 
gaps and 34 tracks of missing sequence, and has been demonstrated to lead to 
improved mapping rates to exomes which benefits more accurate RNA-seq 
analysis319. Therefore once RNA-seq was obtained for samples from batch 10525, 
both batches were aligned and quantified against the newer GRCh38 release - a 
decision which had also been taken by other large consortia such as the 1000 
Genomes Project320. 
3.1.3 Network analysis 
Weighted gene correlation network analysis (WGCNA) is a tool for inferring the 
presence of coordinated programmes of gene expression in cells and tissues321. The 
repeated correlation of a set of genes across many samples implies that their 
expression is under shared control via a particular regulatory system. Given the 
established differences in incidence of colorectal cancer by gender1,9, WGCNA was 
performed to test for any differences in gene expression control active between 
males and females in the colonic mucosa. WGCNA was used in order to 
complement differential expression analyses which have previously been carried 
out. The thesis of Dr Li Yin Ooi found 23 genes more highly expressed in males and 
22 more highly expressed in females when using the limma package322 to analyse 
microarray expression quantification from colonic mucosa samples from 64 males 
and 51 females. However, of those 45 differentially expressed genes, only 6 were 
not from the sex chromosomes (OSCP1, DPM3, CSTF3, ZMYND12, NLRP2, 
COPS8), implying that mainly global gender-specific differences, rather than colon-
specific, may have been observed by differential expression47. WGCNA will allow 
the testing of whether any modules of genes are under control of different regulatory 
pathways in the colonic mucosa of males and females. 
 
  66 
3.2 Methods 
3.2.1 Genomic alignment of reads 
Both batches were aligned using a one-pass alignment to GRCh38.p10 using STAR 
version 2.5.1302 using default parameters2.  
3.2.2 Quantification of RNA-seq using Cufflinks 
Feature expression was quantified from the subsequent bam files against the 
Ensembl gene build v88 using the Cufflinks pipeline303 with default parameters3.  
When Cufflinks quantifies features from bam alignment files, it can assign 4 different 
statuses to the resulting expression value:  
• OK: deconvolution successful 
• LOWDATA: too complex or shallowly sequenced 
• HIDATA: too many fragments in locus 
• FAIL: when an ill-conditioned covariance matrix or other numerical exception 
prevents deconvolution 
Any RNA-seq expression value emanating from a transcript not assigned as "OK" by 
Cufflinks was excluded from the analysis, which constituted 0.0523% of the 
transcripts. 
3.2.3  Salmon expression quantification 
Alignment-free quantification of RNA-seq fastq files was performed using the quasi-
mapping mode of Salmon version 0.8.0301. 
Reference Transcriptomes 
Salmon requires a reference transcriptome against which to quantify expression. 
Both cDNA and ncRNA (non-coding RNA) transcriptomes were downloaded from 
the Ensembl ftp server and manually concatenated to provide a comprehensive 
reference (Table 3.1). 
  
 
2 Credit Dr Alison Meynert for STAR alignment. 
3 Credit Dr Victoria Svinti and Dr Alison Meynert for Cufflinks quantifications. 
 








GRCh38 88 cDNA ftp://ftp.ensembl.org/pub/release-
88/fasta/homo_sapiens/cdna/Homo_sapie
ns.GRCh38.cdna.all.fa.gz 
GRCh38 88 ncRNA ftp://ftp.ensembl.org/pub/release-
88/fasta/homo_sapiens/ncrna/Homo_sapi
ens.GRCh38.ncrna.fa.gz 
Table 3.1 URLs for Reference Transcriptomes 
 
Salmon workflow 
The Salmon workflow firstly required construction of a custom index of the reference 
transcriptome to facilitate its alignment-free algorithm. 59 transcripts from 
GRCh38.v88 shorter than the minimum k-mer length utilised by Salmon for 
quantification (31nt) were flagged by the package, meaning that reads were unlikely 
to be quantified against those transcripts. The default k-mer length for quantification 
could be changed, but the default setting was used for comparability with other 
studies. 
Salmon was run in “quasi-mapping” mode, quantifying feature expression from fastq 
files directly against the combined cDNA and ncRNA reference transcriptome. 
Salmon was run with library option “ISR” to denote that read pairs were facing 
inwards towards each other, were stranded, and with read1 in the reverse 
orientation. 
All three of Salmon’s in-built bias detection and correction algorithms were 
employed, relating to sequence bias, GC content, and positional biases. The bias 
models are trained on the first 1 million reads streamed by Salmon, and because the 
reads are supplied in a random order these are assumed to provide a representative 
sample of all fragments present in the library. A variable-length Markov Model 
(VLMM, similar to that originally developed by Roberts et al. for the 2013 eXpress 
algorithm323) is used to detect any sequence-specific bias at the 5’ and 3’ ends of 
fragments which can occur due to random hexamer priming causing fragments 
beginning or ending with certain motifs to be preferentially sequenced. The second 
correction is applied to account for the likelihood of a sequence being observed 
given its internal GC content, given it has been demonstrated that correcting for this 
bias at the level of individual fragments improves quantification accuracy for 
samples with appreciable levels of GC bias, without impairing accuracy if no 
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significant bias is present301,324. Sequence bias and GC content bias are related, but 
not identical, phenomena, therefore Salmon learns three different fragment-GC bias 
models relating to the start, centre and end of the sequences of fragments. The final 
correction attempts to take account of coverage biases arising from a non-uniform 
distribution of fragment start-sites for a particular feature, learning different models 
for different lengths of transcripts. 
3.2.4 Analysis of Salmon quantification success rate 
Salmon reports the unique identifiers of any reads which were not able to be 
quantified against the reference transcriptome. It was desired to test what proportion 
of these effectively “unmapped” reads were able to be aligned genome-wide by 
STAR, and where in the genome they fell. Any fragments where neither mate pair 
read were quantified by Salmon were extracted from bam files of STAR genomic 
alignments using the “FilterSamReads” function from Picard tools version 1.139325. 
The percentage of Salmon unmapped reads that were able to be aligned by STAR 
was calculated as the number of unique Salmon unmapped reads present in STAR-
generated bam alignments per sample divided by the total number of Salmon 
unmapped reads per sample. 
This percentage was then further partitioned by whether STAR aligned the reads 
within or outwith exonic sequences, which were defined as the union of all exon 
coordinates according to a biomaRt326,327 query of Ensembl gene build 88328 mapped 
to GRCh38.p10329. The “CountReads” function from GATK tools version 4.0.0.0330 
was used to tabulate the numbers of Salmon unmapped reads which fell within or 
outwith the exonic regions. These numbers could be potentially misleading for two 
reasons. Firstly, reads which aligned across the boundaries of exonic regions were 
counted twice by the CountReads algorithm; once as exonic and once as intergenic. 
In order to solve this problem, any reads which mapped across the boundaries were 
removed such that the percentages were only calculated based only on reads which 
unambiguously mapped within or outwith exonic regions. The second issue arises in 
that the bam files containing unmapped Salmon reads had some secondary 
mappings, where the same read could be mapped multiple times. This means that if 
there were different rates of secondary mappings within exonic regions than outside 
them, then the percentages for each region could potentially be skewed. However 
the resulting metrics are still useful for observing an overall trend. 
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The “idxstats” function from SAMtools version 1.6331 was used to count the number 
of reads which were genomically aligned to each sequence contig (chromosome or 
alternative scaffold) by STAR. 
When quantifying the number of reads mapped by STAR to ribosomal RNA genes, 
rRNA sequences were defined from biomaRt326,327 query of Ensembl gene build 
88328 mapped to GRCh38.p10329 for the exons of any gene with the biotype "rRNA". 
5kbp windows were added to either side of these sequences, in order to capture the 
repetitive regions that often surround the annotated locations of rRNA genes, and 
therefore are likely to also attract repetitive ribosomal reads332. The “CountReads” 
function from GATK tools330 was again used to record the numbers of reads falling 
within or outwith these rRNA regions. 
For visualisation in the Integrative Genomics Viewer (IGV)333, bam files were 
converted to bigwig read-density tracks using the function “bam2bw” from the 
package cgpBigWig334. 
3.2.5 Principal Components Analysis 
Principal components analysis (PCA) was run separately at the gene-level and 
transcript-level on log and quantile normalised Salmon counts. Logarithms were 
taken of each count with the formula: 
𝑋𝑋′ =  𝑙𝑙𝑙𝑙𝑙𝑙2(𝑋𝑋 + 1) 
such that values less that one would remain positive after log transformation. 
Quantile normalisation was performed using the “normalize.quantiles” function from 
the preprocessCore R package version 1.32.0 with default settings335. The “prcomp” 
function336,337 from base R338 was used to calculate principal components, with the 
arguments “centre=TRUE” and “scale=FALSE”. 
 
3.2.6 Batch correction with ComBat and PEER factor 
residuals 
ComBat 
ComBat batch correction was run on log2 and quantile normalised transcript-level 
TPM values as quantified by Salmon. 1.46% of the transcripts were discounted for 
exhibiting variance of 0.0. ComBat was run from the sva (surrogate variable 
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analysis) package version 3.18.10339–341 with the argument “par.prior=TRUE”, 
indicating that parametric adjustments as opposed to non-parametric would be 
used. 
PEER factor correction 
Analysts from the Genotype-Tissue Expression Consortium (GTEx) report a 
relationship between the number of samples in an analysis and the number of 
unknown factors which should be corrected for using PEER (probabilistic estimation 
of expression residuals) in order to maximise the number of cis-eQTL associations 
identified. For a sample size n<150 they suggest using 15 factors, for 150≤ n <250 
to use 30 factors, for 250≤ n <350 to use 45 factors and for n≥350 to use 60 
factors342. Therefore 30 factors were used when running PEER on the 221 samples 
in this analysis. 
Firstly an arbitrary low-expression threshold was set requiring transcripts to have ≥6 
counts in ≥10% of the samples. This retained 156,806 out of 217,082 transcripts 
(72.2%). Then TMM (Trimmed mean of M-values343) normalisation was performed 
using the “calcNormFactors” function from the edgeR package version 3.16.5344,345. 
This was followed by using the “rntransform” function from the GenABEL package 
version 1.8.0346 to produce a normal distribution of expression values by matching 
the inverse normalised rank of each transcript to the corresponding quantile of a 
normal distribution. 30 unknown factors were estimated using the “PEER_update” 
function from the peer package version 1.0347,348. As a comparison, PEER factor 
correction was also performed on non-normalised data with only the transcript 
expression threshold imposed.  
 
3.2.7 Differential network analysis using WGCNA 
WCGNA was performed on the male and female samples from batch 10525 only, to 
ensure there would be no confounding effects from differences in library sizes 
between batches which could affect correlations. The larger of the two batches was 
chosen as it contained more individuals and a roughly equal split between the two 
genders. The network analysis was carried out on 124 individuals after a single 
outlier identifiable when PCA was performed on batch 10525 was removed (sample 
MD14398_A, female aged 31, left-sided sample, no history of CRC, BMI 22.4). 
Salmon gene-level counts were filtered to select for the 5,000 most highly expressed 
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genes and the 5,000 genes with the greatest variance to reduce the likelihood of 
false-positive correlations between lowly expressed features or irrelevant 
correlations between stably expressed genes. The intersect of these two sets was 
taken, which resulted in 4,400 genes. Their Salmon counts were log2 and quantile 
normalised as described previously before correlations were calculated to increase 
comparability between samples prepared from different libraries.  
Firstly, a male-specific correlation network was generated from the 66 male 
samples. Pearson correlation coefficients were calculated pairwise between all 
genes, and a network was constructed whereby the genes formed nodes and edges 
between nodes were weighted according to the correlation coefficients. 
Construction of an effective weighted gene correlation network is reliant on 
achieving an approximately “scale free” topology349. Networks approximating this 
classification have the characteristic that the distribution of clustering coefficients 
follows a power law, whereby sparsely-connected nodes are common and there are 
increasingly fewer, more highly-connected hub nodes which are aggregated into 
“modules”350. This model approximates the regulatory hierarchy predicted to be 
active in most biological systems351. In order to achieve scale free properties, the 
correlation coefficients between genes are raised to a power. Given that the vast 
majority of correlations will be <1.0, raising such numbers to a power will 
considerably reduce their magnitude and serve to selectively trim poorly supported 
edges, by penalising them disproportionately more severely (e.g. 0.99^8 = 0.923, 
whereas 0.25^8 = 0.0000153). Each time a network is constructed, the appropriate 
power is selected by estimating the fit of the resultant correlation matrix to a scale-
free topology, with the authors of WGCNA recommending that the coefficient of the 
fit should achieve approximately 0.9349. The networks are unsigned such that any 
significant correlation between genes causes them to be co-located into the same 
module of highly correlated genes (as opposed to signed networks, whereby only 
positively correlated genes are clustered)349. 
In order to detect differences between the expression networks of males and 
females, a second consensus network was then constructed using a combination of 
both genders’ expression data, and the resulting modules of highly connected genes 
was compared to the first male-specific network. Any modules which are discordant 
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between the individual and consensus gender networks are inferred to contain 
genes which are under different regulatory regimens in males and females. 
 
3.3 Results 
3.3.1  Correlation between Cufflinks FPKM and Salmon TPM 
Median Cufflinks FPKM per transcript and median Salmon TPM per transcript were 
compared for the 96 samples from batch 2013152 (Figure 3.1), producing a 
correlation coefficient of Rho=0.678, P=<2.2e-16. The rank-based Spearman 
correlation coefficient was used, because although the TPM and FPKM 
quantification scales are not directly comparable, the rank of features between each 
methodology should be similar if the two methods perform comparably. When 
displayed as a scatter plot on a log scale, it is clear that the best-fit line deviates 
from y=x because of a skew of transcript quantifications which are higher according 
to Salmon than Cufflinks. 
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Figure 3.1 Cufflinks against Salmon transcript-level quantifications. 
Best fit line (lm method from ggplot2) in blue, line of y=x in red. 
 
3.3.2 Quantification success rates of Salmon and STAR 
There was a greater success rate of Salmon quantification for reads from the 18 cell 
line samples which were sequenced as part of batch 10525 than either of the 
batches of primary samples (Figure 3.2). There was a greater STAR mapping 
success rate than Salmon for reads from primary samples from both batches. 
However, the STAR mapping success rate for cell lines was lower than that 
achieved by Salmon. 
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Figure 3.2 Mapping success rates of Salmon and STAR across batches. 
The Salmon quantification success rates of approximately 50% of reads for primary 
samples were lower than expected, however its performance of near 80% from cell 
line samples indicates that it is not an issue of the algorithm itself. Therefore the 
issue of low quantification success of reads by Salmon in primary samples was 
further investigated. 
When STAR-aligned bams were queried for the read IDs which were un-quantifiable 
by Salmon, it was found that a greater percentage of the Salmon unmapped reads 
from batch 2013152 were able to be mapped by STAR than from primary or cell line 
samples from batch 10525 (Figure 3.3 a). The main cause of reads failing to be 
mapped by STAR was the reads being too short (Figure 3.3 b). The majority of 
reads which were not quantifiable by Salmon but which were mapped by STAR 
were mapped to regions outside the transcriptome, as defined by a union of all 
exonic regions (Figure 3.3 c). For all batches, the proportions of secondary 
mappings produced by STAR was greatest in the bams containing reads not 
quantifiable by Salmon (Figure 3.3 d), implying that these reads are enriched for 
lower-quality or more repetitive sequences. 
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Figure 3.3 STAR mapping successes for reads not quantifiable by Salmon 
(a) Percentage of reads not quantified by Salmon which were able to be mapped by STAR 
(b) Percentage of STAR reads per batch which failed for either being too short, mappable to 
too many potential loci, or being unmapped for other reasons (c) Percentage of reads not 
quantified by Salmon which were mapped to non-exonic sequences by STAR (d) 
Proportions of secondary mappings of reads in original STAR bam files, and bams 
containing only the reads not quantified by Salmon but mappable by STAR. 
 
Figure 3.4 plots samples ordered by the percentage of unquantifiable Salmon reads 
which were mapped to exonic regions by STAR. The samples fall into distinct 
clusters, with cell lines having the largest percentage, then batch 10525 of primary 
samples followed by batch 2013152. 
Figure 3.5 displays read counts as opposed to the percentages, and samples are 
ordered by the total number of reads quantifiable by Salmon. This makes the 
boundaries between groups of samples less defined; the cell lines are less well 
clustered because although they all possessed the greatest percentage of reads 
quantifiable by Salmon, some primary tissue samples possessed more overall reads 
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than certain cell line samples. It can also be observed that primary samples from 
batch 2013152 tended to contain fewer reads than batch 10525 which were 
unquantifiable by Salmon but could be aligned to exonic regions by STAR, despite 
having a greater percentage score according to this metric than batch 10525 as 
demonstrated in Figure 3.3 c; a discrepancy resulting from batch 2013152 having a 
lower total read count. 
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Figure 3.4 Percent mapping successes of samples ordered by unquantifiable Salmon reads mapped exonically by STAR 
(Upper) Salmon quantification success in light green (Lower) Of the reads which were not able to be quantified by Salmon, the percentage mapped by 
STAR onto exonic regions are in dark blue, percentage of reads mapped to non-exonic regions in light blue, and also unmappable by STAR in dark 
green. (Tick marks) Indicate batches and cell lines. 
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Figure 3.5 Number of reads quantified or mapped per sample ordered by total number of Salmon quantified reads 
(Upper) Number of reads quantified by Salmon in light green (Lower) Of the reads which were not able to be quantified by Salmon, the number of 
reads mapped by STAR onto exonic regions are in dark blue, number of reads mapped to non-exonic regions in light blue, (Tick marks) Indicate 
batches and cell lines.
 
  79 
Given their lengths, there was a greater number of reads than would be expected 
aligned by STAR to chromosomes 14, 17, 21 (Figure 3.6 solid line). There was also 
unexpectedly large numbers of reads mapping to the alternative chromosome 21 
scaffolds GL000220.1 and KI270733.1 in primary samples, but not in cell lines 
(Figure 3.6 solid line). These five sequences together attracted the greatest 
numbers of reads which were aligned to the genome by STAR but were 
unquantifiable by Salmon in relation to the reference transcriptome (Figure 3.6 
dashed line). A median of 48.8% of the reads from batch 2013152 samples were 
mapped by STAR to the ribosomal sequences on these five chromosomes +/- 5kbp 
windows (Figure 3.7 dashed line). The media was 34.2% of reads for batch 201525, 
and 14.7% for cell lines (Figure 3.7 dashed line). Large numbers of reads mapping 
to these regions can clearly be seen in screen shots from the Integrative Genomics 
Viewer (IGV)333 of representative samples from each data source (Figure 3.8). 
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Figure 3.6 Distribution of reads STAR-aligned reads per chromosome by batch. 
Solid lines indicate all reads, dashed lines indicate those reads which were not able to be quantified by Salmon. 
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Figure 3.7 Reads mapped to genomic regions encoding ribosomal RNAs. 
“rRNA” refers to regions comprising any exons of rRNA genes on chromosomes 14, 17, 21, 
GL000220.1 and KI270733.1 plus or minus a 5kbp window. 
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Figure 3.8 IGV screenshot of chromosome 21, coordinates 8,030,572-8,630,975. 
Reads from three representative samples are shown; MD12049 from batch 2013152, MD13417 from batch 10525, and a sample from the HCT116 cell 
line. 
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3.3.3 Principal components analysis 
PCA demonstrates clear differences between batches and between primary 
tissue samples and cell lines 
20% of the variance in expression between all samples analysed can be explained 
by the first two principal components of Salmon transcript-level counts (Figure 3.9). 
Component 1 captures the difference between primary tissue and cell line samples, 
whilst component 2 captures the variance due to batch effects (Figure 3.10). 
 
Figure 3.9 Proportion of variance explained by first 20 principal components 
Derived from Salmon transcript-level counts (log2 and quantile normalised) for 283 primary 
and 18 cell line samples. Numbers above bars indicate cumulative percentage of variance 
explained. 
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Figure 3.10 First two principal components 
Derived from Salmon transcript-level counts (log2 and quantile normalised) for all 301 
samples both primary and cell lines. 
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No obvious separation of primary samples beyond 1st Principal Component 
When principal components were calculated using transcript-level counts from just 
the 221 primary samples which would be used for identifying sQTLs, the first 
component corresponding to batch-separation explains the most variance (9.26%), 
This was more than 4-fold greater than the second largest component (2.17%) and 
as much as components 2-7 combined (which cumulatively explained 9.31%). There 
is no clear separation in of the first 5 components apart from PC1 (Figure 3.11).  
 
Figure 3.11 First 5 principal components derived from Salmon transcript-level counts 
(log2 and quantile normalised) for all 221 primary colonic mucosa tissue samples. 
Coloured by batch. 
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Gender effects are visible via gene-level PCA of a single batch, with strongest 
effects caused by genes with the 500 largest variances 
There was expected to be a gender-separation uncovered by PCA, however it was 
not apparent when analysing all 221 primary samples together. Batch effects may 
have dominated the variance components and masked the contribution of other 
factors. Lowly expressed transcripts may also have produced noise capable of 
obscuring genuine separations. So PCA was performed again using gene-level 
expression from just the 125 samples from batch 10525. This identified one outlier, 
sample “MD14398” (Figure 3.12), though there was no clear indication in their 
metadata why they should have presented an atypical gene-level expression profile 
that wasn’t apparent in the transcript-level analyses of all 221 primary samples 
(Female aged 31, left-sided sample, no history of CRC, BMI 22.4). 
 
 
Figure 3.12 First two principal components derived from Salmon gene-level counts 
(log2 and quantile normalised) for 125 primary colonic mucosa tissue samples from 
Batch 10525. 
After discounting the female sample MD14398, gene-level PCA was able to identify 
a gender separation in component 3. To increase the clarity of the separation 
further, analysis was re-performed using only the genes with the 500 greatest 
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variances across the 124 samples (Figure 3.13). This threshold was modelled on 
that used by the “plotMDS” function of the edgeR differential expression 
package345,352. The separation between female and male samples became 




Figure 3.13 First 5 principal components derived from Salmon gene-level counts (log2 
and quantile normalised) for 124 primary colonic mucosa tissue samples from Batch 
10525. 
Only the genes with the 500 greatest variances were used. Coloured by gender. 
In order to confirm that this separation was due to the influence of gender-specific 
expression, the same analysis was repeated with any genes from the X or Y 
chromosomes which were in the list of top 500 variances removed (see Table 3.2). 
As expected, this removed any gender separation from the data (not shown). 
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 Gene Chromosome Ensembl_ID 
DDX3X X ENSG00000215301 
FLNA X ENSG00000196924 
HEPH X ENSG00000089472 
MAOA X ENSG00000189221 
OGT X ENSG00000147162 
POF1B X ENSG00000124429 
RPL10 X ENSG00000147403 
CHANGE X ENSG00000198034 
SLC25A5 X ENSG00000005022 
TMSB4X X ENSG00000205542 
XIST X ENSG00000229807 
AC010970.2 Y ENSG00000225840 
TXLNGY Y ENSG00000131002 
Table 3.2 13 genes from X and Y chromosomes which featured in the top 500 greatest 
variance genes across 124 samples from Batch 10525 
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3.3.4 Batches converge after correction with ComBat 
Following batch correction with ComBat340 there was still a single principal 
component which dominated the variance, accounting for 12.45%, compared with 
the next largest of 5.15% and 4.11% respectively. However, when the principal 
components are plotted, the two batches can be seen to have notably converged in 
PC1 compared to previous analyses, with some samples now overlapping at the 
peripheries of each batch (Figure 3.14). 
 
Figure 3.14 First 5 principal components derived from ComBat corrected Salmon 
transcript counts (log and quantile normalised). 
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Negative values introduced following ComBat correction made it unsuitable 
for use with sQTL discovery tools 
After batch correction with ComBat, 14.05% of all resulting expression values were 
negative, and 57.0% of transcripts had at least one negative value across the 221 
samples (Figure 3.15). The magnitude of the majority of the negative values was not 
large, however excessive data manipulation would have been required to make all 
the values positive and therefore compatible for input into sQTL detection 
algorithms. 
 
Figure 3.15 ComBat batch correction introduces negative values 
a) Log and quantile normalised transcript-level counts from 221 primary samples. b) ComBat 
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3.3.5 Negative PEER factor residuals 
PEER factor correction produces a list of covariates which can be used in 
conjunction with linear models to correct for hidden confounding variables in 
expression data. These could have been applicable to FastQTL, but the 
sQTLseekeR algorithm was not able to account for covariates at time of analysis247. 
PEER also returns residuals from the factor analysis, which can be considered a 
matrix of corrected values. These were plotted, however the process introduced 
large numbers of negative values into the data, whether PEER was run on 
normalised or non-normalised expression counts, therefore it was also incompatible 
with sQTLseekeR (Figure 3.16). 
 
Figure 3.16 Distributions of PEER factor analysis residuals run on normalised and raw 
counts. 
Y axes are attenuated for visibility of lower frequency bars. 
 
3.3.6 Differential network analysis between genders 
WGCNA was firstly used to generate a male-specific gene co-expression network 
from 66 samples from batch 10525. Agglomerative hierarchical clustering was 
performed via UPGMA (unweighted pair group method with arithmetic mean) using 
Euclidean distance between gene expression of samples as the distance matrix353. 
No clear outliers were observed in the resulting unrooted dendrogram, nor any 
biases in relation to age or BMI (Figure 3.17). 
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Euclidean distance between two vectors, p and q 
 
 
Figure 3.17 Unrooted dendrogram of 66 male samples from batch 10525. 
Ages range from 24 (light red) to 86 (dark red) and BMI from 18.3 to 48.9. Grey bar indicates 
BMI was unavailable. 
A power threshold of 8 was chosen as it achieved a fit to a scale-free topology of 
approximately 0.9 (Figure 3.18). It can bee seen that as the power which correlation 
coefficients were raised to increases, the mean connectivity of the network 
decreases as more edges are trimmed. 
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Figure 3.18 Fit to scale-free topology and mean connectivity of networks from 66 male 
samples with edges raised to various powers 
The male-specific network was constructed using the “blockwiseModules” function 
from the WGCNA package version 1.66349 with a minimum module-size threshold of 
30 genes and default parameters for merging of related modules. Modules are 
constructed via hierarchical clustering of genes, where dissimilarity between two 
gene vectors is calculated as 1- ωij (where ωij is the Topological Overlap Matrix 
(TOM) as defined by Kaufman and Rousseeuw354) and genes are assigned to 
modules with high TOM similarities. 3,709 of the 4,400 genes with greatest 
expression and variance were able to be assigned to 18 modules, as shown in 
Table 3.3, leaving 691 unassigned.  
Module Genes Module Genes Module Genes 
A 879 G 204 M 111 
B 346 H 183 N 107 
C 316 I 156 O 56 
D 290 J 150 P 49 
E 271 K 125 Q 47 
F 255 L 125 R 39 
Table 3.3 Numbers of genes per module for male-specific correlation network 
A consensus network was then constructed from the colonic mucosa gene 
expression counts from 66 males and 58 females. Samples were again clustered 
according to Euclidean distance to check for outliers, and none were observed since 
the single female outlier identified via PCA of this batch had already been removed. 
The same power of 8 was chosen to raise the correlation coefficients to in order to 
achieve an approximately scale-free topology. The “blockwiseConsensusModules” 
function was used to create consensus modules using male and female expression 
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with ≥30 genes per module. 3,074 genes were able to be assigned to 17 modules 
(Table 3.4), leaving 1,326 unassigned. 
Module Genes Module Genes Module Genes 
A 996 G 145 M 77 
B 314 H 140 N 49 
C 308 I 124 O 48 
D 179 J 95 P 46 
E 171 K 90 Q 39 
F 165 L 88   
Table 3.4 Numbers of genes per module for male and female consensus correlation 
network 
Pairwise Fisher’s tests were computed to assess the comparability of modules 
between male-specific and consensus networks and whether the numbers of genes 
they shared were greater than would be expected by chance. The majority of 
modules from the male network had one primary module from the consensus 
network to which their gene content significantly corresponded (Figure 3.19). The 
male-specific module “Q” with 47 genes had no module in the consensus network 
that it significantly corresponded to. It shared 20 genes with the largest 996 gene 
module “A” from the consensus network, and shared 25 with the list of genes 
unassigned in the consensus network. The lack of correspondence could be 
because this module contained relatively few genes, however other modules of 
similar size did have consensus modules to which they corresponded very closely: 
male module “H” shared 37 of 39 genes with consensus module “Q“; male “P” 
shared 48 of 49 genes with consensus “N”; and male “O” shared 46 of 56 genes 
with consensus “O”. Therefore it can be deduced that the male-specific “Q” module 
ceased to be detectable as a single entity in the consensus network. This is likely 
the module that was lost when 18 became 17, and the genes previously contained 
within it ended up being categorised into the two largest catch-all units of the 
consensus network, “A” and unassigned (“U”), containing 996 and 1,326 genes 
respectively. 
Further observations include that the male module “C” had two separate consensus 
modules which it shared highly significant numbers of genes with. It shares 46 with 
the 46 genes from consensus module “P”, and 88 of its 316 genes with the 171 
gene consensus module “E”. This may be a converse example to male module “Q”, 
whereby a larger module in the male-specific network can be better defined into two 
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more specific, smaller modules using the consensus expression of 124 as opposed 
to 66 samples. The concordance of unassigned genes between the two networks is 
high: 614 of the 691 genes which were unable to be assigned in the male-specific 
network still had no assignable module in the consensus network, which highlights 
the replicability between the two networks and that there are certain genes with 
consistently poor correlations with any others. 
 
 
Figure 3.19 Heatmap of gene overlaps between modules from male-specific and male-
female-consensus networks. 
Numbers in the heatmap correspond to the numbers of shared genes. Cells are coloured by 
the -log10(p-value) of a Fisher’s test for overlap between the corresponding modules. 
“Immune system process” was the top hit in GOrilla pathway analysis355 for the 47 
genes from the male-specific module “Q” which had no clearly corresponding 
module in the consensus network, with a Fisher’s enrichment p-value relative to the 
background expressed genes of 1.00x10-7 (1.06x10-3 after FDR correction). The 20 
genes from module Q which were responsible for producing the enrichment within 
“Immune system process” are listed in Table 3.5. The next 19 most significantly 
enriched pathways were also all related to immune regulation (Table 3.6). 
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Gene Description 
ITGA4  integrin, alpha 4 (antigen cd49d, alpha 4 subunit of vla 4 - receptor) 
IFI16  interferon, gamma - inducible protein 16 
CD44  cd44 molecule 
FGL2  fibrinogen - like 2 
LCP1  lymphocyte cytosolic protein 1 (l-plastin) 
DOCK2  dedicator of cytokinesis 2 
IFI30  interferon, gamma -inducible protein 30 
SAMHD1  sam domain and hd domain 1 
NCKAP1L  nck-associated protein 1-like 
CD74  cd74 molecule, major histocompatibility complex, class ii invariant 
chain 
IKZF3  ikaros family zinc finger 3 (aiolos) 
PTK2B  protein tyrosine kinase 2 beta 
CD68  cd68 molecule 
PTPRC  protein tyrosine phosphatase, receptor type, c 
ETS1  v-ets avian erythroblastosis virus e26 oncogene homolog 1 
DOCK10  dedicator of cytokinesis 10 
PIK3AP1  phosphoinositide-3-kinase adaptor protein 1 
GM2A  gm2 ganglioside activator 
TRIM22  tripartite motif containing 22 
MAP3K1  mitogen-activated protein kinase kinase kinase 1, e3 ubiquitin 
protein ligase 
Table 3.5 20 genes from male-specific module “Q” which produced enrichment in the 
GOrilla pathway classification “immune system process” 
 
 
Table 3.6 GOrilla pathways in which the 47 genes from male-specific module “Q” were 
significantly enriched 
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3.4 Discussion 
3.4.1 Genome assembly justification 
RNA-seq expression data was aligned and quantified against GRCh38 because it 
represents the newest change in reference sequence since 2009. Approximately 
1,000 issues ranging from single base changes to gap-closures have been made 
since the update from GRCh37, and it was desired to have the most up-to-date 
possible reference sequence, especially for resolution at the transcript-level and for 
inclusion of any novel transcripts identified and annotated since the previous 
release. 
3.4.2 Salmon correlation with Cufflinks FPKM 
Whilst some skew in Figure 3.1 may have been attributable to two different 
quantification units being used, the deviation of the best fit line from the line of y=x 
demonstrates that there is a trend for certain transcripts to be quantified with a 
greater expression by Salmon compared to Cufflinks. This trend may be due to the 
way in which Cufflinks attempts to explain observed expression using the minimum 
possible number of isoforms required356. This parsimonious approach is admirable, 
though it may sacrifice sequence-specific information contained within reads which 
can be used by Salmon to increase accuracy of abundance estimates through its 
bias models301. 
The disagreement in quantifications could also be due to differences in the ways the 
two algorithms assign effective transcript lengths to reads shorter than the mean 
read length. In such cases, alignment-dependent algorithms simply use the actual 
transcript length, whereas alignment-independent tools penalise the likelihood of 
sequencing fragments shorter than the mean fragment length according to a 
probability model built from the observed fragment lengths. Additionally, Salmon 
specifically incorporates bias estimates into the effective transcript lengths as a 
means of influencing the likelihood of assigning a read to a transcript feature, which 
could further diverge its approximations from those of Cufflinks. This was 
demonstrated by Zhang et al. who simulated 8 reads from the 100bp long transcript 
SNGH25-002. Whilst both Salmon and Cufflinks correctly assigned 8 counts to the 
feature, their estimates of TPM were 20 and 185.6 respectively356.  
Whilst there is no definitive answer for the way effective transcript length should be 
calculated, the authors then highlight a different example whereby alignment-free 
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methods clearly do outperform alignment-dependent methods. 154 reads were 
simulated for the pseudogene RPS28P7-001, with Salmon accurately recapitulating 
these whilst the alignment-based STAR+Cufflinks approach seriously 
underestimated its expression and instead assigned almost all reads to the 
corresponding gene RPS28. The gene RPS28 is alternatively spliced whereas the 
pseudogene is not. STAR adds bonus alignment scores to spliced reads, precisely 
in an attempt to penalise spurious alignments to pseudogenes which are assumed 
to be less highly expressed than their corresponding gene - however in this example 
and other such cases, alignment-based methods perform poorly compared to 
alignment-free356. This highlights a weakness of alignment-dependent quantification 
in that there are two separate stages at which technical biases can be introduced - 
firstly by the idiosyncrasies of the chosen aligner, and then separately by the 
quantification algorithm - whereas alignment-free algorithms produce results from a 
single unified workflow. 
Salmon quantification was used in this project as opposed to Cufflinks because of its 
faster speed, lower storage requirements and that incorporation of more bias-
correction models. Zhang et al.’s same study of quantification methods found 
Salmon to be more accurate than Cufflinks in a number of metrics when attempting 
to quantify 50M reads simulated using read distribution statistics from Human Brain 
Reference RNA sample HBRR-C4 using the RSEM package357. Salmon estimated 
TPMs had a greater Pearson R2 correlation coefficient than Cufflinks with true 
simulated values of >0.96 compared to >0.94356. Salmon also outperformed 
Cufflinks when the transcript-content of the gene was more complex. For genes with 
>15 transcripts, Salmon’s R2 was >0.94 vs >0.92 for Cuflinks. The metric of MARD 
(Mean Absolute Relative Difference) was also used to quantify differences, 




 (𝑓𝑓𝑙𝑙𝑟𝑟 𝑖𝑖 + 𝑗𝑗 ≠ 0) 
where i is the true simulated value and j the value estimated by the quantification 
algorithms. Again Salmon outperformed Cufflinks by this metric when estimating 
simulated reads, with a lower overall MARD of 0.170 vs 0.224, and for genes with 
>15 transcripts of 0.233 vs 0.270356. 
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Zhang et al. calculated a correlation coefficient of 0.899 between transcript 
quantification by Cufflinks and Salmon356. In addition using Pearson not Spearman 
correlation, this value is also likely different to the R2 of 0.678 observed in this study 
for a number of reasons. Firstly, they performed more stringent filtering before 
calculating their correlation by removing any transcripts with estimated read counts 
<5.0. Perhaps more significantly, their correlation was drawn between Cufflinks and 
Salmon quantifications for a single sample, HBRR-C4, whereas 0.678 was obtained 
when correlating the median quantification for each transcript across 96 samples by 
either Cufflinks or Salmon, so there was more potential for variability to be 
introduced.  
3.4.3 Use of Salmon as an alignment-free expression 
quantification algorithm 
Having established that alignment-free quantification consistently outperformed 
alignment-dependent, Salmon was chosen as the algorithm to use in this thesis.  
The similar alignment-free algorithm Kallisto could have been adopted, however 
there are multiple examples of analyses which have found Salmon to perform better 
in a range of quantifications based on both simulated and actual RNA-seq data. A 
2016 blog by post-doctoral fellow Tom Smith from Oxford University presented one 
of the first direct comparisons between the recently released Kallisto and Salmon 
algorithms358. Using 100 simulations of random numbers of reads from each of the 
human protein-coding genes annotated in GRCh38, he demonstrated that Kallisto 
and Salmon performed very comparably in correlations to ground-truth levels of 
expression, however Salmon had a higher success rate of assigning zero values to 
truly absent transcripts than Kallisto across a range of transcripts possessing 
varying degrees of unique sequence content358. This analysis was executed using 
an earlier version of Salmon, 0.6.0, which did not yet possess the sequence-specific 
bias model added to version 0.8.0 (the version used in this project), or 
improvements made to the implementation of the models to reduce risk of over-
fitting301, meaning the advantages of Salmon may have been understated. 
The paper introducing Salmon contained comparisons with Kallisto for the 
quantification of simulations and real RNA-seq samples. When calculating 
differential expression between 16 RNA-seq libraries simulated to contain realistic 
GC-bias using the Polyester package359 and the estimates calculated by the 
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algorithms, Salmon returned a lower median log fold change of 0.09 compared to 
0.14 by Kallisto - when the true change should have been 0.0301. Salmon also had a 
higher sensitivity of 0.409 compared to Kallisto’s 0.248 for facilitating downstream 
detection of truly differentially expressed genes at FDR 0.05 according to 
simulations301. When analysing isoform expression between two sets of the same 15 
GEAUVADIS samples sequenced at different centres, Salmon succeeded in 
ascribing a lower percentage of genes as harbouring switches in the dominantly 
expressed isoform; only making this mistake for 4.3% of genes compared to 6.8% 
by Kallisto for genes with at least one transcript expressed at >10 TPM301. 
Zhang et al.’s review of RNA-seq quantification also included analyses of Kallisto vs 
Salmon. Whist Kallisto had leaner memory requirements to quantify 50M 76bp 
paired-end reads of 3.8G vs 6.6G by Salmon, Salmon was 1 minute quicker taking 6 
vs 7 minutes. The Pearson correlation coefficient between their resulting TPMs was 
high, at 0.966. To probe any specific differences, the authors constructed a test 
whereby they used the Polyester package359 to simulate reads from six different 
transcripts of TP53; the α, β and γ isoforms, and each harbouring the Δ133 variant. 
The ability to differentiate between such isoforms is of critical biological importance 
as they can have vastly different effects on tumour progression or suppression, with 
the full length TP53β isoform inducing apoptosis in cancer cells whilst Δ133β does 
not360. They initially simulated 100 reads for each isoform as a baseline, then to 
represent different read depths they increased each isoform by 10 and 100-fold. 
Additionally, to test detection of rare isoforms, they increased the expression of just 
isoform α by 10 and 100-fold whilst maintaining the expression of the other five at 
100 reads. Accuracy was measured by mean MARD scores from 5 replicates of 
such conditions. One instance where Kallisto did outperform Salmon was in the 
accurate quantification of the Δ133 isoforms when diluted by isoform α356. However, 
given there were <1 million reads, Salmon could not build bias models during its first 
streaming phase, and therefore could only estimate biases post-hoc. Despite this 
limitation, Salmon clearly outperformed Kallisto at quantifying all isoforms in the 
opposite situation where read depth was simulated to be increased356. Given that 
the libraries analysed in this project were all of very high read depth, Salmon 
presented the clear choice of an alignment-free quantifier. 
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3.4.4 Differences between Salmon quantification success 
rate in primary and cell line samples likely explained by 
incomplete ribosomal depletion 
The success rate for quantification of reads by Salmon was lower than expected for 
the primary samples from both batches (~50%, Figure 3.2), however, the fact that 
Salmon achieved the expected levels (~80%, Figure 3.2) for cell lines indicates that 
the discrepancy must not be a fault of the algorithm, but of the reads supplied to it 
generated from the different cDNA libraries  
Chromosomes 14, 17 and 21, and the alternative scaffolds of chromosome 21, 
GL000220.1 and KI270733.1, attracted greater numbers of read alignments by 
STAR than would have been expected given their lengths (Figure 3.6), and the 
majority of the reads mapping to chromosome 21 and its alternative contigs were 
those not able to be quantified by Salmon (Figure 3.6). The large numbers of reads 
which were aligned to rRNA regions on these chromosomes (Figure 3.7) which are 
not represented by the reference transcriptome likely explains the greater mapping 
success rate by STAR than Salmon for primary samples (Figure 3.2). Accurate 
quantification of transcript expression is the key requirement for this study though, 
meaning that Salmon remains the ideal tool from which to identify sQTLs. 
STAR mapping of reads to chromosome 21 and alternative scaffolds GL000220.1 
and KI270733.1 was less extreme for cell lines than primary samples (Figure 3.6). 
This suggests that excessive ribosomal reads were the cause of poorer than 
expected Salmon quantification success in the primary samples (Figure 3.2), and 
implies that ribosomal depletion was less successful in primary samples than cell 
lines. The depletion protocol involves firstly adding DNA oligos with affinity to rRNA 
sequences followed by incubation with an RNase which digests DNA-RNA hybrids. 
The incubation step was only carried out for 15 minutes, therefore it is possible that 
there was incomplete digestion of these sequences. It could also be possible that 
the digestion was partially successful and created smaller fragments without 
completely removing them, because the principal reason for STAR mapping failures 
was reads being too short (Figure 3.3 d). Fragments would have been size-selected 
prior to sequencing, but given the probabilistic nature of the selection process, some 
smaller fragments may have been included.  
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The manufacturers of the ribosomal depletion kit, New England BioLabs, were 
contacted about the apparent failure of the ribosomal depletion. They suggested a 
number of steps at which the depletion could have been sub-optimal: 
• If the RNase did not fully digest the hybridized rRNA then it would have 
persisted through to sequencing. 
• The kit contains a DNase to digest any unused ssDNA probes which hadn’t 
bound to rRNA, however if this enzyme failed then the probes would be 
sequenced and could appear as rRNA reads. 
• It is also possible for the kits to be overloaded, and if the primary samples 
contained an excess of rRNA then it could have exhausted the reagents and 
persisted through to sequencing. 
It could be that the difference in performance was because the protocol and kit for 
ribosomal depletion was developed using cell lines, not primary tissue samples, and 
therefore is in some way optimised to their specific transcriptomic profile - because 
PCA clearly demonstrated a difference between tissue samples and cell lines 
(Figure 3.10). Or there could be an intrinsic quality of the mucosa-derived primary 
samples which makes rRNA depletion more challenging. 
Zhao et al. compared expression profiles obtained from RNA-seq using either poly-A 
enrichment or ribosomal depletion from 11 fresh frozen primary breast tumour 
samples. Poly-A enrichment produced 62.3% of reads mappable to the 
transcriptome by the genomic aligner MapSplice361, whereas the two different 
ribosomal depletion protocols they used (either Ribo-Zero-Seq or DSN-Seq) only 
produced 31.5% and 22.7% of reads which could be mapped to the 
transcriptome316. This demonstrates that other groups have also observed low 
proportions of transcriptomic reads after ribosomal depletion. 
Lahens et al. used in vitro transcription of >1,000 cDNAs with known abundance 
and sequence content to investigate the technical sources of noise and bias in RNA-
seq protocols. They found that rRNA depletion accounted for the most significant 
variability in sequence coverage across all transcripts362, further highlighting the 
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In cell lines Salmon had a higher quantification success rate than STAR (Figure 
3.2). Perhaps this is because for a library where rRNA depletion has been more 
successful, the multiple bias-detection models constructed by Salmon allow it to 
outperform traditional alignment algorithms. A 2-pass STAR alignment may have 
produced even higher mapping successes, however previous in-house analyses 
showed the additional benefit over 1-pass to be minimal. The absence of large 
amounts of alignments to repetitive rRNA sequences at chromosome 21 or its 
associated contigs in cell lines (Figure 3.7) likely contributed to Salmon achieving a 
greater percentage quantification success rate in these samples. 
The rRNA sequences were not explicitly removed prior to running sQTL detection 
algorithms, however the packages will have automatically disregarded such 
sequences because each rRNA gene only possesses a single annotated transcript, 
therefore an sQTL cannot be called for them. 
3.4.5 Differences in mapping success rate between batches 
likely explained by total read depth 
There was a greater depth of sequencing for samples from batch 10525 (with which 
the cell lines were also sequenced) than batch 2013152, with means of ~155M and 
~130M reads respectively (Figure 3.2). A greater percentage of the reads not 
quantifiable by Salmon were able to be successfully mapped by STAR for batch 
2013152 (~90%) than from 10525 (~65%, Figure 3.3 a). The percentage of reads 
which failed STAR mapping for being too short was lower in batch 2013152 (~10%) 
than 10525 (~30%, Figure 3.3, b). This implies that the extra sequencing depth in 
batch 10525 resulted in the sequencing of more poorly mapping sequences than in 
batch 2013152, as the likelihood of rare fragments being sequenced does not scale 
exactly linearly with sequencing depth363. Another consequence of using ribosomal 
depletion as opposed to poly-A-enrichment is the potential presence of immature 
reads from intergenic regions. With greater sequencing depth of an rRNA depleted 
library, such noisy, low-frequency transcription could be the cause of the poorer 
percentage mapping success by STAR in batch 10525. 
 
3.4.6 PCA and batch effects 
There was clear separation of primary and cell line samples by PCA (Figure 3.10), 
which is to be expected given that the primary samples were normal mucosa and 
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the cell lines were immortalised CRC lines (HCT116, SW480 and LS174T). It was 
initially surprising that there was no gender separation by PCA of the 221 patient 
samples from both batches (Figure 3.11). However, it became clear that the 
differences were being masked by batch effects and the contribution of low variance 
features, because the expected separation became apparent when PCA was 
performed on just the highest variance genes from a single batch (Figure 3.13). 
Correction with ComBat did coalesce the two batches together to some extent 
(Figure 3.14), however it introduced too many negative numbers in to the data for it 
to have been compatible with the sQTL detection algorithms used in this project 
(Figure 3.15). The hidden factors identified by PEER analysis were unable to be 
used with sQTLseekeR due to its inability to accept covariates, and the residuals 
also contained too many negative values (Figure 3.16). 
These procedures were followed in an attempt to remove batch effects and allow the 
combining of the two batches for subsequent sQTL analysis. However, the authors 
of the sQTLseekeR package make the point that because it uses relative transcript 
ratios to call sQTLs, common batch effect confounders such as total library size and 
library content should be considerably ameliorated364. Taking ratios of transcript 
expression will internally normalise each gene’s transcript content within each 
sample, meaning that changes in relative transcript ratios between samples of 
different genotypes will still be detectable regardless of batch differences such as 
library size, as long as there are sufficient read counts of each transcript involved in 
the sQTL for it to be considered statistically significant364. A similar appraisal could 
be made of the relative changes in PSI used by the Leafcutter algorithm261, however 
the FastQTL association tool used in concert with it is able to accept covariates259, 
so both approaches are covered in this thesis. 
3.4.7 WGCNA differential network expression analysis 
The Fisher’s exact test p-values for comparing gene membership between modules 
were not multiple testing corrected by the WGCNA software before plotting the 
heatmap in Figure 3.19. A stringent Bonferroni correction would have required their 
values to be multiplied by the total number of comparisons made between modules 
(342 separate pairwise comparisons for an 18 by 19 matrix), and so any p-values < 
1.46E-4 would have achieved multiple-testing corrected significance. Given that the 
-log10(p-value) scale for Figure 3.19 ranged from 0 to 50, the majority of 
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comparisons with any visible colouration would have remained statistically 
significant after such a correction. 
The majority of gene co-expression modules identified by WGCNA remained stable 
between male-specific and consensus gender networks (Figure 3.19). One male-
specific module, the genes of which were enriched in immune-related functions, was 
not re-created in the consensus network (Table 3.5). A similar level of agreement 
between gender expression networks was observed by Fatima et al. when 
performing WGCNA on 44 male and 42 female peripheral blood mononuclear cell 
(PBMC) samples. They constructed differential networks for each gender, 
comparing RNA-seq from 0 or 240 minute timepoints following oral lipid treatment in 
an attempt to find biomarkers for early-stage diet-related diseases. They found clear 
similarities between the response of the two genders, with three of five genes 
differentially expressed in females being the only three genes differentially 
expressed in males, and the gene module with the most significantly different 
regulation between the 0 and 240 minute networks relating to G-protein coupled 
receptor activity in both genders365. There were only two modules which were 
specific to females, which related to energy metabolism and the innate immune 
inflammatory response365. 
Given the minimal differences observed between gene expression networks, it was 
considered justified to include both male and female samples together in the same 
sQTL analyses in this project. 
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Chapter 4 Generation of sQTLs 
4.1 Introduction 
This chapter focuses on the identification of sQTLs via two separate software 
packages. The significances, effect sizes and classes of sQTL events are analysed, 
in addition to their local distributions relative to the features they correspond to, and 
their genome-wide distributions. The correspondence between the two algorithms is 
explored, and thresholds are set to filter out low effect size events prior to functional 
characterisation in the following results chapter. 
4.1.1 Choice of sQTL detection algorithms 
Using short read alignment to quantify changes in transcript expression is 
challenging due to the high sequence similarity that many transcripts share with 
each other. Therefore to detect as comprehensive a list of sQTLs as possible, two 
complementary algorithms were used: one which works at the transcript-level and 
one which uses PSI. A similar approach was taken by the GTEx Consortium, which 
used sQTLseekeR and Altrans for their 2015 analysis of 9 tissues200. 
A more recently published software package, Leafcutter, outperforms Altrans in 
sQTL identification. When analysing the same population of 372 GEAUVADIS LCLs, 
Leafcutter was able to identify 1,294 and 1,982 sQTLs at 1% and 5% FDR 
respectively, in comparison to 624 and 1,083 by Altrans254,260. Leafcutter is based on 
the concept of quantifying differential intron usage, rather than exon linkages as in 
Altrans, and has greater potential for identifying novel events than Altrans as a result 
of its ability to infer the presence of introns de novo as opposed to requiring a 
reference genome to define exon boundaries. 
sQTLseekeR is more nuanced than simpler measures such as transcript ratio QTLs 
(trQTLs), because it requires a reciprocal change between two transcripts of the 
same gene and takes into account the interdependence of all transcripts within a 
gene. DRIMSeq is another algorithm which takes a multivariate approach to sQTL 
identification; however sQTLseekeR has been demonstrated to identify more sQTLs 
than DRIMSeq from the same dataset. When analysing GEAUVADIS CEU LCLs, 
sQTLseekeR identified 3,699 significant SNP-to-gene associations for 191 genes at 
FDR 0.05, compared to 3,036 in 97 genes by DRIMSeq246. From YRI LCLs 
sQTLseekeR identified 3,449 significant associations in 258 genes compared to 
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1,867 in 63 by DRIMSeq246. sQTLseekeR proved more adept at identifying sQTLs in 
genes with lower expression and fewer constituent transcripts expressed246. The 
improvement in performance should not be due to false positives from high 
transcript ratio variances because sQTLseekeR has the ability to discount candidate 
sQTLs where relative transcript expression variance is different between genotypes 
(svQTLs)247. 
sQTLseeker and Leafcutter have unique advantages and limitations which make 
them theoretically more adept at identifying different classes of splicing event. Whilst 
sQTLseekeR requires a known reference transcriptome, it is able to identify complex 
alternative splicing events capturing changes in expression of multiple exons and 
UTR regions. Leafcutter can identify sQTLs involving the excision of novel introns, 
but is less adept at identifying complex events involving multiple features, and 




Individuals of the Scottish Colorectal Cancer Susceptibility and the Colorectal 
Cancer Genetic Susceptibility (SOCCS or COGS) cohorts (batch 2013152) were 
genotyped on the Illumina HumanOmni5M-4v1_B SNP-Chip, which detects 
4,327,109 variants. Individuals from the Scottish Vitamin D study (SCOVIDS) cohort 
(batch 10525) were genotyped on the Illumina OmniExpressExome BeadChip 
8v1.250 (OEE3), which detects over 270,000 exonic SNPs. Images were obtained 
using the HiScan H166 scanner and .cel files were quantified using GenomeStudio 
v2011.1. Both arrays were imputed to the 1000 Genomes Phase 3 release366 based 
on GRCh37.p13, which generated a total of 47,246,411 SNPs. SNPs common to the 
two datasets were subjected to QC thresholds of 5% MAF and 0.8 imputation quality 
score, which left 5,917,7344. The genotype coordinates were lifted-over to 
GRCh38.p10 using the UCSC Liftover Tool367 with chain file 
“hg19ToHg38.over.chain.gz”. Five individuals were discounted from the study for 
presenting as clear outliers in a PCA of genotypes obtained from the OEE3 SNP 
array (Figure 4.1)i. It should be noted that the apparent separation between two 
clusters in the bottom right quadrant of the plot was not attributable to either gender 
 
4 Genotyping and imputation analysis performed by Dr Maria Timofeeva 
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or batch, and was considered minor enough to submit all such individuals to the 
same analysis so as to increase the power to identify sQTLs by including as many 
samples of expression data as possible. 
 
Figure 4.1 Principal Components Analysis of samples genotyped on OEE3 SNP array 
showing 5 individuals which were excluded from future analysis5. 
Where genotypes were in decimal dosage form, they were rounded to the nearest 
integer; either 0, 1 or 2. 3,309 variants with dosages of exactly 0.5 or 1.5 were 
removed as they could not be definitively assigned to either genotype. Variants with 
<5 individuals in each of the three genotype groups (0, 1 or 2) across the cohort of 
221 samples were removed, reducing the number of SNPs to 3,978,682. The 
approach recommended by the sQTLseekeR authors, and adopted by the GTEx 
consortium, was to only require ≥2 of the 3 genotype groups to contain ≥5 
individuals246,247. With a desire to be more stringent in this study, all 3 genotype 
groups for a given variant were required to contain ≥5 individuals in order to be 
included, because preliminary analyses with more lenient thresholds suggested that 
<5 individuals did not constitute sufficient data to generate reliable mean transcript 
expression ratios. 
INDEL status of the CRC risk locus 30kbp upstream of SHROOM2 previously 
identified by the CCG Group98 was assessed by either WGS or amplicon 
 
5 This principal components analysis was performed by Maria Timofeeva. 
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sequencing. Primers were developed which produced a 184bp amplicon if the 24bp 
sequence was present and 160bp if it was missing. The reverse primer contained a 
fluorescent 6Fam tag on the 5’ end allowing PCR products to be detected on an ABI 
microfluidics machine and analysed via GeneScan software to produce accurate 
sizing6. For the 152 samples for which there were both WGS and amplicon 
performed, 149 agreed and 3 disagreed, with the variant not analysed in any 
samples for which there was a conflict. 
Forward Primer:  CACCCACATCCCGCTGATTG  
Reverse Primer: CCTTACCAAGAGGCGAA 
 
4.2.2 sQTLseekeR 
There were clear batch effects in the RNA-seq data, as detailed in the previous 
chapter. Batch correction was attempted using two separate methods, though each 
produced negative values incompatible with the sQTLseekeR algorithm. The 
sQTLseekeR authors posit that taking transcript expression as a ratio of the total 
expression of the gene from which the transcript originates should internally control 
transcript expression for each individual. Switches in relative transcript expression 
between samples of different genotypes should still be detectable, regardless of 
differences between batches in e.g. library size, read length or insert size 
distribution. They suggest that the most unbiased approach is to simply provide raw 
transcript counts to the algorithm, rather than RPKMs or TPMs, which can be 
influenced by factors such as library size. 
Following the approach taken by the GEAUVADIS Consortium254 and the GTEx 
Consortium200, only protein-coding and lncRNA genes were used for sQTL detection 
in order to reduce the multiple testing burden that would be incurred if other gene 
classes of less interest to this study were included, such as pseudogenes or various 
classes of micro RNAs.  
sQTLseekeR filters expression data prior to calculating transcript expression ratios, 
removing transcripts with low expression by setting a default threshold of requiring a 
transcript to have read counts of above 0.01 across all samples. Decimal counts are 
applicable because Salmon is able to assign probabilistic expression values to 
 
6 Genotyping lab work carried out by Stuart Reid and Marion Walker, WGS by Victoria Svinti. 
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features which need not be integers. Any genes with only one remaining transcript 
passing expression thresholds were excluded. 
Transcript expression ratio is calculated by dividing each transcript’s expression by 
the sum of all transcripts for the gene. Genes with dispersion for transcript 
expression ratio of less than 0.1 were removed because low variability in expression 
between samples would make a gene unlikely to yield a significant reciprocal 
change in transcript expression between genotype groups. The default settings for 
expression filtering were used to ensure comparability with other studies employing 
sQTLseekeR200,247. 
When searching for SNPs to associate with transcriptional changes, sQTLseekeR 
sets a window consisting of the entirety of the gene body +/- a custom search 
window up and downstream of the gene. The authors recommend a default window 
of 5kbp as they make the assertion that SNPs most likely to be causal of 
transcriptional changes will be within or in close proximity to the transcript sequence 
in question. The same window was adopted in this study for the purposes of 
consistency and comparability200,247. FDR correction was run via a built-in function 
from the sQTLseekeR package applying a Storey q-value368 threshold of 0.05. A 
more stringent threshold of 0.01 was applied for the detection of svQTL events, and 
any candidate svQTLs were removed from the resultant pool of sQTL events. 
sQTLseekeR defines the effect size of an sQTL event as the maximum difference 
(MD) in relative transcript expression observed between two genotype groups. For 
the purposes of certain analyses in this chapter, it was desirable to identify the 
“lead” sQTL SNP for a given event, e.g. for a particular pair of reciprocally changing 
transcripts. In such an instance, the most significantly associated SNP per 
transcript-pair was chosen based on the lowest Storey q-value, then if any were tied 
by significance, the SNPs corresponding to the largest MD changes were retained. 
Any further ties were broken arbitrarily by choosing the first row of the remaining 
data. Approximately 25% of sQTLs had >1 SNPs which were equally tied for 
significance and effect size in this way, implying they were in high LD with each 
other. 
In addition to the 3.9M SNPs which passed filtering, sQTLseekeR was also run 
using the INDEL status of SHROOM2 encoded in the form 0, 1 or 2, with 0 denoting 
no copies of the 24bp. 
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4.2.3 Leafcutter data preparation 
Prior to input to Leafcutter, the RNA-seq fastq files were aligned to the GRCh38.p10 
reference genome with the Ensembl v88 gene build using STAR302 1-pass alignment 
with default parameters8. A threshold was applied that intron clusters must be 
supported by at least 50 reads across the cohort of 221 samples, and a given intron 
cluster must have reads supporting it in at least 40% of the samples. Introns of 
length up to 500kbp can be inferred by Leafcutter. 
Intron excision ratios are calculated by dividing the number of reads supporting each 
intron by the sum of all reads supporting all introns in the corresponding intron 
cluster. Intron excision ratios were zero-centred and quantile normalised (using the 
Python scipy.stats package369) to make them compatible with the model 
implemented in the FastQTL package259, which is used to calculate associations 
between intron excision ratios and variants. Peaks in the distributions of raw intron 
excision ratios towards 0.0 and 1.0 indicate that the majority of introns are either 
rarely excised or are commonly excised (Figure 4.2 a). There is a shallow peak 
around 0.5 indicating introns which are included approximately 50% of the time. The 
process of normalisation then results in a clear deviation from the raw distribution of 
intron excision ratios (Figure 4.2 b). However, the authors justify the process 
through citation of a previous study of DNase QTLs, which demonstrated that 
normalisation of feature data increased the number of identifiable QTL 
associations370. A filter removing rows in the bottom 2% of variance was applied 
because these introns would be unlikely to yield alternative splicing QTL events. 
 
8 STAR alignment performed by Dr Alison Meynert 
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Figure 4.2 a) Raw intron excision ratios from all chromosomes of 221 patients as 
quantified by Leafcutter. 
b) Intron excision ratios after zero-centring and quantile normalisation. 
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4.2.4 sQTL associations with FastQTL 
Leafcutter is able to prepare matrices of intron excision ratios, but it requires a 
separate program to calculate correlations between these phenotypes and genetic 
variants. The Leafcutter authors recommend FastQTL259. For each feature, after 
calculating nominal p-values for associations between all SNPs within the search 
window of the feature, permutations of phenotypes between individuals are used to 
model the tail of a null distribution positing no association between the feature and a 
given variant. The tail of the distribution is what determines the corrected 
significance ascribed to an association, and it can be modelled with relatively few 
permutations accurately enough via a beta distribution to calculate adjusted P-
values efficiently for analyses where many millions of associations need to be 
tested. FastQTL was run with a minimum of 1,000 permutations and a maximum of 
10,000 to construct the null distribution per association (the process can be halted 
early by the algorithm to save computational resource if a plateau is reached 
whereby no change in predicted parameters occurs with increasing permutations). 
Figure 4.3 demonstrates strong concordance between the p-values estimated via 
the beta-distribution and empirical p-values, indicating the estimation process 
worked as expected. 
The beta-estimated p-values were corrected for the number of SNP associations 
tested in cis with a given intron, with only the most significant SNP associated with 
each feature returned by FastQTL. The p-values were then Bonferroni corrected371 
for the number of introns tested per intron cluster, because the usage of a given 
intron is not independent of other introns which share the same boundaries. Then, to 
reach full genome-wide significance, all resulting p-values were subjected to 
Benjamini-Hockberg372 correction with a threshold of 0.05, following the methods 
implemented by the Leafcutter authors in their 2018 paper260. 
The first 9 principal components of the intron excision ratios as calculated by 
Leafcutter were supplied as covariates to FastQTL (Figure 4.4). 
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Figure 4.3 Correlation between beta-approximated and empirical p-values generated 
by FastQTL. Red line indicates a vector of y=x. 
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Figure 4.4 Principal components of Leafcutter intron excision ratios 
Samples coloured by sequencing batch, which shows separation in the first principal 
component. 
The effect size of sQTL events for Leafcutter are calculated as twice the absolute 
value of the slope of the FastQTL linear association between intron excision ratio 
and genotype. 
One limitation of FastQTL is that when associating variants in cis, it only sets a 
search window around the single coordinate indicating the start of the feature being 
investigated: in this case the start coordinate of introns inferred by Leafcutter. The 
search window was set to 100kbp in line with that used by the authors’ 2018 
methods paper260. A larger window than for sQTLseekeR is required in order to 
increase the likelihood of capturing the entirety of the gene body - which 
sQTLseekeR does automatically but Leafcutter does not. 93.3% of protein-coding 
and lncRNA genes have a total length of ≤190kbp, as annotated in the Ensembl 
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gene build v88328, which means that a search window of ±100kbp would be capable 
of surveying their entire length plus an additional 5kbp at either end, as 
sQTLseekeR adds. Leafcutter can infer introns up to 500kbp long, which doesn’t 
necessarily tally with a search window of only 100kbp; however features this large 
were extremely rare, only 1,908 introns inferred by Leafcutter (1.104%) had a length 
≥100kbp, and only 30 introns (0.017%) had a length ≥400kbp. It would have been 
overly stringent to penalise the inclusion of introns of this length when relevant sQTL 
SNPs could still have been discovered within ±100kbp of their start coordinates. 
A further caveat is that the intron boundary coordinates inferred by Leafcutter are 
unstranded, because they are agnostic of gene build. The smallest genomic 
coordinate is always annotated as the intron “start”, around which the search 
window is extended. However, in reality, 50% of the time the search window will be 
extended from the end coordinate of an intron relative to the direction its gene of 
origin is oriented genomically, given that there is an approximately equal division of 
genes residing on each strand. 
4.2.5 Filtering of sQTL events 
It is possible that despite FDR correction some of the identified sQTLs may 
represent false positive changes in transcript expression or intron excision due to 
low effect sizes or low total expression. Therefore post-hoc thresholds were applied 
to these parameters to refine the sQTL list to the most likely functionally relevant 
candidates. Where necessary, the lists of filtered sQTLs were compared to all 
significant sQTLs to assess whether they contained larger proportions of putative 
functionally relevant variants. 
Different strategies were attempted to identify suitable effect size thresholds from 
the data in an unsupervised way. These included: attempting to identify the effect 
size threshold which produced the highest agreement of genes containing sQTL 
events between the two packages; choosing an effect size threshold which 
maximised the number of CRC-relevant GWAS gene sQTLs; or increasing the 
threshold until significant and non-significant events formed separate distributions in 
the effect-size dimension. However, none of those approaches yielded a consistent 
or clear threshold. 
The authors of the sQTLseekeR package arbitrarily designate an MD value of ≥0.2 
as a threshold above which changes in transcript level can be considered 
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biologically relevant. Adopting this threshold retained the top 9.29% of sQTLseekeR 
events (Table 4.1). In order to apply a comparable threshold to Leafcutter events, 
the same percentage of events with the largest absolute effect sizes were retained. 
The corresponding 2*absolute slope value which imposed the same percentage was 
2.25284 (Table 4.1). 
A post-hoc threshold was also set for the gene expression or intron-usage counts 
from which sQTLs could be drawn, so as to increase the confidence in any sQTLs 
identified. Figure 4.18 demonstrates that sQTLs associated with lowly expressed 
genes are outliers in the effect size distribution, which contributes to a negative 
correlation between expression and effect size of sQTLs. Therefore an expression 
threshold was set requiring sQTLseekeR-derived events to have emanated from 
genes with a mean log10(count) ≥ 1.0 across all 221 samples. This retained the top 
7.79% of events (Table 4.1). 
A post-hoc filter was also applied to Leafcutter sQTLs, given a similar bias from low 
expression events - though which caused a correlation in the opposite direction 
(Figure 4.19). This filter was set at a less stringent level of log10(count) ≥ 0.5 
because Leafcutter identifies events at the level of individual introns rather than 
whole transcripts, meaning that fewer counts are typically available to support each 
























0.0 0.0 9.29 9.28 
0.5 0.5 8.87 8.37 
1.0 1.0 7.79 5.99 
1.5 1.5 6.54 3.52 
0.15 1.98081 
0.0 0.0 14.8 14.8 
0.5 0.5 14.4 12.6 
1.0 1.0 13.0 8.78 
1.5 1.5 11.1 5.24 
0.10 1.626546 
0.0 0.0 26.2 26.2 
0.5 0.5 25.8 20.8 
1.0 1.0 24.3 13.9 
1.5 1.5 21.5 8.29 
Table 4.1 Thresholds applied to sQTLseekeR and Leafcutter events and the 
percentage of events retained. 
The combinations of thresholds chosen to be applied to each package are underlined. 
sQTLseekeR shortened to “seekeR” in column headers. 
 
4.3 Results 
4.3.1 Distribution of sQTLseekeR events 
sQTLseekeR identified 97,021 significant sQTL SNPs associated with transcript 
switching events in 3,420 different genes at genome wide FDR 0.05. The median 
number of sQTLs identified per gene was 10 and the mean 28. The distribution is 
skewed by 55 genes for which there were >200 significantly associated SNPs 
(Figure 4.5a). These 55 highly associated genes spanned 17 different chromosomes 
and were not solely dominated by genes in the MHC region of chromosome 6, as 
might have been expected due to its dense polymorphisms373,374. The highest 
associated HLA genes from the MHC region were HLA-B with 628 separate 
significant sQTLs, HLA-DPA1 with 204 and HLA-DQB1 with 109. 
Within the 3,420 different genes with sQTL events, there were 5,492 different pairs 
of transcripts which underwent reciprocal changes in expression ratios (Figure 4.5b). 
The distribution of the number of SNPs associated with each transcript-pair was 
similar to that of the SNPs per gene (Figure 4.5c). 
There was a predominance towards lower effect-size (MD) events identified by 
sQTLseekeR, and no clear correlation between MD and significance (Figure 4.6). 
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The “banding” of p-values is caused by limitations of the non-parametric MANOVA-
based test that underlies sQTLseekeR, which reaches a maximum significance it 
can ascribe to an event given the number of samples tested in this analysis. There 
was also no apparent difference between the relationship of these values for 
protein-coding transcript-switches which occurred between transcripts with the same 
or different biotypes, or for transcript-switches that occurred between protein-coding 
or lncRNA genes. The summary of all biotype changes is presented in Table 4.2. 
Transcript Biotype Change Number Percentage 
protein-coding to protein-coding 2776 50.546 
protein-coding to retained_intron 839 15.277 
protein-coding to processed_transcript 639 11.635 
protein-coding to nonsense_mediated_decay 529 9.632 
protein-coding to non_stop_decay 2 0.036 
protein-coding to other 396 7.211 
lncRNA to lncRNA 310 5.645 
lncRNA to retained_intron 1 0.018 
Table 4.2 sQTLseekeR transcript biotype changes 
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Figure 4.5 a) Number of sQTL SNPs significantly associated with each gene 
b) Number of significant transcript-pair switches per gene. The modal number of 
significant transcript-pair switches per gene at FDR 0.05 was 1, the mean was 1.61 
c) Number of sQTL SNPs significantly associated with each transcript pair. The 
median number was 5.00 and the mean 17.67. Any genes or transcript-pairs with ≥200 
associated SNPs are binned for clarity 
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Figure 4.6 Distribution of significance of sQTL events against MD value 
For all 5,492 FDR 0.05 significant transcript-pair switches, the significance of the event 
expressed as -log10(Storey q-value) is plotted against the MD effect size of the event. 
Transcript-pairs are faceted by whether they were from protein-coding or lncRNA genes, and 
the protein-coding events are further separated by whether there was a change in biotype 
between the two transcripts involved in the event or not. Protein-coding with biotype change 
(n = 2205), Protein-coding with no biotype change (n = 2976), lncRNA (n = 311). 
 
4.3.2 Classification of sQTLseekeR Splicing Events 
Sammeth et al. developed an ontology for describing alternative splicing events375 
which formed the basis of the AStalavista package376, and more recently has been 
incorporated into the sQTLseekeR package. The most common class of sQTLs 
identified by sQTLseekeR are complex events (Figure 4.7). Most types of event are 
equally represented whether analysing the 3,420 most significant sQTLs per gene, 
or whether analysing the 5,492 most significant sQTLs per pair of transcripts. This 
implies that where multiple transcript-pair events are found per gene, they do not 
constitute systematically different classes of splicing events to the single per-gene 
events. 
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Figure 4.7 Classification of sQTL splicing events identified by sQTLseekeR 
The proportion of sQTLs which are able to be classified as each type of splicing event sum 
to greater than 1.0 because not all classes are mutually exclusive and some events can 
satisfy the criteria for more than one class. 
 
4.3.3 Distribution of Leafcutter Events 
Leafcutter inferred the presence of 175,792 different introns belonging to 47,977 
separate “intron clusters”. After association with variants via FastQTL, there were 
12,830 significant intron-level sQTL events from 6,153 intron clusters at FDR 0.05 
(Figure 4.8). Plotting effect sizes against significance for Leafcutter sQTL events 
more closely resembles the expected pattern of a volcano plot than was observed 
for the non-parametric sQTLseekeR, with larger effect size events trending towards 
greater significance (Figure 4.9). Because FastQTL calculates the significance of 
associations using a parametric linear model, there is no p-value banding as seen 
with sQTLseekeR. 
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Figure 4.8 Significant introns per intron cluster. 
The modal number of significant introns per cluster was 1.00, the median 2.00 and mean 
2.09. One cluster with 46 significant introns has been excluded for clarity. 
 
 
Figure 4.9 Leafcutter significance against effect size 
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4.3.4 Assignment of Leafcutter events to genes and 
transcripts 
There is no direct way to link an intron-level sQTL event identified by Leafcutter to 
an Ensembl-annotated gene or transcript, because of the intrinsic ability of 
Leafcutter to identify introns agnostically of a reference transcriptome. 
In order to identify the features which the Leafcutter-inferred introns most likely 
correspond to, introns were firstly assigned to any genes annotated in Ensembl 
gene build v88 for which their coordinates fell within the start and end sites of. 
However, multiple genes can overlap the same inferred intron for multiple reasons: 
either because Leafcutter introns are unstranded and genes from both strands can 
overlap them, or because of overlaps with smaller gene types such as miRNA, 
lncRNA, pseudogenes etc. which can reside within the coordinates of larger genes.  
There were a total of 10,762 introns with significant sQTL associations which were 
overlapped by protein-coding or lncRNA gene coordinates, and some of these were 
overlapped by more than one of these classes of gene (Table 4.3). To choose the 
gene best matched to each intron, and to ascertain the extent of novelty of the 
events Leafcutter was able to identify, the inferred intron boundaries were compared 
against annotated exon coordinates from overlapping genes. 7,411 introns matched 
to known exon coordinates by both their start and end sites, 1,342 matched only by 
start site, 1,326 only by end site, and 683 were unmatched by either of their 
coordinates. These may represent novel, previously unannotated “cryptic” introns. 
1,008 significant introns identified by Leafcutter were not fully-overlapped by any 
annotated gene from Ensembl gene build v88 mapped to GRCh38.p10. Of the 3,910 
genes whose coordinates encapsulated an intron with a significantly associated 
sQTL, 3,781 were protein-coding and 129 lncRNA. Some genes harboured many 
different significant intron-level events (Figure 4.10 a). 
Leafcutter introns were also linked to a corresponding transcript in order to facilitate 
a comparison between Leafcutter sQTLs and the transcript-level sQTLseekeR 
events. Introns were assigned to any transcripts which overlapped them, then 
matches were further filtered by checking whether intron boundaries inferred by 
Leafcutter overlapped annotated exon boundaries for those transcripts. Slightly 
fewer significant introns (10,059) were able to be mapped to transcripts (3,720 from 
protein-coding genes and 129 from lncRNAs) using this methodology than were able 
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to be assigned to genes, leaving 2,771 which were not assigned to any known 
transcript. There were cases where an intron could potentially match multiple 
different transcripts (Figure 4.10 b), and some transcripts contained more than one 
significant intron event (Figure 4.10 c). 
Gene_type Number_of_genes Number_of_introns 
protein-coding 4090 10373 
antisense 306 728 
lincRNA 163 433 
transcribed_unprocessed_pseudogene 122 435 
processed_transcript 110 473 
Other 88 298 
NA NA 1008 
Total 4880 13748 
Total unique 4880 12830 
Table 4.3 Number of introns whose coordinates were overlapped by different classes 
of genes 
The total number of introns in the table (13,748) is greater than the 12,830 unique significant 
introns because certain introns can be overlapped by multiple genes and therefore 
represented multiple times in the table. 
 
 
  126 
 
Figure 4.10 a) Number of FDR 0.05 significant Leafcutter intron events assigned to 
each gene based on agreement between intron coordinates and exon boundaries. 
Mode 1.00, median 2.00 and mean 2.58 (n=3,910 genes) 
b) Number of transcripts potentially assignable to each intron 
Zero represents the 2,771 introns unable to be assigned to a known annotated transcript. 
c) Number of introns assigned to each transcript 
Median 2.00, mean 2.279. 
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4.3.5 Local distributions of events 
SNPs associated with transcript-level sQTL events by sQTLseekeR were most 
commonly found within the body of genes (Figure 4.11). There were fewer events 
found up and downstream of genes, without any obvious drop-off in the rate of 
events throughout the 5kbp window.  
 
 
Figure 4.11 Distribution of sQTLseekeR events relative to gene body 
Where sQTL SNPs fall upstream or downstream of the gene they relate to, the distances are 
plotted in kbp. Where a SNP falls within the gene body, the percentage distance along the 
length of the gene is shown. n=614 Upstream, n=4,231 Within, n=647 Downstream. 
The search window set by FastQTL is fundamentally different to sQTLseekeR’s, 
defined as a range around the start-site of each Leafcutter-inferred intron rather than 
the whole gene body plus a window. Because the length of introns can vary greatly, 
a larger window of ±100kbp is required with FastQTL to maximise the likelihood of 
achieving coverage over the gene-body of every gene. As a corollary, FastQTL 
searched much farther up or downstream of certain genes than sQTLseekeR, and a 
clear drop-off in the rate of events can be observed as distance up or downstream 
from a gene increases (Figure 4.12a). There was also a drop-off in significance of 
Leafcutter events as the distance from gene body increased (Figure 4.12b). 
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Figure 4.12 a) Distribution of Leafcutter events relative to gene body. 
In cases of multiple potential mappings, the largest protein-coding gene was selected. Up 
and downstream distances between sQTLs and genes is plotted in kbp; sQTLs falling within 
gene bodies are plotted by percentage distance along the length of the gene. n=1,853 
Upstream, n=6,475 Within, n=1,731 Downstream. 
b) Significance of Leafcutter sQTLs against distance to gene body 
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In case the mapping from introns to genes was imperfect and masked any specific 
patterns in the data, the significance of events relative to simply the distance from 
the start-site of each intron was also plotted. This shows a clear peak around the 
beginning of the intron boundary, and a similar drop-off in significance as distance 
increases (Figure 4.13a). This plot is more indicative of the actual search window 
adopted by FastQTL, given that it only searches relative to the start site of each 
intron and is naïve to the relationship between introns and genes. It also appears 
that effect size of the Leafcutter events decreases further away from the intron start 
site (Figure 4.13b), which is to be expected given the relationship observed between 
these two metrics in Figure 4.9. 
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Figure 4.13 a) Significance of Leafcutter events relative to distance from intron start 
site 
b) Effect size of Leafcutter events relative to distance from intron start site 
The effect size is twice the absolute slope for the FastQTL linear association between 
genotype and Leafcutter intron usage ratio. 
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4.3.6 Genome wide distributions of sQTL SNPs 
When viewed genome-wide, it is difficult to identify any hot-spots denoting clusters 
of significant sQTLs due to the issue of p-value banding from the sQTLseekeR 
algorithm, caused by there being a limit to the maximum significance which can be 
ascribed to an event using a non-parametric approach with 221 samples (Figure 
4.14a). 
The Leafcutter results do not suffer from p-value banding, and so hot-spots of 
sQTLs are more clearly discernible (Figure 4.14b). The MHC region on 6p21 is the 
densest region of sQTLs, however it does not contain the most highly significant 
events. 
There were fewer highly significant events identified by either package on 
chromosome 23 (X). This could be because of the sparsity of variants probed for by 
SNP arrays for the X chromosome, or because with ~50% of the samples being 
male, there is decreased power on the X chromosome to call sQTLs because there 
are fewer heterozygous individuals. Overall expression will also be lower on the X 
chromosome because males will have no expression from female-specific X 
chromosome genes, meaning that fewer genes will pass the thresholds set by the 
packages for inclusion in the sQTL-detection algorithms. 
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Figure 4.14 Manhattan plots of sQTL distributions 
FDR 0.05 significant results and a random selection of 5% of the nominally significant events 
for a) sQTLseekR (red line = genome-wide significance threshold) and b) Leafcutter (a 
single genome-wide significance threshold is not applicable due to the FDR correction being 
tailored to each individual intron). Plots generated with the qqman package377. 
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Despite the Manhattan plots being of differing quality between the two sets of 
results, when examining the distribution of the total number of events identified per 
chromosome, a strikingly similar pattern is observed (Figure 4.15). It is clear that the 
potential for finding sQTLs is dependent on the number of protein-coding genes 
available to be tested. 
 
Figure 4.15 Number of sQTL events found by each package per chromosome 
Background bars denote number of protein-coding genes located on each chromosome. The 
number of sQTLs found by Leafcutter on Chromosome 7 is greater than the number of total 
protein-coding genes on that chromosome because Leafcutter identifies intron-level sQTL 
events independent of gene annotation. n=5,492 sQTLseekeR events, n=12,830 Leafcutter 
events, n=19,741 protein-coding genes. 
 
4.3.7 Comparisons between sQTLseekeR and Leafcutter 
sQTLs 
There was an intersect of 1,387 genes for which sQTLs were identified by both 
packages, which is equivalent to 40.5% of the sQTLseekeR genes and 35.5% of the 
Leafcutter genes (Figure 4.16). Of these, sQTLseekeR identified sQTLs in 209 
lncRNA genes, whilst Leafcutter identified 129. The intersect of lncRNAs was 39, 
which is 18.7% of the sQTLseekeR lncRNA genes and 30.2% of the Leafcutter 
(Figure 4.16). 
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Figure 4.16 Intersect of genes with associated sQTL events identified by sQTLseekeR 
and Leafcutter. 
Protein-coding genes are in upper circles, and lncRNA in lower. 
The degree of correspondence between sQTL events identified by the two packages 
was compared by correlating the effect sizes of sQTLs where the intron identified by 
Leafcutter matched at least one exon boundary of one of the transcripts involved in 
an sQTLseekeR event (Figure 4.17). This produced a Spearman Rho correlation of 
0.087 (n=8,144, p=3.61e−15). The low correlation could be explained by multiple 
factors. The MD values of sQTLseekeR are scaled to a ratio between 0.0 and 1.0, 
whereas the effect sizes for Leafcutter are based on the slope of the linear 
correlation calculated by FastQTL in normalised space, so it is not surprising that 
the two are poorly comparable. Also, because Leafcutter introns have the potential 
to correspond to multiple transcripts and therefore to multiple different transcript-
level sQTL events, there is rarely a perfect one-to-one comparison between effect 
sizes for the exact same change in alternative splicing of a given feature (transcript 
or intron). One single sQTLseekeR MD value for a complex alternative splicing 
event may be represented across multiple Leafcutter sQTLs. 
If correspondences are filtered to only include the most significant of the potentially 
corresponding pairs of events between packages, then the correlation increases to 
0.114 (n=2,337, p= 3.56e−08). The correlation also increases further to 0.216 if only 
events with exactly the same “lead” associated SNP are used (n=123, p=0.0163). 
However, the correlation still remains low, and this serves to further highlight the 
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differences between the outputs of the two algorithms and the challenges in drawing 
relevant comparisons between them. 
 
Figure 4.17 Effect size correlation of events between packages 
Best fit lines are a linear model fitted by the “lm” linear model function in ggplot2. 
4.3.8 Filtering of sQTL events 
Filtering of sQTL events was carried out so as to supply a higher-confidence list of 
sQTLs for the functional characterisations carried out in the following chapter.  
sQTLs derived from lowly expressed genes were excluded. There was a negative 
correlation between effect size and mean gene expression level for events identified 
by sQTLseekeR (Figure 4.18). This is likely because events supported by only a low 
number of counts have less scope to generate smaller ratios of transcript expression 
for a given genotype group, and therefore the MD effect size can only adopt a 
limited range of values. Conversely, there is a positive correlation between effect 
size and the number of read counts supporting introns associated with sQTLs by 
Leafcutter + FastQTL. The tool’s effect sizes are not ratios, but are calculated from 
linear associations; therefore the more reads available for a given intron, the steeper 
the gradient of linear association that is can be produced (Figure 4.19). 
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Figure 4.18 sQTLseekeR effect size against mean gene expression across 221 
samples 
Salmon transcript-level counts were aggregated to gene-level by tximport and the mean 
gene expression calculated across 221 samples. Blue line represents a linear model fitted by 
the “lm” function in ggplot2 with Spearman Rho: −0.369, p−value: 1.44e−110. Red points 
passed a threshold of 0.2 effect size and 1.0 log10(mean gene count). 
 
Figure 4.19 Leafcutter effect size against mean read counts supporting intron excision 
Mean read counts assigned to introns by Leafcutter across the 221 samples are plotted 
against 2* the absolute slope of correlation. Blue line represents a linear model fitted by the 
“lm” function in ggplot2 with Spearman Rho: 0.289, p−value: 4.01e−246. Red points passed 
a threshold of 2.25284 effect size (2*absolute slope) and 0.5 log10(mean intron count). 
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4.4 Discussion 
4.4.1 Reliability of sQTL identification 
Accurate quantification of transcript expression is key to the identification of sQTLs. 
The Leafcutter authors benchmarked their algorithm using either OLEGO or a two-
pass STAR alignment and found little difference between the two: 4.8% of junctions 
differed by a fold difference of 1.1 and only 0.94% of junction counts differed by a 
fold difference of >2.0260. This study only used a single-pass STAR alignment9, so 
this may have slightly reduced the number of reads mapped and so the scope of 
Leafcutter to infer sQTLs relating to the usage of novel intron junctions; however 
OLEGO also only runs a single-pass alignment, so any gains from the additional 
alignment pass would likely have been negligible. 
There is some intrinsic uncertainty in the calling of variants from fluorescence-based 
SNP arrays and in the imputation of genome-wide variants from exome-only chips. 
The simple conversion of decimal genotype dosages to integers may have masked 
some uncertainty in the calling of variants; however it was a necessary step for input 
of the data into sQTLseekeR. If a threshold had been set requiring the SNPs to have 
dosages ≤0.1 away from an integer for >90% of the samples in order to be 
accepted, then this would only have removed 5.17% of the total variants. Thus the 
scope for false positive observations as a result of not having imposed any such 
thresholds is limited. FastQTL was run directly on the original decimal genotype 
dosages without any filtering, and so had the opportunity to account for the 
uncertainty of decimal values in its linear model. 
Allele-specific expression (or biases in detection or half-life of certain allele-specific 
transcripts) may influence the identification of sQTLs and introduce false positive 
results. The authors of Leafcutter suggest running a tool called “WASP” prior to any 
expression-dependent QTL analyses in order to identify and screen out such 
variants378, but they did not apply WASP for their 2018 analysis of GEAUVADIS 
CEU expression data to maintain comparability with previous analyses260. Panousis 
et al. demonstrated in their 2014 study that allelic bias arising from preferential 
mapping of reference alleles over alternative alleles is not a major source of false 
positive eQTLs, with only 3.67% fewer genes identified as having an eQTL with 
 
9 STAR alignment performed by Dr Alison Meynert. 
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allele-specific reads filtered out379. Based on this observation of minimal gains, 
correction for allele-specific expression was not performed in this study - although it 
could be argued that mapping biases of allele-specific reads may have more 
potential to influence sQTLs than eQTLs because the sequences of individual 
transcripts matter more when not being summed to total gene expression. 
There were often multiple variants associated with each alternative splicing event 
(Figure 4.5 and Figure 4.10), a common pattern in QTL studies200. In this project, 
where a “lead” SNP was chosen, the significance and effect size were used to 
prioritise the most likely variant. Lappalainen et al. showed in their 2013 analysis of 
QTLs in GEAUVADIS that using these metrics did identify the most likely causal 
variant in between 34% and 74% of cases, depending on the population analysed, 
although they derived genotypes from whole genome sequencing data, and 
therefore had access to more variants254. They report that the lead SNP was present 
in WGS from 1000 Genomes but not on an Omni 2.5M SNP array in 81% of cases. 
Variants in this study were imputed to 1000 Genomes to increase the potential to 
identify causal sQTL SNPs not captured by arrays alone. The instances in this 
analysis where multiple SNPs were associated with an sQTL event with exactly the 
same significance and effect size likely means the variants were in particularly high 
LD with each other, and there were the same numbers of the 221 individuals falling 
in each of the genotype groups for the linked SNPs, and so their effects were not 
able to be differentiated. Other more advanced methods do exist to fine-map the 
causal SNP for a QTL event, for example RASQUAL uses other genomic features 
such as DNA-accessibility in the form of ATAC-seq to narrow down the most likely 
candidate causative variants for eQTLs380. A similar approach could have been 
adapted to sQTLs, however high depth ATAC-seq was not available from normal 
colonic mucosa at the time of this analysis. 
De novo transcriptome assembly with tools such as Trinity381 or StringTie382 was not 
performed for this study because the RNA-seq data was obtained from normal 
mucosa samples, and the transcriptomes were therefore assumed to be normal. If 
matched tumour RNA-seq were used for future comparisons with this normal data, 
then there would be greater motivation to search for novel splicing patterns. Some 
authors suggest that even when analysing normal tissue there is novelty to be 
found: when analysing non-tumour RNA-seq from 75 individuals from 1000 
Genomes consortium, Stein et al. were able to identify 437 novel splice junctions 
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that were not mappable to the human reference genome by constructing “personal 
genomes”383. This implies some additional novelty may have been missed by not 
taking this approach in this study, however it is likely to be small. 
The sQTLseekeR authors propose that their algorithm should be reasonably 
immune to batch effects because it relies on transcript expression ratios which are 
internally controlled against the total expression of each gene. When identifying 
sQTLs from Leafcutter-inferred intron usages, FastQTL is able to use covariates to 
account for potential confounding factors, of which the clearest component from 
PCA corresponded to batch (Figure 4.4). Therefore, there is an argument to be 
made that each batch could have been analysed separately so as to avoid this 
potential confounding factor, and then the sQTLs from each combined together. 
However, both batches were combined so as to increase power when testing for 
differences in transcript expression or intron usage ratios between genotype groups, 
and to have higher likelihood of being able to analyse rarer variants. When calling 
sQTLs from GEAUVADIS LCLs in their 2014 study, the sQTLseekeR authors ran 
their analysis on each of the subpopulations of CEU, FIN, GBR, TSI and YRI, which 
consisted of 91, 95, 94, 93 and 89 samples respectively. They found a 92% sharing 
of sQTLs between groups247, which in addition to demonstrating the transcriptional 
similarities of the populations also implies that power would be wasted analysing 
smaller cohorts separately and finding the same sQTLs repeatedly when combining 
the samples may have allowed other, rarer sQTLs to be identified. Similarly, when 
deriving QTLs from 44 tissues, the GTEx Consortium found that greater numbers of 
eQTLs were discovered when expression data from multiple tissues were combined 
together than when each tissue was analysed separately200. In a preliminary 
analysis carried out at the beginning of this project, sQTLseekeR was able to 
identify sQTLs for 1,658 unique genes from 92 samples from batch 2013152 at FDR 
0.05. This is roughly half the 3,420 genes with sQTLs identified from the 
combination of batches 2013152 and 10525, demonstrating the utility of combining 
the two cohorts together for increased power. 
Instead of relying on transcript expression quantification at all, methods have been 
derived to predict alternative splicing based on sequence alone. Jaganathan et al. 
trained a 32-layered deep neural network to predict patterns of alternative splicing 
from pre-mRNA sequences, using 5kbp-worth of sequence up and downstream of 
each base to predict whether it constituted a splice donor or splice acceptor. The 
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events it predicted had a 75% validation rate from RNA-seq216, and when perturbing 
the sequences artificially, it was found that the bases most contributing to the 
model’s predictions were upstream splice acceptor sites, or the binding sites of SR-
family proteins or branchpoint spliceosome binding motifs216. 
4.4.2 sQTLseekeR events 
In their 2014 analysis of GEAUVADIS LCLs, the sQTLseekeR authors identified an 
average of 2,900 sQTLs at 5% FDR for each of the populations they analysed247. 
This is likely fewer than the 5,492 different significant transcript-pair sQTLs identified 
in this study because they analysed smaller individual populations separately. They 
also had a lower number of genotyped SNPs (1.3M as opposed to 3.9M), and had 
shorter read lengths and a lower depth of expression data: 75bp paired-end RNA-
seq with a mean of 48.9M reads per sample compared to 100bp or 150bp paired 
end reads with means of ~130M and ~150M mapped reads per sample (batches 
2013152 and 10525 respectively). Increased read length has been demonstrated to 
improve splice-junction detection by Chhangawala et al. based on analysis of 
ENCODE samples, with 100bp reads shown to identify up to 25% more splice 
junctions compared to 75bp384. There were also differences in the alignment and 
quantification of transcript expression: they used the GEM385 aligner and quantified 
transcript expression from the genomically-aligned reads with Flux Capacitor249, as 
opposed to the alignment-free quantification via Salmon301 which was used in this 
study. 
There was no clear drop in the rate of sQTLs identified along the 5kbp search 
window up or downstream of genes for sQTLseekeR (Figure 4.11). Searching within 
sequences proximal to gene bodies was justified because this is where most 
variants influencing regulation are expected to occur254,386, however the lack of drop 
in rate could imply that it may have been useful to extend the search region further - 
though perhaps not as far as the 100kbp window that Leafcutter used, which 
displayed a clear drop-off in events (Figure 4.12). Statistical power may have been 
diminished by FastQTL evaluating more SNPs farther away from genes and 
consequently requiring greater multiple testing correction. 
DRIMSeq is a newer algorithm than sQTLseekeR, which instead of using a non-
parametric MANOVA to analyse expression ratios of each transcript, directly models 
the transcript expression of all isoforms of a gene using a Dirichlet Multinomial 
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distribution246. An advantage it confers over sQTLseekeR is that the model can 
include a representation of the expression of each transcript and account for this 
when quantifying uncertainty in the estimated expression ratio which the transcript 
contributes to total gene expression. Expression ratios calculated by sQTLseekeR 
from lower-expressed transcripts will have lower certainty and wider intervals of 
confidence, which is not currently taken into consideration by the algorithm. 
However, the setting of low expression thresholds and post-hoc filtering should have 
reduced the contribution of inaccurate ratio quantification to this study. The risks of 
inaccuracy are also greater when there are fewer samples, which further justifies the 
combination of both batches for the purposes of this analysis. When analysing RNA-
seq from 91 CEU samples and 89 YRI samples, DRIMSeq found fewer genes 
containing sQTLs than sQTLseekeR. sQTLseekeR was able to find more 
associations in lower expressed genes and in genes with fewer different expressed 
transcripts, and found more associations with SNPs farther away from the nearest 
proximal exon246. It was desired in this study to perform as comprehensive as 
possible a survey of alternative splicing events, hence the utilisation of sQTLseekeR 
is justified. 
One clear limitation of the sQTLseekeR package is its lack of ability to accept 
covariates, though other transcript-level sQTL association tools such as DRIMSeq 
do not include covariates either246. It may not be an essential addition, however. 
Singh et al. studied eQTLs in colonic tissues using linear regression of microarray 
probe intensities against genotype based on an additive model with either no 
covariates, or covariates including age, gender, population-level principal 
components and clinical metadata including disease status (23 patients had 
ulcerative colitis, 16 Crohn’s disease, 33 no disease)222. They concluded that there 
was a reduction of power when all possible covariates were included, and that there 
was robust concordance of results between models with or without the inclusion of 
covariates, and so they decided to report as their final results the direct pairwise 
regressions between array probe intensities and variants222. This lessens the 
motivation for adding covariates to sQTL detection algorithms which do not currently 
account for them, particularly sQTLseekeR, which would not be able to accept them 
in its current non-parametric form. 
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4.4.3 Leafcutter events 
In this study, Leafcutter inferred the presence of 175,792 different introns exhibiting 
differential excision. “SplAdder” is a similar programme which also infers differential 
intron useage based on RNA-seq alignments, however it first employs a genome 
annotation file to building a splicing graph, then uses genomically-aligned RNA-seq 
reads to assign confidence to predicted introns and prune or augment the graph 
appropriately387. SplAdder was used by Lehmann et al. to search for cancer-specific 
splicing patterns by comparing the frequency of intron usage from 282 kidney renal 
clear cell carcinoma (KIRC) samples to normal samples from the same patients, 
plus 140 GEAUVADIS and 460 ENCODE RNA-seq samples. 160,208 introns with 
alternative usage were identified - similar to the 175,792 seen in this study using 
Leafcutter - though with less stringent thresholds of only requiring an intron to be 
supported by at least 10 reads in any one of the 882 samples248. They used an older 
version of the genome build as a basis for SplAdder to augment (Gencode version 
14, which corresponds to the Ensembl release version 69 from the 4th quarter 2012), 
and each of the TCGA samples had fewer reads than this study with approximately 
70M.  
Novelty of introns inferred by Leafcutter 
The Leafcutter authors found in their 2018 analysis of GTEx tissues that 10.8%, 
19.3% and 48.5% of the introns they inferred from pancreas, spleen and testes (a 
notable outlier) respectively were previously unannotated in either of GENCODE 
v19, Ensembl v75 or UCSC v19 gene builds. Leafcutter was also used by Raj et al. 
to investigate alternative splicing in brain autopsy samples from 450 individuals 
partaking in prospective cohort studies of aging, and 30% of the 53,251 intron 
clusters identified were novel to the extent that they had not been previously 
reported in other sQTL studies265. 
Using vast-tools388, an algorithm which similarly to Leafcutter is designed to predict 
alternative usage of exonic sequences from genomically-aligned RNA-seq reads, 
the creators of the Vertebrate Alternative Splicing and Transcription Database 
(VastDB) found that 13.9% of the alternative-splicing events they identified from 108 
human individuals were not previously annotated in Ensembl389. In this study, 7.86% 
of Leafcutter-inferred introns with a significant sQTL did not overlap any gene 
annotation from Ensembl version 88, and so would be considered novel. Of the 
10,762 introns which fell within the coordinates of protein-coding or lncRNA genes, 
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68.9% shared both their intron boundaries with exon coordinates annotated in 
Ensembl GRCh38v88. 24.8% shared at least one boundary with an exon coordinate 
and 6.35% shared none. Taking the sum of these last two categories would make 
31.2% of introns which could be considered at least partially novel. This falls 
between the extremes identified by the Leafcutter authors of 10.8% to 48.5% from 
pancreas and testes. The numbers in this study may be higher than they observed 
for other non-germline tissues because it was not assessed whether introns 
identified by Leafcutter shared intron boundaries with annotated genetic elements 
outside of the coding sequence such as alternative 3’ or 5’ UTR regions. Some 
intron sQTL events may have occurred due to changes in usage of known 
untranslated elements and therefore estimates of novelty here may to some degree 
be inflated. 
Numbers of sQTLs identified 
In their 2016 study the Leafcutter authors identified 2,893 sQTLs in 2,313 genes at 
10% FDR from the 89 LCL samples from the GEAUVADIS YRI population261. In their 
2018 study, the same group identified 5,774 sQTLs at 5% FDR from 372 LCL 
samples from the GEAUVADIS EUR population260. This is compared to 12,830 from 
this analysis of 221 samples. As discussed in relation to sQTLseekeR, the 
GEAUVADIS data has deficits when compared to this study in terms of SNP density 
and read depth, which perhaps limited the number of associations they were able to 
find. Prior to running the sQTL associations in their 2018 study, Leafcutter had 
identified 42,716 intron clusters with alternatively excised introns. This is only 
marginally fewer than the 47,977 clusters able to be identified by this study, implying 
that perhaps the SNP density rather than the numbers of aligned reads was more of 
a limiting factor in identifying sQTL events, because close to the same number of 
intron clusters with alternative patterns of splicing was identified. 
Lehmann et al. only identified 915 splice QTLs from KIRC and normal samples from 
282 individuals248, using PSI of exons as the phenotypic measure. However they 
only calculated associations with 458,266 variants, called from exome-sequencing 
by the HaplotypeCaller390 tool from GATK391 for germline, and the MuTect392 tool for 
somatic variants. This is further suggestive that the number of variants available to 
be associated with splicing events is a limiting factor in sQTL discovery. 
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Using Leafcutter and FastQTL Raj et al. identified 9,028 sQTLs in 3,006 genes from 
brain samples of 450 individuals at 5% FDR265. This corroborates the result in this 
study that multiple significant sQTL events can emanate from the same intron 
cluster from the same genomic coordinates (Figure 4.8). Their analysis may have 
found fewer significant sQTLs than the 12,830 from this study because even though 
they sampled more individuals, their samples came from autopsy as opposed to 
during live surgery. The negative correlation between RNA-integrity and post-
moretem interval has been well documented across multiple tissues by the GTEx 
Consortium393, and in colonic tissues specifically by Musella et al.394, meaning RNA 
may have been more degraded and so increasing the challenge of extracting signals 
of alternative splicing.  
4.4.4 Comparison of sQTLseekeR and Leafcutter 
Although the two packages have been run by both of their respective authors on 
GEAUVADIS LCL expression data, sQTLseekeR was run individually for each of the 
5 populations whilst all 4 European populations were combined for the Leafcutter 
2018 study. Both have been run individually on the 89 samples of the YRI 
GEAUVADIS LCLs, however the reported results were at 5% FDR from 
sQTLseekeR and 10% FDR from Leafcutter247,261. This project offers the opportunity 
to compare the performance of these two packages on the same sample of 221 
individuals at the same level of FDR. 
Leafcutter identified more significant sQTL events than sQTLseekeR at FDR 5%: 
12,830 as opposed to 5,492. This could be due to multiple factors, such as its larger 
search window, or its ability to identify novel intron events whilst sQTLseekeR is 
limited to finding events relating to known annotated transcripts. Also, there may be 
multiple different intron-level Leafcutter events which are captured by just a single 
sQTLseekeR event because it is able to identify more complex splicing changes 
than Leafcutter. The majority of events identified by sQTLseekeR were classified as 
being “complex” (Figure 4.7), and would therefore have required multiple Leafcutter 
events to capture. The Leafcutter authors noted in their 2016 study that 60% of the 
sQTLs they identified related to simple exon skipping of one or more exons in 
series, 20% of events corresponded to alternative splice acceptor or donor sites for 
a single exon, 10% corresponded to an alternative exon at the 5’ or 3’ end of the 
gene, and only the remaining 10% could be classified as a more “complex” event261. 
When using Altrans and sQTLseekeR, the GTEx Consortium also observed the 
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number of sQTLs identified from the exon-based algorithm to far exceed those from 
the transcript-based (1,900 vs 250)200. 
The agreement of 40.5% between genes for which sQTLs were identified between 
the two packages seems reasonable given the substantial differences in the way 
their algorithms operate, and the fact that Leafcutter was technically designed to run 
independently of a gene build meaning that genes could only be assigned to events 
post-hoc (Section 4.3.4). sQTLseekeR used raw read counts as quantified by the 
pseudo-aligner Salmon and did not perform any normalisation before using a non-
parametric significance test without any associated covariates. In contrast, 
Leafcutter used genomically aligned reads to infer intron excision ratios, which were 
then centred and normalised prior to running through a parametric linear model with 
associated covariates. The previous chapter explored the lack of perfect correlation 
between genomically-aligned and alignment-free expression quantification when 
correlating Cufflinks vs Salmon, which may further explain differences in the sQTL 
events identified. The GTEx consortium observed a similar agreement to that seen 
in this study of 36% of sQTLs found by both sQTLseekeR and Altrans, though this 
was only for exon-skipping events, which both packages should be proficient at 
identifying200. A group investigating the effects of toxic lead doses on the 
development of Drosophila melanogaster used both whole-transcript-based and 
PSI-based methods to identify sQTLs. They found a similar concordance between 
the two methods, identifying 374 via transcripts and 974 via exons, with an 
agreement of 112 (29.9% or 11.5% respectively)395. 
sQTLseekeR was more adept at finding sQTLs associated with lncRNAs, identifying 
209 compared to 129 by Leafcutter+FastQTL. This could be expected given the 
trend for lncRNAs to have fewer introns than regular protein-coding genes, therefore 
there would be fewer opportunities for Leafcutter to call an sQTL based on intron 
excision (mean number of exons according to Ensembl GRCh38v88: protein-coding: 
27.8, lncRNA: 4.45328). The 39 lncRNAs which both packages identified may warrant 
further follow up, as a recent study by Huyghe et al. linked rare variants in lncRNAs 
to colorectal cancer risk, including one at 7p13 which has been demonstrated to 
promote pancreatic cancer proliferation through epigenetic repression of KLF2231. 
The potential of lncRNAs to influence the initiation and progression of colorectal 
cancer is also highlighted by a recent paper from Forrest et al., which identified the 
long non-coding RNA lincDUSP as being over-expressed from an analysis of 22 
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CRC tumours vs 22 normal mucosa controls396. With lincDUSP knocked down, 
patient-derived cancer cell lines showed reduced cell viability and increased 
susceptibility to cell death and apoptosis396. 
4.4.5 Effect size of sQTLs 
The effect sizes of the majority of sQTLs identified by both packages were modest. 
The sQTLseekeR authors arbitrarily ascribe any event with an MD value of ≥0.2 as 
being probably biologically relevant. 9.27% of the sQTLseekeR events in this study 
had an MD value of ≥0.20, 14.8% ≥0.15 and 26.2% ≥0.10 (Figure 4.6). 
The effect sizes correlated poorly between the packages (Figure 4.17), likely due to 
the different scales and distributions of effect size calculated by each package. 
Being a non-parametric test based on ranks, there was some vertical banding 
observed in the sQTLseekeR effect sizes, whereas having made use of a linear 
association, the effect sizes for Leafcutter’s results were continuous. Perhaps the 
effect sizes may have correlated better if they had been transformed to a more 
comparable scale to one another, e.g via quantile normalisation. Additionally, the 
fact that there was never a perfect 1-to-1 relationship when trying to link events 
identified by the packages likely contributed to the poor concordance.  
In the supplementary methods of their 2016 paper, the Leafcutter authors define 
effect size of their sQTL events as being twice the slope of the linear regression 
against genotype, as calculated by FastQTL261. They found that only 13.8% of their 
sQTLs had an effect size ≥10%, whilst 76.6% were over 1%, meaning that 23.4% of 
the events they analysed had an effect size of ≤1%. They accepted that events with 
an effect size ≤1% are “expected to have modest impact in general”, and justified 
their inclusion in their analyses by claiming it is likely that certain sQTLs might have 
larger effects at different developmental stages or in other cell types, or that certain 
changes in splicing could result in the generation of toxic pepties which would have 
a large effect even at low levels. This study is specifically concerned with sQTLs 
presented in the colonic mucosa as it is the site of initiation of colorectal cancer, 
therefore low-effect size sQTLs in this tissue are of considerably less relevance to 
this study. Low effect size sQTLs are liable to be dominated by simple fluctuations of 
noise in the expression ratios of transcripts or introns (Figure 4.18 and Figure 4.19), 
hence thresholding of low effect size events is important prior to functional 
characterisation. 
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4.4.6 Thresholding 
Thresholds were applied to sQTLs for two reasons: firstly to address expression 
thresholds which were potentially too lenient during intial sQTL identification, and 
secondly in an attempt to filter for only the most functionally relevant events. The 
distributions of effect size against expression for both packages display clouds of 
points which could feasibly have been driven by noisy associations of low-effect size 
changes in transcript expression or intron utilisation (Figure 4.18 and Figure 4.19).  
It is not desirable to set arbitrary thresholds, however the approach taken was 
considered favourable compared to potentially reaching misleading conclusions 
influenced by false-positives. An alternative strategy to find naïve thresholds may 
have been to fit an unsupervised Gaussian mixture-model to the effect sizes, and if 
there was a divergence between two components, this would have indicated a 
suitable division between two separate populations of low and high effect size 
events. However, exploratory plots of these distributions indicated that a clear 
divergence was unlikely.  
A further strategy may have been to identify a threshold at which the majority of 
sQTL events displayed “stable” effect sizes. It would be predicted that sQTLs with 
larger effect sizes would tend to always have the same transcript most highly 
expressed in relation to a particular allele, whereas conversely it could be envisaged 
that sQTLs with lower effect-sizes values (e.g. an MD value around 0.01) may 
simply be due to noise, and therefore could fluctuate which transcript is most highly 
expressed if there was repeat sampling of the same individual. If individuals were 
sampled at multiple timepoints, then it could be tested what effect size threshold 
produces sQTL events which are most “stable” over time. Such a test would require 
the same individuals to be repeatedly sampled at multiple timepoints with no 
external treatments applied. 50 individuals from batch 10525 were sampled at 0, 6 
and 12 week timepoints; however they had received interventional vitamin D 
supplementation as part of the SCOVIDS study which could confound any 
conclusions, and additionally the relatively small number of individuals is not ideal 
for accurate quantification of sQTL events. 
Other sQTL studies rarely report applying filters to their events, or plot distributions 
showing the effect sizes of identified sQTLs. Some authors openly acknowledge the 
propensity towards low effect size events in their results, though without imposing 
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any thresholds their conclusions risk being spurious or unreliable. When identifying 
sQTLs from normal kidney tissue and kidney renal cell carcinoma, Lehmann et al. 
identified 915 sQTLs, of which they concede only 251 had an effect size >5%248. As 
discussed, the Leafcutter authors comment in the supplementary methods of their 
2016 paper that 86.2% of their sQTLs have an effect size of <10%, and 23.4% have 
an effect size <1%. However, instead of applying thresholds to these low-effect size 
sQTLs, they justify their inclusion by positing that these events might be important in 
other developmental stages, or could produce highly toxic aberrant peptides. The 
figures presented in this chapter (Figure 4.18 and Figure 4.19) suggest that low-
effect size sQTLs are more likely to simply be noise in a dataset, as opposed to 
conserved events with highly deleterious effects in specific contexts.  
4.4.7 trans-sQTLs 
A common search window around a gene for cis-eQTL studies is 1Mbp200. With the 
advent of higher memory computing facilities, trans-eQTL studies have now become 
wide-spread397,398, with some attributing greater influence to all cumulative trans 
effects genome-wide than individual per-gene cis effects. Pritchard et al. have 
posited an “omnigenic inheritance” model, with core genes directly affecting a 
phenotype being modulated by many trans effects from across the genome, and 
they estimate that up to 70% of heritability of a trait may be explained by trans as 
opposed to cis effects399. 
trans-sQTLs were attempted to be calculated for this project, however the 
computational requirements proved too great. It is feasible for gene-level eQTLs, 
however when expression of all the individual transcripts of all genes need to be 
analysed, the combination of each of those features with genome wide SNP variants 
meant that the analysis failed, even with maximum possible resources allocated 
from the University of Edinburgh compute cluster. The sQTLseekeR authors 
performed a rudimentary trans-sQTL analysis whereby they attempted to associate 
SNPs from random genes to changes in alternative splicing of distant, unrelated 
genes. This was intended as a test to prove that the sQTLs they identified in cis 
were more reliable and were the most likely causative SNPs. However the test 
actually resulted in an elementary insight into potential trans-sQTLs: they only found 
107 significant associations between SNPs and the splicing of distant genes, 
however of these approximately a quarter (25) of the variants were within genes with 
known functions in RNA processing and transcription - implying the trans-sQTL 
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variants associated with them could truly play a role in influencing alternative 
splicing of distant genes247. trans-sQTLs have been identified genome-wide in 
Drosophila melanogaster by Qu et al., however they have a smaller genome with 
fewer genes and fewer variants to assess correlations between395. A hotspot of 
trans-sQTLs was identified on Chr 3L, mimicking previous discoveries of trans-eQTL 
hotspots400. 
Other groups have examined somatic trans-sQTLs specifically in the context of 
cancer. Kahles et al. specifically considered only somatic variants arising in TCGA 
samples and tested them for evidence of trans-sQTL effects, thus greatly reducing 
the numbers of tests required297. The trans effects they did identify were primarily 
mutations in core spliceosome machinery which had wide-ranging trans effects on 
the splicing of many genes, highlighting the influence that alternative splicing can 
play in tumour progression.  
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Chapter 5 Genomic Characterisation of sQTLs 
5.1 Introduction 
The previous results chapter presented the distribution of the identified sQTL events 
in their local and genome-wide context, and set thresholds to prioritise sQTLs from 
more highly expressed features and with larger effect sizes. This chapter will focus 
on the functional relevance of the sQTLs in terms of variant effect prediction and 
enrichment within epigenetic marks and regions of DNA 
accessibility200,247,258,260,261,264,265. The relationship between sQTLs and eQTLs will 
also be analysed to determine whether sQTL variants originate independently from 
eQTLs; this will help to clarify whether using sQTLs in addition to eQTLs in the 
identification and prioritisation of CRC predisposition signals would add power265,401. 
A meta-GWAS of 58,640 individuals is used to assess whether sQTL SNPs are 
enriched for greater associations with CRC predisposition than would be expected 
by chance. Finally, a number of examples of sQTLs in genes linked to CRC 
predisposition or progression are given. 
5.1.1 Linkage disequilibrium 
As demonstrated in the previous results chapter, it is rare for a single variant to be 
associated with an sQTL event: most commonly multiple SNPs correlate 
significantly with each change in transcript expression. This is because SNPs on the 
same chromosome can be re-assorted via chiasmata during meiosis, with the 
likelihood of SNPs being separated increasing as a function of the physical distance 
between SNPs. This means contiguous stretches of DNA are more commonly 
inherited together, and so individuals from the same population may commonly 
inherit the same small groups of variants, making it difficult to dissect effects 
pertaining from different alleles of nearby SNPs because they are rarely separated 
in different individuals. SNPs which are more commonly co-inherited together than 
would be expected by chance are said to be in linkage disequilibrium (LD), and 
haplotype blocks are defined as groups of SNPs in high LD with each other213,402.  
A limitation of QTL studies performed using SNP array genotyping is that only a 
subset of variants have been surveyed, and therefore there is a non-exhaustive list 
of possible SNPs with which to draw associations. This complicates analysis of 
quantitative traits because the “lead” SNP associated most significantly with an 
event might not be the causative SNP, but could simply be in high linkage 
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disequilibrium with that variant. It is therefore important to take into account the LD 
structure of the sQTL variants identified in this study. When analysing the overlap of 
genomic features with sQTLs, the whole LD block containing the sQTL must be 
considered in order to have the highest likelihood of including the causative SNP. 
5.1.2 Functional annotation and epigenetic states 
True sQTLs should fall within functionally relevant and transcriptionally active 
regions of the genome258, therefore exploring the predicted functional impacts of 
candidate sQTLs and the genomic environments in which they reside is important 
for assessing the reliability of their discovery. 
Some causative variants identified as sQTLs would be predicted to have splice-
relevant effects by disrupting intron-exon boundary motifs264. However, synonymous 
variants have also been observed to affect splicing and are theorised to mediate 
their effects by disrupting hexameric sequences located in the flanks of exons within 
70bp of splice sites which enhance or suppress splicing157,403. These exonic splice 
enhancers (ESEs) and exonic splice suppressors (ESSs) act either by recruiting 
Serine/Arginine-rich (SR) proteins which help to recruit the U1 spliceosome 
complex, or by attracting heterogeneous nuclear ribonucleoproteins (hnRNPs) which 
inhibit binding of the U2AF spliceosome subunit to intronic branch point 
sequences156. 
Modifications to the tails of histone proteins can impact the compaction of 
chromatin404,405 or promote the binding of proteins which influence transcription183, 
and therefore have a significant effect on the expression of nearby genes406. The 
presence of such marks can be located via ChIP-seq (Chromatin 
ImmunoPrecipitation followed by sequencing407) and the accessibility or relative 
compaction of chromatin can be profiled by DNase sensitivity assays408. Germline 
variants do not act independently of such epigenetic marks, and their effects can be 
modulated by the local chromatin landscape406. Therefore it is important to 
characterise the epigenetic features in which sQTLs are located. 
5.2 Data 
5.2.1 Linkage disequilibrium blocks 
Linkage disequilibrium blocks computed from 1000 Genomes Phase 1 Release 3 
were downloaded from the EURAC consortium in March 2019: 
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http://www.eurac.edu/en/research/health/biomed/services/Documents/1000G_CEP
H_ldblocks_wp_16102013.tar.gz 
These blocks were calculated from 11 million SNPs using individuals from the CEU 
population (Utah individuals with European Ancestry)409,410. The blocks were 
calculated using an implementation of Gabriel’s widely adopted 2002 definition of 
LD213 developed by the EURAC consortium which prunes the search space to only 
the SNPs most likely to contribute to haplotype blocks411. The blocks were called by 
the consortium based on GRCh37 coordinates, so they were lifted-over to GRCh38 
coordinates using the UCSC Liftover Tool367 with chain file 
“hg19ToHg38.over.chain.gz”. Only 442 of 412,206 regions were unable to be lifted 
over successfully: 125 were deleted in the newer assembly, 147 partially deleted 
and 170 split. 
There were no LD blocks available from EURAC for the X chromosome, so an 
additional set of LD blocks was calculated using 6.6M variants for the 221 
individuals from both batches using Plink version 1.9412,413, which implements the 
same LD-approximation algorithm developed by the EURAC consortium410. The 
maximum block size was set to 500kbp, 2-SNP blocks were limited to a maximum of 
20kbp and 3-SNP blocks to 30kbp. 
There were 245,832 LD blocks inferred from the 221 Scottish patients compared to 
411,605 from 1000 Genomes. The LD blocks calculated from 1000 Genomes data 
were consistently smaller and so of higher resolution (Table 5.1). The same overall 
trend of block size was comparable between the two datasets, justifying the use of 
the autosomal 1000 Genomes LD blocks supplemented by the X chromosome 
blocks generated from in-house data. Blocks for the X chromosome are likely to be 
larger due to the sparser coverage of SNP-genotyping. 
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1 30285 17137 2.29 3.16 
2 33598 19552 2.16 2.82 
3 27421 15936 2.16 2.66 
4 26026 14656 2.06 2.96 
5 24450 14380 2.23 2.83 
6 25863 14357 1.67 2.48 
7 24541 14161 1.83 2.53 
8 21905 13260 1.78 2.34 
9 19805 12267 1.70 2.05 
10 20430 12092 1.91 2.46 
11 20079 11612 1.92 2.62 
12 19933 11330 2.03 2.75 
13 14192 8348 2.10 2.81 
14 13757 8013 1.88 2.56 
15 13583 8033 1.75 2.29 
16 15498 9593 1.37 1.73 
17 12825 7365 1.72 2.32 
18 11844 7542 1.98 2.36 
19 12201 6981 1.30 1.84 
20 9969 6437 1.86 2.21 
21 6142 3789 1.59 2.33 
22 7258 4186 1.42 1.92 
23 NA 4805 NA 6.70 
Table 5.1 LD block sizes and numbers of blocks per chromosome derived from 1000 
Genomes Phase 3 release v5 (1KG) or the CCGG cohorts  
 
5.2.2 Minor Allele Frequencies 
The “Scotland Combined” cohort is an ever-growing dataset of genotypes collected 
by the CCG Group for the purposes of understanding CRC risk factors in the 
Scottish population. The size of the cohort also makes it amenable to assessing the 
allele frequencies of Scottish cohorts. Allele frequencies were extracted for SNPs 
from a data-freeze of this cohort when it contained 16,000 individuals from the 
Generation Scotland study414, 1,800 from the “Scotland Phase 1” cohort109, and 287 
patients who had undergone surgery or observation as part of the SOCCS or 
SCOVIDS cohorts. Where the analyses in the chapter necessitated background sets 
of SNPs with matching allele frequencies, the sQTL SNPs were binned into 50 
intervals of minor allele frequency (MAF) from 0.0 to 0.5, and 100,000 random SNPs 
which were non-significant for sQTLs were chosen with the same proportion from 
each bin, resulting in a margin of error for MAF-matching of 0.01. 
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When comparing the functional attributes of significant sQTL SNPs to a background 
set of non-significant SNPs, some groups performed LD-pruning of the background 
SNPs first264. Whilst there is merit in this approach so as to ensure that all SNPs in 
the background set were independent, background sets were not LD-pruned in this 
study because the process leaves only a single SNP per LD block. The pruning 
process could potentially bias the distribution of remaining SNP effects, and obscure 
or promote certain categorisations. Not having pruned means that there could be 
multiple SNPs from the same LD block contributing to the background set; however, 
by choosing a relatively large set of 100,000 background SNPs, the contribution of 
any instances of LD blocks with multiple sampled SNPs should be evenly distributed 
across the whole genome. 
The distribution of allele frequencies from the in-house Scotland Combined cohort 
was compared with an external database to ensure there were no idiosyncratic 
biases present. Allele frequencies from the 1000 Genomes phase 3 version 5a 
release, using data from dbSNP release 149, were downloaded from the EBI 
(European Bioinformatics Institute) ftp site for the autosomes and chromosome X in 
March 2019: ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/ 
supporting/GRCh38_positions/ 
The original genotyping was relative to GRCh37 coordinates, but was lifted over to 
GRCh38 by the EBI409. Allele frequencies for the EUR population specifically were 
extracted and compared to 6,551,177 variants from the Scotland Combined cohort, 
yielding a Spearman’s rho correlation of 0.99 (Figure 5.1). 
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Figure 5.1 Correlation between allele frequencies from the “Scotland Combined” 
cohort and 1000 Genomes phase 3 release 5a EUR cohort. 
A random sample of 10,000 points are plotted for clarity. 
 
5.2.3 Functional elements and chromatin marks 
The ENCODE project aims to characterise all functional elements within the human 
genome415,416. They initially studied histone modifications and DNase accessibility in 
human cell lines417, and the Roadmap Epigenetics Consortium extended this to 
human tissue samples418 (Table 5.2). The 2015 GTEx pilot study included an 
analysis of the co-localisation of quantitative trait loci within epigenetic features. 
They called sQTLs from nine different tissues (adipose, whole blood, blood vessel, 
heart, lung, muscle, nerve, skin and thyroid), and found significant enrichment of 
these sQTLs, and eQTLs from 43 tissues, within regulatory features identified by 
ChIP-seq200.  
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Feature Functional annotations Reference 
H3K4me1 Associated with enhancers and active TSSs Barski 2007419 
H3K4me3 Usually a strong mark of active 
transcription. When found within a larger 
region of H3K27me3, defines 
Bivalent/Poised promoters  
Voigt 2013420 
H3K9ac Activating Karmodiya 2012421 
H3K9me3 Repressive Lehnertz 2003422 
H3K27ac Activating Tie 2009423 
H3K27me3 Repressive Ferrari 2014424 
H3K36me3 A mark of actively transcribed genes, often 
found to demark exon boundaries 
Schwartz 2009184 
Table 5.2 ChIP-seq peaks available for colonic mucosa from the Roadmap Epigenetics 
Consortium425 and their most common influences on gene expression. 
In addition to individual chromatin peaks, the chromatin “state” of regions can be 
inferred. The Roadmap Consortium used a Hidden Markov Model, ChromHMM426, to 
identify 15 different states from a combination of the 5 highest quality ChIP-seq 
data, annotating among other things active promoters, enhancers, repressed 
polycomb and heterochromatic regions425 (Table 5.3). 
Feature Description Average % Genome 
TssA Active TSS 0.7 
TssAFlnk Flanking active TSS 0.5 
TxFlnk Transcription at gene 5’ and 3’ 0.1 
Tx Strong transcription 3.6 
TxWk Weak transcription 11.6 
EnhG Genic enhancers 0.4 
Enh Enhancers 2.8 
ZNF_Rpts ZNF genes and Repeats 0.2 
Het Heterochromatin 2.6 
TssBiv Bivalent/Poised TSS 0.1 
BivFlnk Flanking Bivalent TSS/Enhancer 0.1 
EnhBiv Bivalent Enhancer 0.1 
ReprPC Repressed PolyComb 1.2 
ReprPCWk Weak Repressed PolyComb 8.3 
Quies Quiescent/Low signal region 67.8 
Table 5.3 Definitions of 15 inferred Chromatin States 
Percentages are the average genome coverage from 111 reference epigenomes 
characterised by the Roadmap Epigenetics Consortium425. 
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5.2.4 Epigenetic and functional element annotations 
Sample “E075” from the Roadmap Epigenetics Consortium represents colonic 
mucosa sampled from a 73 year old female425. Narrow peak bed files of ChIP-seq 
for the histone modifications H3K4me1, H3K4me3, H3K9ac, H3K9me3, H3K27ac, 
H3K27me3 and H3K36me3 were downloaded from the ENCODE portal427 in March 
2019: https://www.encodeproject.org/reference-epigenomes/ENCSR055HAB/ 
(Table 5.4, Table 5.5). 
The ENCODE Consortium also predicted candidate regulatory elements based on 
an integrative analysis of DNase I hypersensitivity, H3K4me3, H3K27ac, and CTCF 
peaks417 (Table 5.4, Table 5.5), which were downloaded for sample E075 from the 
ENCODE portal in March 2019: 
https://www.encodeproject.org/annotations/ENCSR212XWK/. 
Consensus DNase I hypersensitivity data for 125 cell types was used because the 
DNA accessibility data for just sample E075 was of low quality (Table 5.4, Table 
5.5). The ENCODE Analysis Working Group uniformly processed DNase I 
hypersensitivity data from teams at Duke and Washington Universities and extracted 
narrow peaks at a threshold of 1% FDR428. Clusters of DNase peaks supported by 
only one cell type were removed. The data was downloaded from the UCSC table 
browser in March 2019: http://genome-preview.ucsc.edu/cgi-
bin/hgTrackUi?db=hg19&g=wgEncodeRegDnaseClusteredV2. 




E075 H3K4me1 ENCFF908AYT GRCh38 
E075 H3K4me3 ENCFF637OKI GRCh38 
E075 H3K9ac ENCFF647QYV GRCh38 
E075 H3K9me3 ENCFF591QMA GRCh38 
E075 H3K27ac ENCFF051OAR GRCh38 
E075 H3K27me3 ENCFF839CHE GRCh38 










hypersensitivity wgEncodeRegDnaseClusteredV2 hg19 
E075 ChromHMM E075_15_coreMarks_dense hg19 
Table 5.4 Accession numbers of downloaded ENCODE data 
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Feature n regions Total coverage (Mbp) Median width Mean width 
Regulatory 1309805 549.4 342 419 
DNase 1281642 387.2 255 302 
H3K27ac 67306 52.6 557 781 
H3K36me3 107557 44.6 315 415 
H3K4me3 42873 40.1 609 935 
H3K4me1 74058 39.1 410 527 
H3K9ac 41636 26.9 478 647 
H3K27me3 48188 20.9 309 433 
H3K9me3 29194 12.1 335 414 
Table 5.5 Sizes of epigenetic features. 
Table is ordered in descending size of total genomic region covered by each feature. 
Number of regions and median and mean width of the regions are presented. 
The Roadmap Epigenetics Consortium used the ChromHMM tool v1.10426 to 
implement a Hidden Markov model to distil 15 distinct chromatin states based on the 
co-occurrences of 5 different ChIP-seq peaks (H3K4me1, H3K4me3, H3K9me3, 
H3K27me3 and H3K36me3). They used the 60 highest quality epigenomes, which 
included the colonic mucosa sample E075425. The resulting regions were annotated 
as characterising: active TSS (TssA), flanking active TSS (TssAFlnk), transcription 
at gene 5' and 3' (TxFlnk), strong transcription (Tx), weak transcription (TxWk), 
genic enhancers (EnhG), enhancers (Enh), ZNF genes & repeats (ZNF_Rpts), 
heterochromatin (Het), bivalent/poised TSS (TssBiv), flanking bivalent 
TSS/enhancer (BivFlnk), bivalent enhancer (EnhBiv), repressed polycomb 
(ReprPC), weak repressed polycomb (ReprPCWk) and quiescent/low activity 
regions (Quies) (Table 5.6). The corresponding regions were downloaded in March 
2019 from: 
http://egg2.wustl.edu/roadmap/web_portal/chr_state_learning.html#core_15state. 
Any feature files originally aligned to hg19 were were lifted-over to GRCh38 
coordinates using the UCSC Liftover Tool367 with chain file 
“hg19ToHg38.over.chain.gz”.  
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Feature n regions Total coverage (Mbp) Median width Mean width 
Quies 39788 2182.0 21000 54840 
TxWk 55217 321.2 2800 5817 
ReprPCWk 17806 143.6 4400 8064 
Tx 23123 63.0 1600 2725 
Enh 45922 32.7 400 712 
Het 12987 25.1 1000 1933 
TssA 24207 23.4 600 967 
TssAFlnk 24982 12.3 400 493 
ReprPC 9379 11.9 800 1264 
EnhG 4878 4.1 600 837 
BivFlnk 6917 3.5 400 512 
ZNF_Rpts 2281 3.5 600 1535 
TssBiv 5172 2.8 400 536 
EnhBiv 6012 2.5 200 409 
TxFlnk 1329 0.9 400 644 
Table 5.6 Sizes of ChromHMM predicted chromatin states 
 
5.2.5 GWAS associated and COSMIC genes 
The NHGRI-EBI GWAS catalog429 was queried for the trait “colorectal cancer” in 
September 2019 from the URL: https://www.ebi.ac.uk/gwas/efotraits/EFO_0005842 
Any studies in African or Asian populations were excluded to leave only associations 
derived from populations with European ancestry, to best reflect the Scottish cohort 
used in this project. 
The COSMIC catalog430 release v90 was queried for all curated genes linked to 
cancer progression, including those linked to colorectal cancer specifically, in 
September 2019 from the URL: https://cancer.sanger.ac.uk/census 
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5.3 Methods 
5.3.1 Variant effect prediction 
The effects of sQTL SNPs were predicted using SnpEff version 4.3431 with the 
SnpEff GRCh38v86 database (the most closely matched available database to the 
GRCh38v88 gene build used for sQTL predictions). Canonical and non-canonical 
transcripts were included in the predictions, and the default interval size of 5kbp was 
used to classify a variant as up or downstream of a given transcript. The MISO 
Sequence Ontology Browser432,433 was consulted when grouping different variant 
effects together. The umbrella term “Splicing variant” was applied to any terms 
including “splice_acceptor_variant”, “splice_donor_variant”, “splice_region_variant” 
or “exon_loss_variant”. “splice_region_variant” is defined by the Sequence Ontology 
as “A sequence variant in which a change has occurred within the region of the 
splice site, either within 1-3 bases of the exon or 3-8 bases of the intron”432. 
5.3.2 Circular permutation 
Circular permutation is a method for testing enrichment of genomic features within 
sets of annotated regions. It involves artificially circularizing chromosomes in silico, 
and performing permutations of a test set of regions against a query set which is 
shifted by a random number of bases with each iteration. Circularizing the 
chromosomes means that biologically relevant clustering/patterns of features and 
the relative distances between features are maintained whilst being shifted. Circular 
permutations were performed with the regioneR package434, using the UCSC hg38 
genome masked for assembly gaps and intra-contig ambiguities 
(BSgenome.Hsapiens.UCSC.hg38.masked v1.3.99)435. 
There may be instances whereby one set of features significantly overlaps another, 
though only due to the second feature completely encapsulating the first. This could 
be caused by one set of features being significantly larger than the other, meaning 
that there is a large window whereby one can be shifted and still significantly overlap 
the other. In order to control for instances such as this, the regioneR package 
performs local Z-score analyses, whereby the test features are shifted a short 
distance either side of their native locus and the overlap with the test regions are re-
analysed. If the enrichment is genuine and not simply due to inequalities between 
the sizes of the features, then there should be a peak of greatest Z-score 
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enrichments centred around the original positions of the features, which decay as 
the shifted distances increase. 
5.3.3 Obtaining and filtering eQTLs 
eQTLs were called using the 221 individuals from batches 2013152 and 10525 by 
Dr Victoria Svinti. Protein-coding and lncRNA genes were retained for analysis if 
they had at least 6 counts in at least 10% of the samples, as quantified by Salmon 
against GRCh38v88. Expression was TMM normalised, and rank transformation 
was applied to impose a normal distribution. FastQTL was run using 10 PEER 
factors as covariates, in addition to age, gender, and the site within the colon from 
which the samples were obtained. Resulting nominal p-values were FDR corrected 
following the methodology of the GTEx Consortium200. 734,788 eQTL variants 
passed FDR 0.05 correction, relating to 11,688 different protein-coding or lncRNA 
genes. Choosing the “lead” variant per gene based on the greatest significance and 
largest effect size left 11,039 unique variants. 
eQTLs identified by the GTEx Consortium were also downloaded for transverse and 
sigmoid colon tissues in March 2019 from: 
https://storage.googleapis.com/gtex_analysis_v7/single_tissue_eqtl_data/GTEx_An
alysis_v7_eQTL.tar.gz. 
A considerable caveat of using eQTLs from the GTEx Consortium is that their tissue 
samples were obtained post mortem and the samples may have been subjected to 
lengthy periods of ischaemia (mean of approximately 6 hours, to as long as 21 
hours)200. The sigmoid and transverse colon samples were found to have some of 
the fastest rates of decay of RNA integrity post mortem of any of the 43 tissues 
surveyed by GTEx393. The sampling method of GTEx also meant that colonic 
mucosa samples were prone to also including a stromal component, whereas great 
care was taken by the investigators obtaining samples from the Scottish cohort 
analysed in this study to strip the colonic mucosa from the surrounding muscle layer. 
5.3.4 GWAS enrichment via lambda inflation 
sQTL variants were tested for genomic enrichment within a meta-GWAS for CRC 
carried out by Dr Maria Timofeeva, which combined summary statistics from 10 
different cohorts with European ancestry (Table 5.7). All cohorts, or subsequent 
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iterations thereof, have since been used as part of a larger meta-analysis by Law et 
al.96. 
Study  Curating Institute Cases Controls 
Generation Scotland  Edinburgh University 4,551 8,804 
Scotland Phase 1 Cohort Edinburgh University 932 943 
UK Biobank Edinburgh University 1,100 3,637 
VICTOR trial with 1958 birth cohort controls  Oxford University 1,794 2,686 
Colorectal Tumour Gene Identification 
Consortium 
Oxford University 890 900 
Finnish Colorectal Cancer Predisposition 
Study 
Helsinki University 1,172 8,266 
National Study of Colorectal Cancer Genetics ICR London 6,459 7,191 
COIN trial Cardiff University 1,950 2,162 
Colon Cancer Family Registry Cohort 1  University of Southern 
California 
1,175 999 
Colon Cancer Family Registry Cohort 2 University of Southern 
California 
795 2,234 
 Totals 20,818 37,822 
Table 5.7 Cohorts used for meta-GWAS of CRC predisposition. 
 Lambda inflation was calculated using the GWAS p-values corresponding to the 
thresholded sQTLs from each package according to Yang et al.’s 2011 definition, 
which accounts for the median expected chi-squared association of SNPs to a 
quantitative trait via GWAS436. 
To create null distributions, lambda inflation was calculated for the same number of 
SNPs as the thresholded sQTLs from each package which were able to be mapped 
to SNPs used in the meta-GWAS (375 for sQTLseekeR, 776 for Leafcutter) 100,000 
times, randomly selecting GWAS p-values for SNPs from within the search windows 
of each package, and MAF-matching by increments of 0.0125. Significance was 
quantified via a two-tailed test on a Z-score calculated by comparing the lambda 
inflation score for each package’s list of thresholded SNPs to the corresponding null 
distribution. 
Expected p-values for quantile-quantile plots (QQ-plots) were calculated based on a 
null chi-squared distribution using the qchisq function from base R437. 
5.3.5 Differential Splicing Analysis 
In order to generate a sashimi plot for CASP3, differential splicing was performed 
according the Leafcutter Authors’ protocol260, with individuals of genotype dosage 0 
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(n=163) compared to dosage 2 (n=5) for variant rs4647609 with no covariates 
added (including covariates was found to make no appreciable difference to the 
results). The results of the differential splicing were then visualised using the R 
Shiny app, LeafViz, developed by the Leafcutter Authors260. 
For visualisation in the Integrative Genomics Viewer (IGV)333, bam files were 




5.4.1 Variant effect prediction 
SnpEff variant effect predictions were made for sQTLs from sQTLseekeR and 
Leafcutter, and for background sets of 100,000 variants randomly selected from 
within the search windows of each package. Effect predictions were made for all 
significant sQTL SNPs and for only the sQTLs passing the expression and effect 
size thresholds assigned to each package in the previous chapter (Table 5.8). 
SnpEff consequences are assigned at the transcript-level, so multiple results were 
returned per variant if it fell within multiple transcripts for the same or multiple genes. 
If effects are partitioned into either exonic or non-exonic (intronic, upstream, 
downstream, intergenic, TF binding site), there is an enrichment of sQTLs in exonic 
regions compared to non-exonic for significant sQTL SNPs from both packages 
(sQTLseekeR: two-tail Fisher’s p-value= 7.74e-260, OR=2.28; Leafcutter: p-value= 
4.28e-72, OR=2.34). This implies that sQTLs are more commonly located in 
functionally-relevant exonic regions than would be expected by chance. In both 
packages, the enrichment was greater for SNPs from sQTLs passing expression 
and effect size thresholds compared to the entire population of significant sQTL 
SNPs (sQTLseekeR: p-value < 2.2x10-16, OR=3.62; Leafcutter: p-value= 5.94x10-88, 
OR=2.98). 
The proportion of variants falling within 5kbp up or downstream of transcripts is 
consistently greater for sQTLs than background SNPs in both packages, however 
there is a greater proportion of significant sQTL variants in intergenic regions for 
Leafcutter as opposed to sQTLseekeR (2.86% vs 1.34%), as would be expected 
given its wider search window (Table 5.8). 
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The enrichment or depletion of individual SnpEff annotation classes was also 
analysed, with p-values Bonferroni corrected for the number of different classes 
tested. The enrichments were of greater magnitude within thresholded sQTL SNPs 
than all significant sQTL SNPs (Figure 5.2). Splicing-related variants were the most 
highly enriched in the Leafcutter package, and among the top most enriched 
variants for sQTLseekeR (Figure 5.2). sQTLs were more enriched in 5’ than 3’ UTR 
regions for both packages. Although the majority of functional annotations assigned 
to sQTLs were intronic (44.5-57.4%, Table 5.8), this class is the least enriched 
relative to the background test set (Figure 5.2). Intronic SNPs were the most 
common and the least enriched class of variants, however lack of enrichment is not 
purely a function of frequency, as illustrated by intergenic SNPs which were much 
less common (1.34-2.86%, Table 5.8) whilst also being the second least enriched 
class (Figure 5.2).  
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a) sQTLseekeR Significant Significant % Thresholded Thresholded % Background Background % 
Intronic 26758 52.2 1716 44.5 467724 75.9 
Downstream 10849 21.1 892 23.1 64000 10.4 
Upstream 10389 20.2 873 22.7 63271 10.3 
Non-coding 799 1.56 91 2.36 3862 0.627 
Intergenic 687 1.34 71 1.84 6777 1.1 
3' UTR 644 1.26 71 1.84 3463 0.562 
5' UTR 347 0.676 41 1.06 1105 0.179 
Synonymous 268 0.522 36 0.934 1281 0.208 
Splicing variant 176 0.343 17 0.441 703 0.114 
Other 174 0.339 7 0.182 2955 0.48 
Missense/Frameshift/INDEL 173 0.337 31 0.804 652 0.106 
TF binding site 35 0.0682 2 0.0519 220 0.0357 
Stop gained/retained/lost 7 0.0136 6 0.156 10 0.00162 
b) Leafcutter Significant Significant % Thresholded Thresholded % Background Background % 
Intronic 40268 57.4 3866 56.2 288041 67.2 
Upstream 12013 17.1 1116 16.2 47834 11.2 
Downstream 11885 16.9 1250 18.2 47779 11.1 
Intergenic 2007 2.86 155 2.25 34087 7.95 
Non-coding 1204 1.71 145 2.11 3458 0.807 
3' UTR 728 1.04 50 0.727 2586 0.603 
5' UTR 586 0.835 67 0.974 938 0.219 
Splicing variant 464 0.661 102 1.48 504 0.118 
Synonymous 398 0.567 72 1.05 932 0.217 
Other 360 0.513 21 0.305 1813 0.423 
Missense/Frameshift/INDEL 243 0.346 33 0.48 499 0.116 
TF binding site 48 0.0684 2 0.0291 234 0.0546 
Stop gained/retained/lost 3 0.00427 0 0.0 11 0.00257 
Table 5.8 Number and percentage of variant effects assigned by SnpEff to all significant sQTLs, thresholded significant sQTLs or 100,000 
randomly selected background lists of sQTLs from the search windows of sQTLseekeR or Leafcutter 
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Figure 5.2 Enrichment of SnpEff consequence classes 
Enrichment calculated between either all significant sQTLs or thresholded sQTLs and a set 
of 100,000 randomly chosen, MAF-matched SNPs from within the search window of each 
package. Enrichments calculated by two-tailed Fisher’s test. 
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5.4.2 Enrichment of sQTLs in epigenetic and functional 
annotations 
The thresholded sQTLs from both sQTLseekeR and Leafcutter were combined 
together and assigned to the set of LD blocks created by combining autosomes from 
1000 Genomes and X chromosome from the 221 Scottish individuals. The 1,280 
SNPs fell within 965 different LD blocks. The LD block coordinates were circularly 
permuted against 7 different ChIP-seq peaks: candidate regulatory regions 
predicted from Epigenetics Roadmap colonic mucosa sample E075, and consensus 
DNase I hypersensitivity peaks from 125 ENCODE cell types. Z-scores of 
enrichment were calculated by comparing the observed number of overlaps 
between the original positions of sQTL LD blocks and the given features against a 
distribution of overlaps obtained from 10,000 circular permutations of the features. 
Nominal p-values derived from the z-scores were Bonferroni-corrected. 
Significant enrichments were found relative to ChIP-seq peaks H3K4me1, 
H3K4me3, H3K9ac, H3K27ac and H3K36me3, as well as the predicted candidate 
regulatory regions and consensus DNase I hypersensitivity sites (Table 5.9 and 
Figure 5.3). There was a nominally significant depletion in ChIP-seq peaks of 
H3K9me3 which did not survive multiple testing correction, and the number of 
overlaps observed against H3K27me3 peaks did not significantly deviate from the 
random permutations. Local Z-score plots demonstrate that the majority of the 
significant associations are dependent on the specific position of the features as 
demonstrated by a pronounced peak or valley of Z scores (Figure 5.4). 
Feature Observed 
overlaps 






H3K4me1 337 13.20 1.00E-04 greater 9.00E-04 
H3K4me3 339 17.35 1.00E-04 greater 9.00E-04 
H3K9ac 304 17.33 1.00E-04 greater 9.00E-04 
H3K9me3 73 -2.04 2.31E-02 less 2.08E-01 
H3K27ac 366 17.14 1.00E-04 greater 9.00E-04 
H3K27me3 91 -0.88 2.04E-01 less 1.00 
H3K36me3 396 21.16 1.00E-04 greater 9.00E-04 
Regulatory 849 8.19 1.00E-04 greater 9.00E-04 
DNase 855 9.35 1.00E-04 greater 9.00E-04 
Table 5.9 Significance of overlaps between combined thresholded sQTLs and 
individual ChIP-seq peaks, predicted regulatory regions and DNase I hypersensitivity 
sites. Observed overlaps of 965 sQTL-containing LD-blocks. Z-score and p-value relative to 
10,000 circular permutations of features using with respect to stated alternative hypothesis. 
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Figure 5.3 Distribution of numbers of overlaps between random permutations of ChIP-
seq peaks, predicted regulatory regions and DNase I hypersensitivity sites and LD 
blocks containing combined thresholded sQTLs from sQTLseekeR and Leafcutter. 
Grey bars represent the null distributions obtained from 10,000 random permutations of 
features. Red lines indicate the number of overlaps between the original feature positions 
and LD blocks containing sQTLs.  
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Figure 5.4 Local Z scores calculated by shifting permuted features up to +/-100kbp 
when overlapping ChIP-seq peaks, predicted regulatory regions and DNase I 
hypersensitivity sites with LD blocks containing combined thresholded sQTLs. 
The combined sQTLseekeR and Leafcutter thresholded sQTLs were also tested for 
enrichment within the 15 chromatin states identified by ChromHMM, with Bonferroni 
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correction for the number of states tested. There were significant enrichments of 
sQTLs within all markers of active transcription and enhancer regions, and 
significant depletion of sQTLs within regions marked as quiescent (Table 5.10 and 
Figure 5.5). There was a depletion of sQTLs in heterochromatic regions which 
approached but did not pass significance, and there were no significant enrichments 
or depletions in bivalent/poised TSSs, repressed polycomb or weakly repressed 
polycomb (Table 5.10). The local Z scores again showed the expected peaks and 
troughs corresponding to enrichments or depletions (Figure 5.6). 
Feature Observed 
overlaps 




TssA 284 19.19 1.00E-04 greater 1.50E-03 
TssAFlnk 227 16.25 1.00E-04 greater 1.50E-03 
TxFlnk 38 10.48 1.00E-04 greater 1.50E-03 
Tx 306 21.68 1.00E-04 greater 1.50E-03 
TxWk 535 19.06 1.00E-04 greater 1.50E-03 
EnhG 93 14.60 1.00E-04 greater 1.50E-03 
Enh 292 13.42 1.00E-04 greater 1.50E-03 
ZNF_Rpts 36 6.93 1.00E-04 greater 1.50E-03 
Het 47 -1.67 5.09E-02 less 7.63E-01 
TssBiv 26 0.84 2.26E-01 greater 1.00 
BivFlnk 35 1.75 5.42E-02 greater 8.13E-01 
EnhBiv 32 2.21 2.48E-02 greater 3.72E-01 
ReprPC 33 -0.04 5.33E-01 less 1.00 
ReprPCWk 101 -0.18 4.69E-01 less 1.00 
Quies 532 -10.10 1.00E-04 less 1.50E-03 
Table 5.10 Significance of overlaps between combined thresholded sQTLs and 15 
chromatin states predicted by ChromHMM.  
 
  171 
 
Figure 5.5 Distribution of numbers of overlaps between random permutations of 15 
predicted chromatin states and LD blocks containing combined thresholded sQTLs 
from sQTLseekeR and Leafcutter. 
Grey bars represent the null distributions obtained from 10,000 random permutations of 
chromatin states. Red lines indicate the number of overlaps between the original states and 
LD blocks containing sQTLs.  
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Figure 5.6 Local Z scores calculated by shifting permuted states up to +/-100kbp when 
overlapping 15 chromatin states with LD blocks containing combined thresholded 
sQTLs. 
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5.4.3 Relationship between sQTLs and eQTLs 
68.8-71.3% of genes for which there were sQTLs also had eQTLs associated with 
them. However, few of the lead sQTLs, either per feature (per transcript-pair for 
sQTLseekeR or per intron for Leafcutter) or per gene, were also a lead eQTL SNP 
(2.14-2.79%, Table 5.11).  
Comparison sQTLseekeR Leafcutter Combined 
Lead SNPs per Feature (%) 117 (2.14) 229 (2.26) 332 (2.16) 
Lead SNPs per Gene (%) 95 (2.79) 101 (2.54) 188 (2.58) 
Total SNPs (%) 49328 (51.6) 4768 (47.0) 52947 (51.0) 
Genes (%) 2380 (69.6) 2873 (71.3) 4148 (68.8) 
Table 5.11 sQTLs which are also eQTLs. 
Numbers of sQTLs which are also eQTLs for: the lead sQTL SNP per feature (per transcript-
pair for sQTLseekeR and per intron for Leafcutter); the lead sQTL SNP per gene; all FDR 
significant SNPs; and genes which have QTL events. sQTLs tested were from sQTLseekeR, 
Leafcutter or a combination of the two. 
LD blocks containing the combined sQTLseekeR and Leafcutter thresholded sQTLs 
were circularly permutated against LD blocks containing the eQTLs derived from the 
Scottish dataset, and also against eQTLs called by the GTEx Consortium from 
sigmoid colon and transverse colon tissues4. When the two sets of QTLs were 
assigned to the same set of LD blocks derived from the 1000 Genomes Phase 1 
Release 3 CEPH population, the circular permutations produced significant overlaps 
against all 3 selections of eQTLs (Table 1.12).  However, there was an unexpected 
trough observed at the centre of plots tracing the Z-scores when coordinates of the 
LD blocks were locally shifted (Figure 1.7). This likely resulted from permuting the 
same set of LD blocks against one other. 
Feature Observed 
overlaps 




eQTLs CCGG 257 9.9491 1.00E-04 greater 3.00E-04 
GTEx Sigmoid 167 10.7213 1.00E-04 greater 3.00E-04 
GTEx Transverse 212 14.0646 1.00E-04 greater 3.00E-04 
Table 5.12 Significance of overlaps between eQTLs and sQTLs assigned to same set 
of LD blocks 
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Figure 5.7 Circular Permutations of sQTLs and eQTLs assigned to same LD blocks 
a) Distribution of numbers of overlaps between random permutations of LD blocks containing 
eQTLs from the Scottish cohort or from GTEx sigmoid or transverse colon tissues and LD 
blocks containing combined thresholded sQTLs. Grey bars represent the null distributions 
obtained from 10,000 random permutations of eQTLs, red lines indicate the number of 
overlaps between the original LD blocks containing eQTLs and sQTLs. b) Local Z scores 
calculated by shifting permuted eQTL LD blocks up to +/-100kbp when overlapping LD 
blocks containing eQTLs and sQTLs. 
Circular permutations were therefore run a second time with sQTLs assigned to the 
LD blocks derived directly from the genotypes of the 221 individuals in the Scottish 
cohort. These LD blocks were derived from a relatively small population, and so are 
consistently larger than the LD blocks derived from 1000 Genomes (Table 5.1). It is 
not ideal to use LD blocks derived from a specific population to then test hypotheses 
in that same population, however it was considered justified in this instance to use 
an available set of different LD blocks in order to re-assess the circular 
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permutations. The sQTLs were chosen to be assigned to LD blocks from the 
Scottish cohort in order to minimise the impact of using larger blocks, because there 
were fewer sQTLs than eQTLs being tested. As there were no LD blocks available 
for the X chromosome from the 1000 Genomes dataset, it was not included. There 
were once again significant overlaps of LD block containing sQTLs with LD blocks 
containing eQTLs (Table 5.13), and the local Z-scores from these permutations 
displayed the expected central peaks, indicating that the specific location of the 
features being tested produced the significance (Figure 5.8). 
Feature Observed 
overlaps 




eQTLs CCGG 442 16.90 1.00E-04 greater 3.00E-04 
GTEx Sigmoid 306 18.46 1.00E-04 greater 3.00E-04 
GTEx Transverse 346 19.88 1.00E-04 greater 3.00E-04 
Table 5.13 Significance of overlaps between sQTLs and eQTLs assigned to different 
sets of LD blocks 
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Figure 5.8 Circular Permutations of sQTLs and eQTLs assigned to different LD blocks 
a) Distribution of numbers of overlaps between random permutations of LD blocks containing 
eQTLs from the Scottish cohort or from GTEx sigmoid or transverse colon tissues and LD 
blocks containing combined thresholded sQTLs. Grey bars represent the null distributions 
obtained from 10,000 random permutations of eQTLs, red lines indicate the number of 
overlaps between the original LD blocks containing eQTLs and sQTLs. b) Local Z scores 
calculated by shifting permuted eQTL LD blocks up to +/-100kbp when overlapping LD 
blocks containing eQTLs and sQTLs. 
 
5.4.4 GWAS enrichment via lambda inflation 
The null distribution of lambda inflation calculated using meta-GWAS p-values from 
SNPs within the sQTLseekeR search window had a mean of 1.243 and median of 
1.236. The lambda inflation of the 375 thresholded sQTLseekeR sQTLs using p-
values from the meta-GWAS for CRC was 1.305, which produced a Z-score of 
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0.408 and two-tailed p-value of 0.682 (Figure 5.9). The null distribution for Leafcutter 
had a mean and median lambda inflation of 1.278 and 1.274, compared to the score 
for the 776 thresholded sQTL SNPs of 1.595, which produced a Z-score of 2.996 
and a p-value of 0.00273 (Figure 5.9). 
 
Figure 5.9 Lambda inflation distributions from 100,000 SNPs MAF-matched and 
selected from the same search windows as sQTLseekeR and Leafcutter 
Despite not being significantly enriched compared to their corresponding 
background distribution of lambda inflation scores, there were sQTL variants 
identified by sQTLseekeR which deviated markedly from the null distribution of 
expected quantiles of meta-GWAS p-values (Figure 5.10). 
 
Figure 5.10 Observed against expected CRC meta-GWAS p-values for sQTL SNPs and 
SNPs from within the search windows of the respective packages. 
For clarity of plotting, 100,000 of the genome-wide variants from the meta-GWAS were 
chosen, equally stratified across the quantiles of p-values. 
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5.4.5 sQTLs in GWAS-implicated and COSMIC genes 
sQTLseekeR identified sQTLs in three genes which have been associated with CRC 
via GWAS (Table 5.14), and Leafcutter identified six (Table 5.15). 
sQTLseekeR identified an sQTL for the SCG5 gene which involved a 44% change in 
mean relative transcript expression ratio. ENST00000413748, the 211 amino acid 
canonical protein-coding transcript, reduced in expression relative to 
ENST0000030015, which has a different 5’ splice site of exon 3 leading to the 
inclusion of an extra alanine (Figure 5.11). ENST00000498069, a 612bp non 
protein-coding lncRNA, remained stable at a low level in relation to the genotype of 
rs72715244. 
 
Figure 5.11 Change in SCG5 transcript expression ratio. Reference and alternative 
alleles are shown, and numbers of individuals of each genotype are detailed in brackets. 
sQTLseekeR identified sQTLs in 13 genes recorded in the COSMIC catalog430 as 
associated with the progression of cancer, including PTPRT which has been 
specifically linked to CRC (Table 5.16). Leafcutter identified 23 COSMIC genes, 
including EIF3A, POLE, and SIRPA which have been observed to be recurrently 
mutated in CRC (Table 5.17). 
 
















SCG5 rs72715244 0.13 intronic 0.44 2.13E-05 195.9 3.00E-27 1.22 [1.18-1.27] Law et al.
96 
2.00E-08 1.18 [1.11-1.24] Peters et al.438 
HLA-DQA1 rs9272330 0.57 intronic 0.51 2.13E-05 2196.3 4.00E-08 1.08 [1.05-1.11] Law et al.96 
C8orf37-AS1 rs4236835 0.12 intronic 0.21 1.23E-02 25.0 4.00E-06 1.27 [1.14-1.40] Fernandez-Rozadilla et al.439 
Table 5.14 Genes associated with CRC from the NHGRI-EBI catalog for which there were sQTLseekeR sQTLs passing expression and effect 



















HLA-DQA1 rs41268942 0.17 3’ UTR -3.24 1.85E-35 607.1 4.00E-08 1.08 [1.05-1.11] Law et al.96 
HLA-DRB1 rs2395516 0.31 intergenic -2.46 1.83E-17 499.0 4.00E-08 1.08 [1.05-1.11] Law et al.96 
FEN1 rs61897793 0.15 intronic -2.44 1.44E-18 93.9 1.00E-06 1.06 [1.03-1.08] Law et al.96 
PLEKHG6 rs12828469 0.62 intronic 2.52 1.77E-38 15.4 1.00E-10 1.12 [1.08-1.16] Law et al.96 
FADS2 rs7943728 0.15 intronic 2.26 1.83E-19 33.7 1.00E-06 1.06 [1.03-1.08] Law et al.96 
ERAP1 rs26500 0.79 intronic -2.36 7.00E-12 378.5 7.00E-08 1.51 [1.23-1.86] Al-Tassan et al.227 
Table 5.15 Genes associated with CRC from the NHGRI-EBI catalog for which there were Leafcutter sQTLs passing expression and effect 
size thresholds. “Mean counts”: mean number of reads aligned to each intron inferred by Leafcutter across all 221 primary samples. 
  
 










PTPRT rs6030443 0.19 intronic 0.29 3.59E-02 102.1 colorectal, HNSCC, gastric, lung, 
melanoma 
ERBB4* rs10192485 0.57 intronic 0.27 6.58E-03 28.2 melanoma, gastric, NSCLC 
CASP3 rs200872527 0.02 1bp intronic insertion 0.29 2.13E-05 4924.4 ovarian  
COX6C rs10542429 0.14 intronic 0.42 2.13E-05 8601.0 uterine leiomyoma 
PAX8 rs3748915 0.16 intronic 0.40 2.13E-05 759.5 follicular thyroid 
CNOT3 rs36634 0.44 intronic 0.26 2.13E-05 605.8 T-ALL 
LPP rs4686480 0.29 intronic 0.29 2.13E-05 51218.4 lipoma, leukaemia 
MUC4 rs11922145 0.15 intronic 0.35 2.40E-02 1518.7 HNSCC 
TRIM27 rs929042 0.26 intronic 0.24 2.13E-05 1050.0 papillary thyroid 
PAX3 rs72960894 0.11 intronic 0.49 5.86E-05 27.1 alveolar rhabdomyosarcoma 
CNTNAP2 rs10215201 0.34 intronic 0.25 2.13E-05 716.9 glioma, melanoma 
MYCN rs34039085 0.49 4bp deletion 0.26 1.47E-02 31.8 neuroblastoma, Wilms tumour 
ECT2L rs1157388 0.35 intronic 0.20 1.56E-02 254.0 ETP-ALL 
Table 5.16 Genes in the COSMIC database for which there was an sQTL identified by sQTLseekeR. * denotes the gene has also been linked to 
germline predisposition to cancer. ETP-ALL: early T-cell precursor acute lymphoblastic leukaemia, HNSCC: head and neck squamous cell carcinoma, 
NSCLC: non small cell lung cancer, T-ALL: T-cell acute lymphoblastic leukaemia. 
  
 














EIF3E rs674391 0.60 intronic 2.26 1.56E-23 38.5 colorectal 
POLE* rs4077170 0.70 NMD 2.62 6.23E-33 73.9 colorectal, endometrioid, stomach, skin 
SIRPA rs56301259 0.37 intronic -2.40 6.88E-33 34.9 HNSCC, colorectal, lung SCC 
FANCA* rs12925427 0.32 intronic -2.78 2.02E-32 34.5 AML, leukaemia 
FEN1* rs61897793 0.15 intronic -2.44 1.44E-18 93.9 breast  
LPP rs9877579 0.30 intronic 3.20 5.73E-77 177.9 lipoma, leukaemia 
COX6C rs34830464 0.18 intronic -3.22 5.00E-43 39.7 uterine leiomyoma 
ZNF429 rs59654184 0.20 intronic 3.52 1.18E-60 11.8 GBM 
ACSL3 rs6726737 0.34 non-coding 2.80 7.80E-45 129.3 prostate 
EML4 rs10490555 0.31 intronic -2.74 3.03E-35 321.1 NSCLC 
MUC1 rs2974937 0.55 intronic 2.98 3.16E-75 28.2 B-NHL 
ITGAV rs9333290 0.30 intronic 2.98 1.13E-66 6.8 large intestine carcinoma 
NFE2L2 rs10930786 0.82 intronic 4.24 1.31E-70 15.5 NSCLC, HNSCC 
SS18 rs994729 0.27 upstream -2.42 1.93E-28 161.5 synovial sarcoma 
CREB3L2 rs66593747 0.64 inframe deletion -2.60 2.96E-38 62.4 fibromyxoid sarcoma 
CANT1 rs12452918 0.11 intronic -2.32 6.37E-17 27.4 prostate 
CASP3 rs4647609 0.15 intronic 2.40 7.13E-17 80.7 ovarian  
DROSHA rs17409803 0.26 intronic -2.40 8.20E-35 11.9 Wilms tumour, NSCLC, bladder carcinoma 
NT5C2 rs1163248 0.77 intronic -2.76 1.32E-29 18.7 relapse ALL 
NCOR2 rs1244053 0.14 intronic -2.28 8.70E-14 29.0 prostate 
A1CF rs12254249 0.28 intronic -2.38 1.03E-26 9.8 melanoma 
NUP98 rs12271649 0.13 intronic 2.26 2.00E-10 11.0 AML 
AKAP9 rs6950470 0.39 intronic -2.36 2.27E-28 6.3 papillary thyroid 
Table 5.17 Genes in the COSMIC database for which there was an sQTL identified by Leafcutter. * denotes the gene has also been linked to 
germline predisposition to cancer. ALL: acute lymphocytic leukaemia, AML: acute myeloid leukaemia, B-NHL: B-cell non-Hodgkin lymphoma, GBM: 
glioblastoma multiforme, lung SCC: lung squamous cell carcinoma. 
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In relation to rs6030443, there was a reciprocal 29% change in transcript expression 
ratio within PTPRT, with the 31 exon transcript ENST00000373109 decreasing 
whilst transcript ENST00000612229, which lacks the last 7 exons, increased (Figure 
5.12). Transcript ENST00000373201, which has a single 9 amino acid exon fewer 
than ENST00000373109, was also decreased to a lesser extent in relation to 
rs6030443, whilst transcript ENST00000620410, which contains only 5 exons, 
remained stable. 
 
Figure 5.12 Change in PTPRT transcript expression ratio. Reference and alternative 
alleles are shown, and numbers of individuals of each genotype are detailed in brackets. 
The COSMIC database contains curated associations between somatic and 
germline mutations in ERBB4 and a number of cancers including melanoma, gastric 
and NSCLC430. It has not yet been recorded in the database as associated with 
CRC, though examples of this link are present in the wider medical literature440,441. 
In relation to the variant rs10192485, the 1,266 amino acid transcript 
ENST00000402597 decreased by an average of 27% relative to 
ENST00000436443, which includes an extra 26 amino acid final exon (Figure 5.13). 
The 5 exon non-coding lncRNA ENST00000484474 remained stable at a low level. 
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Figure 5.13 Change in ERBB4 transcript expression ratio. Reference and alternative 
alleles are shown, and numbers of individuals of each genotype are detailed in brackets. 
An sQTL was identified for CASP3 by sQTLseekeR linking the presence of a 1bp 
insertion caused by the rare SNP rs200872527 (MAF in 1000 Genomes 0.02) to a 
29% decrease in the transcript expression ratio of ENST00000308394, and an 
equivalent increase of ENST00000523916 which skips the second exon of the gene 
(Figure 5.14). Leafcutter also identified an sQTL for CASP3, which related to 
inclusion of an intron with coordinates of 4:184638468-184649395, which exactly 
correspond to the first intron of CASP3 (Figure 5.15). A sashimi plot generated by 
LeafViz shows that individuals with the alternative genotype (a genotype dosage of 
2 as opposed to 0) for rs200872527 have an average of 72% of reads supporting 
the skipping of exon 2 via inclusion of an intron spanning exon 1 to exon 3, 
compared to only 37% of reads supporting this same transcript in individuals 
homozygous for the reference allele (Figure 5.16). Additionally, greater proportional 
utilisation of exon 1 compared to exon 2 can be seen in the reads aligned to CASP3 
from two samples representative of the 0 and 2 genotype dosages (Figure 5.17). 
The Leafcutter sQTL was most significantly associated with rs4647609, only 
4.76kbp upstream of rs200872527, implying that both packages detected the same 
sQTL event in this gene. 
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Figure 5.14 Change in CASP3 transcript expression ratio. Reference and alternative 
alleles are shown, and numbers of individuals of each genotype are detailed in brackets. 
 
Figure 5.15 Ensembl browser view detailing the final intron of CASP3. 
The intron with coordinates 4:184638468-184649395 corresponds to the first intron of 
transcript ENST00000523916 (CASP3-206) which skips the second exon of 
ENST00000308394 (CASP3-201)328. Note, CASP3 is located on the negative strand. 
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Figure 5.16 Sashimi plot detailing the changes in intron usage between individuals of 
genotype dosage 0 or 2 across the first 3 exons of CASP3. 
Introns inferred by Leafcutter are labelled a-g. dPSI is mean change in percent spliced in. 
 
Figure 5.17 IGV screenshot detailing reads mapping to exons 1 and 2 of CASP3. 
Bigwig files representing the density of reads mapped to CASP3 are shown for two separate 
samples which represent each of the opposing genotypes. It can be seen that the ratio of 
reads aligned to exon 1 compared to exon 2 is much greater in the individual of genotype 2, 
which promotes skipping of exon 2. 
Leafcutter identified an sQTL in POLE corresponding to a change in the PSI of an 
intron with coordinates 12:132676184-132676546. These positions perfectly 
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correspond to intron 9 of transcript ENST00000537064, which is identical to the 
canonical protein-coding transcript ENST00000535270 until the presence of this 
intron, which introduces a nonsense-mediated decay motif328 (Figure 5.18). 
 
Figure 5.18 Ensembl browser view detailing intron 9 of POLE. 
The presence of the intron with coordinates 12:132676184-132676546 causes a change 
from the protein-coding transcript ENST00000535270 (POLE-207) to the nonsense 
mediated decay transcript ENST00000537064 (POLE-210)328. 
 
5.5 Discussion 
5.5.1 Variant effect prediction 
This study found sQTLs to be more enriched in putatively functional exonic regions 
than non-exonic (Figure 5.2). Other groups have made the same observation: 
sQTLs identified from brain tissue by Takata et al. were enriched in exonic regions 
with an odds ratio of 3.84 compared to a background set of 48,068 non-significant, 
LD-pruned sQTL SNPs264. The Leafcutter authors found a greater proportion of 
exonic SNPs in the sQTLs they derived from GEUVADIS LCL cell lines compared to 
a background set of 200,000 randomly chosen variants from within the vicinity of 
genes260. 
The strongest enrichments of sQTLs in this study was within the SnpEff 
consequence class of splicing-related variants (Figure 5.2). This result was mirrored 
by many other groups investigating sQTLs: The GTEx Consortium, Takata et al., the 
Leafcutter authors, Altrans authors and Humphrey et al. all found enrichments in 
splicing-related variants200,258,260,264,265. Although these classifications were relatively 
rare (0.34-1.48% of tested sQTL SNPs, Table 5.8), they produced the greatest 
enrichments relative to the background sets (Figure 5.2). This is why all significant 
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sQTLs were included in this facet of the analysis, not just the lead SNPs, in order to 
capture all possible causative SNPs within LD of an event. It could be that these 
SNPs with putative effects on splicing are the most likely to be responsible for the 
sQTLs, even if they are not the most statistically significant “lead” SNP. Where 
numbers were available, this pattern is seen in other studies: Takata et al. found 
only 0.3% of sQTLs to be in canonical splice sites and 0.6% in splice regions; 
however they represented some of the greatest enrichments relative to their non-
significant background set with Z-scores of >9.0 and >4.0 respectively264. Only 
0.44% of sQTLs identified by the sQTLseekeR authors from GEAUVADIS LCLs 
were within splice sites, but this was ~5x greater than the 0.09% of non-sQTL SNPs 
which were located in positions with the same classification247. 
There was significant enrichment of synonymous variants and missense variants in 
the sQTLs identified by this study compared to background sets (Figure 5.2), as was 
also seen by GTEx, Takata et al., the Leafcutter authors and the Altrans 
authors200,258,260,264. Synonymous variants have been observed to affect splicing, and 
are theorised to mediate such effects by disrupting exonic splice enhancers and 
exonic splice suppressors (ESEs and ESSs)157,403. Hurst and Batada saw 17% 
reduced rates of somatic synonymous mutations in exon flanks, and a further lower 
density of somatic mutations in ESE motifs specifically, in cancer, implying a degree 
of purifying selection acting against mutations disrupting splicing in this way442. 
Synonymous variants have also been observed to be under negative selection in the 
germline of human populations443,444 - implying that any aberrations caused by 
sQTLs could be significant in influencing predisposition to disease. 
A greater significant enrichment of sQTLs within 5’ UTR than 3’ UTR regions was 
observed in this study, in agreement with Takata et al., the Leafcutter authors and 
the Altrans authors258,260,264. This implies that regions at the beginning of a transcript 
may have more influence on its subsequent splicing than those at the end. Whilst 
the 3’ UTR can affect transcript stability through the presence of micro-RNA binding 
sites445, the 5’ end can contain sequences influencing transcription initiation sites 
and mRNA capping446. Hurst and Batada also identified more purifying selection at 
5’ exon flanks than 3’: further evidence that sequences earlier in a transcript may 
play a more critical role in influencing splicing442. The GTEx pilot study of nine 
tissues in 2015 found the opposite pattern for sQTLs identified by sQTLseekeR200, 
however they only identified an average of 250 genes with sQTLs per tissue, 
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therefore they may not have identified the entire population of possible sQTLs. For 
the sQTLs they identified via Altrans (of which there was an average of 1,900 genes 
with sQTLs per tissue), there was again a greater enrichment within 5’ than 3’ 
UTRs200. 
These enrichments of the sQTLs identified in this study within functionally relevant 
sequences relative to randomly chosen background SNPs increases confidence in 
their validity. Even though the exonic and functionally-relevant SNP classifications 
are enriched within the vicinity of genes, and the sQTLs were specifically sampled 
from search windows containing genes, the background sets were drawn from 
windows matching the test sets, thus accounting for this bias. 
Any variants associated with sQTLs by this study are likely to be relatively common 
in the wider population, given that thresholds were set requiring at least 5 individuals 
of each genotype group to be present in the cohort of 221 samples, meaning that 
they are less likely to be highly deleterious. This makes the enrichment of sQTLs in 
high effect consequence classes particularly noteworthy, and these are strong 
candidates for further functional investigation and fine-mapping. 
5.5.2 Epigenetic and functional marks 
When investigating sQTLs derived from dorsolateral prefrontal cortex brain tissue, 
Takata et al. identified a significant enrichment within ChIP-seq peaks for 
H3K4me3264,  a relationship which was also observed in this study (Table 5.9 and 
Figure 5.3). H3K4me3 was also one of the chromatin marks found to be most 
strongly enriched for sQTLs identified by the GTEx 2015 pilot study200, and for 
sQTLs identified by Altrans from GEAUVADIS samples258. This makes functional 
sense as H3K4me3 is associated with TSSs of genes undergoing active 
transcription419,447. 
Surprisingly, Takata et al. calculated a significant depletion of sQTLs within 
H3K4me1 and H3K27ac - two other marks usually associated with active genes - 
whereas this study found an enrichment. The GTEx 2015 study also failed to find a 
significant enrichment of sQTLs identified by sQTLseekeR in H3K4me1 ChIP-seq 
peaks; however they did find an enrichment in H3K27ac200. H3K4me1 localizes 
around active enhancers448 and can recruit the chromatin remodelling enzyme 
CHD7449. It is not as strongly enriched as H3K4me3 in 5’ active promoter regions419, 
which could explain its lower Z-score of 13.20 compared to 17.35 when permutated 
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against sQTL LD blocks. The search windows for sQTLs around genes would more 
likely encompass proximal promoter rather than distal enhancer regions. H3K27ac 
marks transcriptionally active regions450 and primarily decompacts chromatin as a 
result of bringing a net neutral charge to histones, and by being antagonistic to the 
strongly repressive H3K27me3 mark, as a lysine cannot be simultaneously 
acetylated and methylated451. H3K27ac marks are often found to co-occur with 
H3K4me3423, which could explain the very similar Z-scores of 17.14 and 17.35. 
The discrepancies in H3K4me1 and H3K27ac enrichment in relation to the Takata 
analysis could be that they used a consensus set of histone marks derived from cell 
lines analysed by ENCODE, whereas this study used tissue-matched colonic 
mucosa epigenetic data from the Roadmap Epigenetics Consortium. Other studies 
have explored the tissue-specificity of epigenetic marks: Heintzman et al. found a 
Pearson correlation of 0.71 between H3K4me1, H3K4me3 and H3K27ac at 
promoters of 5 different cell lines, whereas they observed highly cell-type-specific 
histone modification patterns at previously identified and newly-predicted enhancer 
sequences450. The FANTOM Consortium produced an atlas of cell-type-specific 
enhancer sequences based on correlations between gene expression data, DNase I 
hypersensitivity, H3K4me1 and H3K27ac marks, and found many differences even 
between physiologically closely related cells, e.g. CD4+, CD8+, CD14+, CD19+ and 
CD56+ white blood cells452. 
This study saw a significant enrichment of sQTLs within H3K9ac and H3K36me3 
marks (Table 5.9 and Figure 5.3), observations which were capitulated in GTEx 
data200 and by the Altrans authors258. In its acetylated form, H3K9 is a marker of an 
active promoter state, and is localised to active promoters and enhancers421. 
H3K36me3 is deposited in the gene bodies of actively transcribed genes424, and 
may serve to recruit de-acetylating enzymes as part of a negative feedback loop to 
prevent active genes in open chromatin undergoing aberrant intragenic transcription 
initiation in the presence of RNA Polymerase II453,454. H3K36me3 has also been 
hypothesised to play a role in facilitating alternative splicing because H3K36me3 
peaks are highly enriched within nucleosomes specifically occupying exonic 
sequences455, and the mark is hypothesised to recruit additional splicing factors to 
aid the excision of intronic sequences from around exon boundaries184. Therefore 
enrichment of sQTLs in both of these marks also makes functional sense. 
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This study showed a nominally significant depletion of sQTLs in H3K9me3 marks 
and no significant association with H3K27me3 (Table 5.9 and Figure 5.3). The GTEx 
consortium found a significant depletion of sQTLs in H3K27me3 regions, though 
they did not assess H3K9me3200. Both of these modifications mark inactive regions. 
H3K9me3 has been found to be enriched within 10kbp of the promoters of 
transcriptionally silenced genes419, and it has also been shown to recruit DNA 
methyltransferases which subsequently promote the formation of condensed 
heterochromatin422. Tri-methylated H3K27 acts antagonistically to its activating, 
acetylated form450, and is found in higher levels at silenced than transcriptionally 
active promoters419. Therefore depletion of sQTLs in these areas of repressed 
expression would be expected - and even though the associations did not pass 
multiple testing significance, there was no enrichment of sQTLs within these 
chromatin marks. The lack of significance in relation to overlap between sQTLs and 
either H3K9me3 or H3K27me3 could be because these marks covered the smallest 
percentages of the genome of all the histone modifications analysed; 12.1 and 20.9 
Mbp respectively (Table 5.5). This means the random permutations used to ascribe 
significance will have been constrained towards fewer overlaps, producing a 
distribution that was less tractable for the actual numbers of overlaps with sQTLs to 
be significantly different from, even though they produced the fewest overlaps 
(73/965 and 91/965, Table 5.9). The relative paucity of H3K27me3 could be 
because it is especially implicated in the repression of genes during development, 
being laid down by a component of the PRC2 complex which is a key transcriptional 
repressor during the embryonic life stage of metazoans456, whereas this epigenetic 
data was sampled from adult, differentiated colonic mucosa. Perhaps GTEx were 
able to find an enrichment because they profiled a wide range of tissues, and 
therefore may have been able to pick up signals from a more diverse set of tissue-
specific promoters which are still active after differentiation. 
Candidate regulatory elements were constructed by ENCODE from combined 
signals of the highest quality DNase I hypersensitivity, H3K4me3, H3K27ac, and 
CTCF ChIP-seq peaks427. There was a significant enrichment of sQTLs within these 
regions as well as the consensus DNase I hypersensitivity peaks combined across 
125 cell lines profiled by ENCODE. Given these two region sets encompassed a 
similar proportion of the genome, it is an encouraging result that both were enriched 
for sQTLs with Z-scores of similar magnitudes of 8.19 and 9.35 respectively (Table 
5.9). However, enrichment might have been expected given that these two regions 
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cover the greatest portion of the genome (548 and 387 Mbp respectively, Table 5.5), 
and the observed number of overlaps between them and sQTLs were high (849/965 
and 855/965). The Altrans authors also observed a significant enrichment of sQTLs 
within DNase I hypersensitivity peaks258. 
sQTLs were found to be enriched in all of the ChromHMM states relating to 
transcription (TssAFlnk, TxFlnk, Tx, TxWk), except for those indicating bivalent 
transcription start sites (TssBiv, BivFlnk, Table 5.10). Similarly, there was 
enrichment within enhancer and genic enhancer regions (Enh, EnhG) but not 
bivalent enhancers (EnhBiv, Table 5.10). Bivalent regions are identified by a 
combination of both activating and repressive chromatin marks, often H3K4me3 
within a broader region of H3K27me3425,457,458, and are theorised to be “poised” 
ready to release repression from transcription factors which promote 
differentiation420,456. Therefore, similar to the lack of enrichment of sQTLs within the 
individual H3K27me3 mark, it could be that because these analyses were performed 
on adult, differentiated tissue, there were fewer regulatory regions being held in this 
bivalent state. Raj et al. found a similar enrichment of sQTLs in actively transcribed 
but not bivalent regions when analysing expression data from dorsolateral prefrontal 
cortex brain tissue265. This was mirrored by the Leafcutter 2018 study which 
observed an enrichment of sQTLs from GEAVADIS CEU LCLs in strong enhancers 
and active promoters, but not poised promoters260. The Roadmap Epigenetic 
Consortium found enrichment of evolutionary conservation of non-coding sequences 
identified as containing enhancers and promoters425,459, indicating the potential 
disease-relevance of germline variants in these regions. 
This study observed a significant depletion of sQTLs in regions assigned a 
chromatin state of quiescent (Quies, Table 5.10), as would be expected due to these 
mainly representing intergenic regions458. However, there was no depletion in 
regions predicted to have high levels of polycomb-protein binding which cause 
compaction of chromatin and result in gene silencing460 (ReprPC or ReprPCWk). 
Similarly, depletion within heterochromatic regions (Het), which usually correlate 
with lower gene expression461, was not significant. The Leafcutter authors did 
observe a significant depletion of GEAUVADIS sQTLs in regions assigned as being 
heterochromatic and polycomb-repressed260, and Raj et al. found a significant 
depletion within polycomb-repressed and quiescent regions, and a nominally 
significant depletion in heterochromatic regions265. The lack of significant depletion 
 
  192 
of sQTLs in heterochromatin in this study is a surprising result given that there was 
a significant enrichment of sQTLs within regions predicted to contain zinc finger 
repeat sequences (ZNF_Rpts), and that heterochromatin is often targeted to 
repetitive regions such as these to prevent them undergoing aberrant homologous 
recombination462. Perhaps this discrepancy between heterochromatic and zinc-
finger domains could be explained by the regions assigned as ZNF_Rpts covering a 
smaller overall region of the genome than heterochromatin (7x fewer bases covered 
(3.5Mbp vs 25.1Mbp) and 5.7x fewer regions (2,281 vs 12,987), Table 5.6). The 
Roadmap Epigenetics Consortium ran ChromHMM predictions with outputs ranging 
from 10 to 25 states, and chose to use 15 different states because larger numbers 
failed to sufficiently distinguish between biologically distinct regions425. However 
perhaps some of the resulting states became too rare for this kind of enrichment 
testing to be appropriate: Takata et al. didn’t test for enrichment of sQTLs in any 
ChIP-seq dataset which had fewer than 50,000 peaks264, which the majority of the 
ChromHMM states do not have (Table 5.6). Therefore a limitation of analysing 
individual ChromHMM states could be the relative scarcity of the rarer classes. A 
new implementation of ChromHMM trained on continuous annotation which 
accounts for the strength of experimentally-derived peaks rather than using discrete 
presence or absence calls of features may bring additional certainty to the study of 
integrated epigenetic states463. 
A caveat to all the observed enrichments of sQTLs in relation to epigenetic marks is 
that the search windows for sQTLs were constrained around genes or inferred 
introns, and many of the chromatin marks analysed tend to be located in the 
proximity of genes - regardless of the state of their activity. This co-localization may 
have served to intrinsically augment the strength of all enrichments, which could 
explain why there were nominally significant or non-significant depletions of sQTLs 
in repressive H3K9me3 and H3K27me3 regions when significant depletions would 
have been expected. However, the local Z-score plots do tend to show distinct 
peaks and troughs where expected more often than not, which indicates that these 
observations are not purely artefactual and that the specific position of the test set of 
regions relative to the permuted set does influence the significance of enrichments. 
The colonic tissue sample E075 from which the Roadmap Epigenetics Consortium 
derived the individual ChIP-seq peaks used in this chapter was from a female donor. 
However, network analysis detailed in the first results chapter concluded that there 
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was little difference between the gene expression networks in colonic mucosa of 
males and females, which would imply that epigenetic regulatory profiles obtained 
by ChIP-seq should be applicable between genders. Tissue specificity was the most 
important consideration for this analysis of alternative splicing, hence sample E075 
was used for the majority of ChIP-seq peaks as opposed to a conglomeration across 
multiple samples. 
5.5.3 Comparing eQTLs and sQTLs 
This study found that only a small percentage (2.14-2.79%, Table 5.11) of lead 
sQTL SNPs are also lead eQTLs. Raj et al. saw a similarly low degree of sharing 
noting that only 42 of 9,045 lead sQTL SNPs from DLPFC were also lead eQTL 
SNPs (0.46%)265. From their 2016 analysis, the Leafcutter authors found that of 275 
genes for which there was an eQTL and an sQTL, only 14 variants were the lead 
SNP for both QTL types, and that >74% of lead sQTL SNPs did not have any 
detectable effect on total expression levels of the genes they affected261. 
Circular permutation found significant overlaps of LD blocks containing sQTLs with 
LD blocks containing eQTLs identified from the same Scottish dataset or from GTEx 
tissues (Table 5.12, Table 5.13). However, whilst there were significant enrichments 
compared to random circular permutations, when SNPs were assigned to the same 
set of LD blocks, the actual number of blocks which overlapped was low relative to 
the number of different sQTL and eQTL-containing blocks tested. 257 sQTL LD 
blocks overlapped with eQTL blocks from the Scottish dataset, out of 10,110 sQTL 
and 11,478 eQTL LD blocks respectively (Table 5.12) 
Of 4,148 genes for which there was an sQTL identified by either sQTLseekeR or 
Leafcutter, 68.8% also had an eQTL identified in the Scottish cohort (Table 5.11). 
When identifying eQTLs and sQTLs from nine separate tissues, the GTEx 
consortium observed a similar degree of co-occurrence, with up to 70% of genes for 
which sQTLseekeR identified an sQTL also having an eQTL (13%-70%, mean 
48%)200. This level of agreement is likely attributable to the fact that the level of 
expression influences the propensity for a gene to have either an eQTL or an sQTL 
associated with it. 
Therefore it appears that although many of the same genes possess both an sQTL 
and an eQTL, the signals often originate from independent SNPs located in 
separate LD blocks. This is an important observation of the apparent independence 
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between the majority of sQTL and eQTL events identified from colonic mucosa, and 
implies that accounting for loci implicated in alternative splicing phenotypes may add 
additional power when prioritising disease-linked GWAS variants for colorectal 
cancer via colocalisation analyses or TWAS265,401,464–466. 
5.5.4 GWAS enrichment 
Yang et al. demonstrated that in the absence of population structure, the lambda 
genomic inflation factor is dependent on heritability of the quantitative trait in 
question, the number of causative variants for the trait, the sample size analysed 
and the LD structure within the cohort436.  Both the mean and median lambda 
inflation increase with heritability, and the median increases as a function of the 
number of causative variants, because more SNPs will then be in LD with these 
variants and so their p-values of association will deviate further from the null 
expected chi-squared distribution. Yang et al. observed mean and median lambda 
inflations of 1.035 and 1.029 respectively in a GWAS for height using 294,831 
genotyped SNPs in a relatively small cohort of 3,925 unrelated individuals in which 
they had previously determined there was negligible detectable population structure. 
This indicates that some degree of inflation is detectable even under such 
theoretically ideal conditions, and therefore the background genomic inflation for a 
given cohort needs to be accounted for. By sampling 100,000 randomly selected 
loci, they estimated there to be an average of 188 SNPs in LD at each locus, with an 
average r-squared of 0.026. In a larger meta-GWAS cohort of 133,000 individuals 
and 2.8M genotyped and imputed variants, Yang et al. observed mean and median 
lambda inflations of 1.95 and 1.55 respectively in the p-values of association with 
height. The meta-GWAS of 58,640 individuals from which CRC association p-values 
were utilised for this analysis presented mean and median lambda inflation values 
intermediate between these two cohorts studied by Yang et al., of 1.243 and 1.236 
for sQTLseekeR and 1.278 and 1.274 for Leafcutter (Figure 5.9), as would be 
expected given its size and the relatively lower estimates of heritability of CRC of 
between 7.42-26.0% compared to 54% estimated for height. The fact that the 
median lambda inflation of CRC meta-GWAS p-values corresponding to thresholded 
Leafcutter sQTL SNPs (1.595) deviated significantly from a corresponding null 
distribution of MAF and window-matched SNPs (p-value=0.00273) implies that the 
Leafcutter sQTLs are more commonly in higher LD with causative SNPs for CRC 
than would be expected by chance, and that they have more significant p-values of 
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association with CRC predisposition than would be expected by chance (Figure 5.9). 
The fact that the median lambda inflation (1.305) of the thresholded sQTLseekeR 
sQTL SNPs was not significantly different from its null distribution (p-value  = 0.682) 
could be as a result of it not being as prolific as Leafcutter at identifying sQTLs. In 
addition, the meta-GWAS of CRC from which summary statistics of association were 
used in this analysis has since been superseded by larger meta-analyses which 
have uncovered dozens more loci significantly associated with CRC 
predisposition96,231, meaning that it is possible this analysis underestimated the 
significance of sQTL SNPs, and the sQTLs identified by sQTLseekeR may 
constitute a significantly associated set if tested in the context of these updated 
association statistics. 
The Leafcutter authors observed significant enrichment of sQTLs they identified 
from two different GEAUVDIS populations of LCLs in GWAS association statistics 
for rheumatoid arthritis and multiple sclerosis, and observed clear deviation from the 
expected quantiles in QQplots260,261. The observed deviation was less marked in this 
study, however they did not filter their sQTLs for effect size or for read counts 
supporting the inferred introns, and they compared against all genome-wide SNPs 
not just those within the search window of the algorithm, meaning their inflations 
may have been exaggerated260. 
Takata et al. found enrichment of PSI sQTL SNPs identified from DLPFC tissue in 
loci associated with schizophrenia using a 1-talied Fisher’s test (OR=3.72, p-
value=9.90E-05). They defined disease-associated loci as any SNPs in LD of r-
squared >0.6 with lead GWAS SNPs for schizophrenia sourced from the NHGRI 
GWAS catalog429 or the Psychiatric Genomics Consortium467. They defined a set of 
MAF-matched (by 0.02 bins) non-sQTL SNPs as those which had nominal p-values 
>0.05, and used these in conjunction with the significant sQTLs to construct a 2x2 
table with columns: sQTL SNPs vs non-sQTL SNPs and rows: within vs outwith 
disease-associate loci, from which to perform their Fisher’s test. 
5.5.5 sQTLs in cancer-relevant genes 
Hereditary mixed polyposis syndrome (HMPS) is a rare Mendelian trait which 
predisposes to the presence of adenomas and hyperplastic polyps, with a mean age 
of first presentation of 33 years468. The causative genomic aberration has been 
traced by multiple groups to germline copy number duplications of a 20kbp region 
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encompassing exons 3 to 6 at the 3’ end of the SCG5 gene and extending into the 
region upstream of the BMP agonist GREM1469,470. SCG5 is a secretogratin gene 
which binds cargo proteins in the endoplasmic reticulum and chaperones them 
through the secretory pathway to the cell surface471. An sQTL was found in this 
study which lead to a 44% increase in relative expression of a transcript of SCG5 
which includes an extra alanine at the beginning of exon 3. The variant most 
significantly associated with this event, rs72715244, is located 53kbp upstream of 
rs4779584 which has been implicated in CRC predisposition by a meta-GWAS of 
11,769 cases and 14,328 controls472. 
PTPRT is a member of a super family of tyrosine phosphatases which can act as 
tumour suppressors by tempering kinase signalling cascades mediating cell-cell 
adhesion473. PTPRT is the family member which most commonly suffers deleterious 
mutations in CRC474, and has also been observed to undergo promoter 
hypermethylation as a mechanism of being downregulated475. This study identified 
rs6030443 as being the SNP most significantly associated with an alternative 
splicing event causing a 29% increase in expression of a non-canonical transcript of 
PTPRT which does not possess the last 7 exons of the gene. These exons include 
regions coding for the intracellular phosphatase domains476. It is possible that 
reduced expression of the full length version of this tumour suppressor gene in the 
colonic mucosa throughout the course of an individual’s lifespan may increase their 
likelihood of developing CRC. 
ERBB4 (previously known as HER4) is a member of the subfamily of EGFR receptor 
tyrosine kinases, which promote cell proliferation, differentiation and migration upon 
binding of ligands including EGF477. Deep sequencing of 91 hotspot regions of 653 
cases of sporadic CRC by Malapelle et al. determined that ERBB4 was mutated in 
0.6% of cases440, and the presence of such mutations stratified survival in 276 
TCGA patients, corresponding to lower mean survival times (p-value=0.00942)441. 
RNA-seq analysis of 250 CRC samples from the Vanderbilt Medical Centre found 
ERBB4 to be over expressed relative to normal tissue in samples from all of the 
CRC stages I-IV, and its over expression in mouse xenografts harbouring APCmin 
and v-Ha-Ras produced tumours of double the size compared to those with wildtype 
expression levels441. This study found an sQTL event comprising a 27% increase in 
expression of an ERBB4 transcript with an additional final exon in relation to 
rs10192485, which is located 146kbp upstream of another intronic ERBB4 variant, 
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rs10932384, which has been significantly associated with recurrence and overall 
survival in renal clear cell carcinoma478. 
CASP3 is part of the caspase family of proteases involved in the execution-phase of 
cellular apoptosis, which are cleaved to form two subunits which then dimerize to 
constitute the active version of the enzyme479. Caspases often undergo mutations in 
cancer which allow tumour cells to evade programmed cell death, with higher levels 
of cleaved CASP3 predicting better prognosis and survival in CRC480. Both 
sQTLseekeR and Leafcutter appeared to identify the same sQTL for CASP3, which 
corresponded to greater relative expression of a transcript which skipped the second 
exon of the gene. It could be that perturbing the sequence of such a key tumour 
suppressor could reduce the ability of cells to respond to pro-oncogenic signals and 
curtail proliferation of an incipient cancer cell by instructing them to undergo 
programmed cell death. 
POLE has strong links to CRC, both in terms of germline predisposition481 and 
somatic mutations which lead to hypermutator phenotypes482. In this study, 
Leafcutter identified a variant, rs4077170, which was associated with inclusion of an 
intron causing nonsense mediated decay of the canonical protein-coding POLE 
transcript. POLE is the DNA polymerase most commonly used for synthesising the 
leading strand483. The mean counts supporting inclusion of the nonsense mediated 
decay intron across all 3 genotype groups was relatively low, 73.9, and the allele of 
the variant associated with inclusion of the intron had a frequency of 0.70 in the 
1000 Genomes EUR population (Table 5.17). This means that the sQTL itself is 
likely neutral, as opposed to deleterious.  
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Chapter 6 Conclusions 
6.1 Results 
This project is the first to comprehensively identify cis-sQTLs in colonic mucosa, by 
applying two different algorithms with complementary approaches; the transcript-
aware sQTLseekeR247 and intron-centric Leafcutter261, to RNA-seq from a Scottish 
cohort of 221 genotyped individuals. The variants associated with these sQTL 
events tended to fall within gene bodies, or lie proximal to the 5’ and 3’ ends of 
genes. Thresholds were implemented to prioritise a set of higher confidence sQTLs 
with larger effect sizes originating from features with greater expression. These 
retained the top 7.79% of sQTLseekeR events and 8.37% of Leafcutter events. 
Compared to background sets of non-significant SNPs matched for MAF and 
position, sQTL SNPs were most highly enriched within splicing related variants. 
There were also enrichments within synonymous coding variants, and there was a 
greater enrichment within 5’ than 3’ UTRs, perhaps indicating that variants situated 
earlier in a transcript can have a greater influence on splicing. Using circular 
permutations, the LD blocks containing sQTLs were found to be enriched within a 
range of histone modifications indicating actively transcribed genes, according to 
data obtained by the Roadmap Epigenetics Consortium from colonic mucosa 
tissue418. The sQTLs were similarly enriched within active chromatin states and 
significantly depleted in quiescent regions. 
68% of genes for which an sQTL was identified in this study also possessed an 
eQTL according to the same expression data; however only 2.79% of lead sQTL 
SNPs were also lead eQTL SNPs, and only 2.54% of LD blocks containing sQTLs 
overlapped with LD blocks containing eQTLs. This suggests that there is 
independence between these two classes of QTLs, and therefore this study 
expands our knowledge of non-coding variants influencing transcriptional regulation 
in human colonic mucosa. 
Thresholded sQTL SNPs were tested for genomic inflation in relation to loci 
predisposing to CRC using their corresponding p-values from a meta-GWAS of 
20,181 cases and 30,822 controls. The median lambda inflation for the thresholded 
Leafcutter sQTL variants deviated significantly from their corresponding null 
distribution, while the thresholded sQTLseekeR SNPs did not. This could be 
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because there were not as many SNPs in the sQTLseekR set, or because the meta-
GWAS from which GWAS p-values were obtained may not have represented a 
comprehensive set and as a result may have underestimated the significance of 
associations for certain loci. 
sQTLseekeR and Leafcutter together identified sQTLs in 9 genes with associations 
to CRC listed in the NHGRI-EBI GWAS catalog, 4 genes curated in the COSMIC 
database as being relevant to CRC progression, and a further 29 genes implicated 
by COSMIC in any of the cancers they assess. PTPRT is the tyrosine phosphatase 
most commonly mutated in CRC474, and sQTLseekeR identified an sQTL causing a 
reciprocal 29% change in expression of the canonical transcript and one which lacks 
the final 7 exons coding for intracellular phosphatase domains476. sQTLseekeR and 
Leafcutter both identified sQTLs affecting the relative expression of CASP3 
transcripts, a tumour suppressor gene involved in regulating programmed cell death, 
and which if not properly expressed could reduce the likelihood of abnormally 
proliferative cells being ablated from the colonic mucosa. Leafcutter identified an 
sQTL in POLE, which is strongly implicated in both predisposition to and 
progression of CRC481,482, corresponding to inclusion of a non-canonical intron which 
produces a nonsense mediated decay transcript. The mean counts supporting the 
presence of the intron were relatively low, and the SNP most significantly associated 
with the event had a frequency of 0.70 in the 1000 Genomes EUR population, 
implying it represents a tolerable, neutral change. 
6.1.1 Limitations 
This analysis of 221 individuals is among the largest cohorts in the literature from 
which sQTLs have been identified. However, the requirement of ≥5 individuals 
possessing each of the three possible genotypes of a biallelic SNP means that this 
study is still limited to identifying relatively common variants tagging loci associated 
with an sQTL. There may be more rarer variants associated with sQTLs to be 
discovered, which could potentially be under stronger purifying selection in the 
population. Additionally, this study has been carried out in a Scottish cohort. This will 
have made population-specific signals clearer and more readily identifiable, however 
it limits the scope of any conclusions to a Scottish population. 
The decision was taken to combine two batches of RNA sequencing for this 
analysis, given the findings of previous studies that using greater numbers of 
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samples leads to the identification of more sQTLs246,247. sQTLseekeR should have 
been immune to batch effects by using ratios of transcript expression as opposed to 
absolute values, and FastQTL was able to take as covariates principal components 
derived from the Leafcutter intron usage values which captured the batch effects. 
Samples were also combined from both the left and right sides of the colon. There 
were not sufficient right-sided samples to perform an adequately powered separate 
sQTL analysis. It could be that samples originating from different sides of the colon 
may have had different transcripts preferentially expressed, which could have 
reduced power to identify sQTLs in this study. However, previous analyses of total 
gene expression found few differentially expressed genes between the two sides47, 
implying their transcriptional divergence is low. 
The identification of sQTLs by sQTLseekeR rests on the accurate quantification of 
transcript expression. The alignment-free quantification algorithm Salmon has been 
demonstrated to outperform traditional two-step quantification pipelines301. Despite 
this, all transcript quantification is inherently probabilistic. There are certain 
conditions under which the accuracy of transcript-level quantification has been 
called into question, such as in the assignment of TPM values to transcripts shorter 
than the read length of the library356. This discrepancy originates from the method 
used by alignment-free algorithms to assign effective transcript length to features, 
however this analysis should be mostly immune to such shortcomings because raw 
counts instead of TPMs were supplied to sQTLseekeR. 
Recent advances in the field of long-read technologies by PacBio and Oxford 
Nanopore facilitate the capture of full-length transcripts, and so can definitively 
survey the transcriptome without requiring probabilistic inference of transcript 
structure484. Such technologies are still currently less cost effective than Illumina 
short-read sequencing, and suffer from a lower per-base accuracy; however future 
improvements may see them become more widely adopted. They currently find 
application in hybrid approaches with short-read technologies for the assembly of 
novel transcriptomes from species with little existing sequencing data by providing 
scaffolds to which the shorter reads can be aligned to correct any sequencing 
errors485. 
A de novo transcriptome assembly was not performed in this study because the 
sequencing was from normal tissue samples which would be assumed to possess a 
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fairly regular transcriptome, well represented by the Ensembl gene build v88328. 
Gupta et al. performed full length isoform sequencing of single cells from a variety of 
mouse cerebral tissues and identified a multitude of putatively novel transcripts not 
captured by the latest gene builds486, however they were often rare and may 
represent transcriptional noise as opposed to new canonical transcripts. If 
sequencing was performed on CRC tumour samples then a de novo transcriptome 
assembly may be more relevant as there could be cancer-specific transcripts 
expressed. 
None of the sQTLs in this study have yet been validated by an alternative 
quantification technology such as qPCR. The actual functional activity of the SNPs 
associated with the events could also be tested by minigene splicing reporter 
assays487. The sQTLs relating to genes associated with CRC predisposition or 
progression would be the highest priority candidates for follow up using such 
techniques. 
6.2 Future work 
6.2.1 Use of sQTLs for fine-mapping causative GWAS 
variants 
sQTLs have been shown to significantly contribute to predisposition of other 
complex traits including Alzheimer’s265, schizophrenia264, multiple sclerosis and 
rheumatoid arthritis261, sometimes to a greater degree than eQTLs261. 
The sQTLs identified in this project could be used to perform colocalisation in 
association with GWAS summary statistics in order to fine-map the most likely 
causative variants in loci tagged as contributing to CRC predisposition. Nica et al. 
developed a regression framework testing the proportionality of coefficients for two 
traits (in this case GWAS association and eQTL coefficients) across a set of the 
same SNPs within a given locus to assess the likelihood of colocalisation464. Whilst 
this approach accounts for LD structure, a limitation is the set of SNPs to test must 
be defined a priori  and genotype data at the resolution of each individual is 
required464. Giambartolomei et al. developed the coloc package which uses 
approximate Bayes factors to assess whether a shared causal variant is likely 
present in a region given the LD at the locus488. It is able to use simply summary 
GWAS and QTL association statistics, and only suffers a minor loss of power when 
using imputed variants. However it makes assumptions that the causal SNP is 
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present in the set of SNPs analysed from the locus, and assumes that there is only 
a single causal SNP present for each or both traits. Zhu et al. propose the summary 
data-based Mendelian randomization analysis (SMR) in concert with heterogeneity 
in dependent instruments (HEIDI)466. They perform Mendelian randomization (MR) 
for genes with eQTLs in the vicinity of a GWAS locus, checking whether the 
genotype groups corresponding to different expression levels also harbour more 
individuals of the given disease trait than would be expected by chance. In order to 
distinguish between pleiotropy, where the same SNP is causative of both the eQTL 
and the disease trait which would allow accurate prioritisation of disease genes, and 
linkage, whereby the causative eQTL SNP is simply in LD with the causative 
disease SNP and therefore the corresponding eQTL gene is not of relevance to the 
disease, they carry out MR for all SNPs in LD with the eQTL. If there is 
heterogeneity of the MR results then it implies simple linkage, however if there is no 
heterogeneity then it demonstrates consistency between the expression and 
disease phenotypes in each genotype group of the variant, meaning the variant 
likely influences both the eQTL and the disease trait, thus implicating the gene in the 
aetiology of the disease466. 
Law et al. performed a GWAS for CRC using 34,000 cases and 76,000 controls of 
European ancestry and were able to identify 31 new risk loci. They used SMR based 
on eQTLs identified from an in-house cohort and GTEx transverse colon samples, 
and were able to fine-map with high confidence the genes through which the 
associated variants at three of these loci mediated their effects, though almost 50% 
of loci had no cis-eQTLs detectable96. Whilst the majority of colocalisation studies to 
date have used eQTL SNPs, given the observation in this analysis of frequent 
independence between eQTLs and sQTLs from colonic mucosa, combining both 
sets of events together may allow greater probing of CRC-relevant GWAS signals. 
Liu et al. warn against the now abundant availability of eQTLs confounding such 
colocalisation studies489. However the tissue-specificity of this study in terms of the 
source of QTLs and the associated GWAS trait, combined with the expression and 
effect size thresholding applied to the sQTLs, should have reduced the risk of such 
false positive associations being observed. 
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6.2.2 Transcriptome-wide association studies (TWAS) and 
sQTLs 
Transcriptome-wide association studies have recently become adopted as a method 
of integrating variants known to influence gene expression regulation in order to 
increase the power of GWAS studies to identify new predisposition loci for complex 
traits. Li et al. used sQTLs and eQTLs they identified from LCLs using Leafcutter as 
input to the S-PrediXcan association algorithm262 to identify new loci predisposing to 
rheumatoid arthritis260. They were able to identify 18 new associations using the PSI 
splicing phenotypes from Leafcutter, of which 13 were not able to be identified using 
gene expression alone260. Similarly, Raj et al. observed more associations when 
using splicing vs gene expression phenotypes from dorsolateral prefrontal cortex in 
two separate TWAS to search for novel associations with Alzheimer’s, finding 16 vs 
5 loci respectively, of which 8 were not able to be identified from GWAS alone265. 
The scope to further expand CRC association studies via TWAS using the sQTLs 
identified in this analysis is clear. 
6.2.3 Polygenic risk scores 
Whilst they may not provide information about the clinical prognosis of CRC, 
polygenic risk scores have proven useful in predicting the likelihood of individuals 
developing CRC490. If additional CRC risk loci could be discovered through the 
inclusion of sQTLs in TWAS analyses, their inclusion into such metrics would further 
increase the accuracy of prediction of risk. This is particularly relevant to CRC given 
that survival rates are highest if the cancer is identified and treated in its earlier 
stages5,6. Screening resources could be more effectively targeted to individuals at 
higher risk, and such monitoring will become increasing feasible at a large scale as 
the costs of genotyping and sequencing continue to fall. 
6.2.4 Inclusion of other cohorts to increase power 
Future work could include expanding the size of the cohort analysed, so as to be 
able to detect signals from rarer variants and to increase certainty in transcript 
expression quantification for each genotype group. RNA-seq data is available for 
sigmoid and transverse colon samples collected by the GTEx Consortium, which 
could be used to call sQTLs. However such samples were demonstrated to have 
some of the poorest RNA integrities following ischaemia393,394, and the collection 
procedure led to significant amounts of stroma being captured along with the 
mucosa, which would dilute the tissue-specific signal from the precise tissue of 
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origin of CRC. In contrast, the samples used in this study specifically had stroma 
and muscle layers removed before sequencing. Analysis of sequencing from 
unrelated populations may also identify further sQTLs not detectable in this Scottish 
cohort. 
6.2.5 Analysing CRC expression in relation to germline 
sQTLs 
This investigation could be extended using RNA-seq from matched tumour samples 
from the same individuals from which normal tissue was obtained. It could be 
ascertained whether sQTLs observed in normal tissue persist into tumours, or 
whether patients who did not possess the germline variants go on to acquire them 
somatically. This could provide evidence of putative non-coding sQTL driver events, 
which have been hypothesised by other groups276. Data obtained in-house by Dr 
Debbie Baishnab using RNA Scope on histological samples of crypts from normal 
and tumour samples from the same individuals suggested that the SHROOM2 
eQTL, which has been linked to CRC predisposition98, does persist from normal into 
tumour tissue. Or alternatively it could be that sQTLs which predispose to CRC 
simply create a transcriptional environment which is favourable for the initiation of 
cancer, but do not themselves contribute to progression. This supposition would be 
supported by the fact that polygenic risk scores based on the current known loci 
associated with CRC did not prove effective in predicting survival outcomes in 
patients with CRC245. 
Having matched tumour RNA-seq available would allow the classification of cancers 
into one of the four consensus molecular subtypes of CRC67. It could then be tested 
whether certain germline sQTLs predispose to the development of cancers 
belonging to particular molecular subtypes, which have been shown to have 
different clinical outcomes and responses to treatments491. 
6.3 Summary 
This project has performed a comprehensive analysis of alternative splicing 
quantitative trait loci in normal human colonic mucosa from a Scottish cohort of 221 
individuals. 
Given the significant lambda inflation of Leafcutter sQTLs within a meta-GWAS, the 
number of CRC-specific and cancer-relevant sQTL events identified by both 
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packages, and the precedent of other studies observing sQTLs to significantly 
predispose to other complex traits260,264,265, it is likely that common germline sQTLs 
explain some portion of the non-coding variants which predispose to CRC.  
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